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The Self-Assembly Phenomenon of Poloxamers and Its Effect on the Dissolution of a Poorly
Soluble Drug from Solid Dispersions Obtained by Solvent Methods
Reprinted from: Pharmaceutics 2019, 11, 130, doi:10.3390/pharmaceutics11030130 . . . . . . . . . 107
Hanah Mesallati, Anita Umerska and Lidia Tajber
Fluoroquinolone Amorphous Polymeric Salts and Dispersions for Veterinary Uses
Reprinted from: Pharmaceutics 2019, 11, 268, doi:10.3390/pharmaceutics11060268 . . . . . . . . . 129
Tuan-Tu Le, Abdul Khaliq Elzhry Elyafi, Afzal R. Mohammed and Ali Al-Khattawi
Delivery of Poorly Soluble Drugs via Mesoporous Silica: Impact of Drug Overloading on
Release and Thermal Profiles
Reprinted from: Pharmaceutics 2019, 11, 269, doi:10.3390/pharmaceutics11060269 . . . . . . . . . 149
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Preface to ”Recent Progress in Solid Dispersion
Technology”
Amorphous solid dispersion (ASD) has been recognized as a powerful formulation technology 
to improve oral absorption of poorly soluble drugs for more than half a century. Because ASD is in 
non-equilibrium state, it is sometimes challenging to control its stability and performance. 
Remarkable advances have recently been made in ASD technology and have led to the finding that 
supersaturation created after dissolution of ASDs may not be a simple solution but may involve 
colloidal structure. This knowledge can transform our ability to design superior ASDs capable of 
effectively maintain a supersaturated state. Another current hot topic in ASD is the crystallization 
behavior of active pharmaceutical ingredients. General understanding on the crystallization of small 
organic compounds is particularly challenging, as their dynamics are affected by both strong 
(covalent) and weak (noncovalent) interactions, unlike inorganic glasses. Industrial formulators who 
employ ASDs are therefore particularly concerned about the solid state stability of ASDs (especially 
their physical stability), which cannot be predicted from conventional accelerated testing protocols. 
Many studies using various experimental and computational methods are ongoing in hopes of 
deepening our understanding of the physical stability of ASDs.
Because of such technological innovations, the hurdles for the development of ASDs have been 
greatly reduced compared to a decade ago. This Special Issue therefore focuses on topics regarding 
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Abstract: Amorphous solid dispersions (ASDs) are important formulation strategies for improving the
dissolution process and oral bioavailability of poorly soluble drugs. Physical stability of a candidate
drug must be clearly understood to design ASDs with superior properties. The crystallization
tendency of small organics is frequently estimated by applying rapid cooling or a cooling/reheating
cycle to their melt using differential scanning calorimetry. The crystallization tendency determined in
this way does not directly correlate with the physical stability during isothermal storage, which is of
great interest to pharmaceutical researchers. Nevertheless, it provides important insights into strategy
for the formulation design and the crystallization mechanism of the drug molecules. The initiation
time for isothermal crystallization can be explained using the ratio of the glass transition and storage
temperatures (Tg/T). Although some formulation processes such as milling and compaction can
enhance nucleation, the Tg/T ratio still works for roughly predicting the crystallization behavior.
Thus, design of accelerated physical stability test may be possible for ASDs. The crystallization
tendency during the formulation process and the supersaturation ability of ASDs may also be related
to the crystallization tendency determined by thermal analysis. In this review, the assessment of
the crystallization tendency of pharmaceutical glasses and its relevance to developmental studies of
ASDs are discussed.
Keywords: pharmaceutical glass; crystallization tendency; crystallization; nucleation; milling;
accelerated stability test
1. Introduction
Amorphous solid dispersions (ASDs) are among of the most effective enabling formulations for
improving the dissolution process and therefore the oral absorption of poorly soluble drugs [1–7].
Because of their high energy, amorphous solids can reach a supersaturated state during their dissolution
process. Although solubilization techniques that increase the equilibrium solubility, including the
use of micelles and organic solvents, can inhibit membrane permeation [8,9], it does not happen for
supersaturated systems originated from ASDs [10]. It is now widely recognized that the supersaturation
created by ASDs can cause phase separation into concentrated and diluted phases, based on the
spinodal decomposition mechanism, followed by the formation of a quasi-equilibrium colloidal
structure consisting of a concentrated dispersed phase suspended in a diluted continuum phase [11,12].
Although the role of the dispersed phase in the oral absorption is still under debate, this process
can maintain high levels of supersaturation for the continuum phase, which are beneficial for oral
absorption [13]. The stability of the colloidal phase is significantly influenced by the polymer
Pharmaceutics 2019, 11, 202; doi:10.3390/pharmaceutics11050202 www.mdpi.com/journal/pharmaceutics1
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species [13–15]. Since the supersaturation behavior of ASDs, including phase separation and its impact
on membrane transport and oral absorption, are outside the scope of this review, readers interested in
these aspects are referred to recent studies [11,13,16–18] for further details.
Drug molecules in ASDs must remain in the amorphous state to exert their beneficial effects during
the dissolution process. Even a trace amount of crystals would undermine these favorable effects,
because it induces crystallization after suspension of the ASD in aqueous media [19,20]. Polymeric
excipients in ASDs serve not only for improving the supersaturation behavior as mentioned above,
but also for inhibiting crystallization of the drug. Miscibility is an important factor for exploiting
the stabilization effect by the polymer [21–23]. Obviously, the crystallization tendency of the drug
molecule itself is another important factor affecting the storage stability.
Table 1 summarizes generally accepted ideas for good glass formers in the case of small organic
compounds. Good glass formers tend to have a large molecular weight [24]; other chemical-structural
properties of these compounds include a low number of benzene rings, a high degree of molecular
asymmetry, as well as large numbers of rotatable bonds, branched carbon skeletons, and electronegative
atoms [25–27]. Specific tendencies can be found for the physicochemical properties as well. Good glass
formers should have a high melting temperature and enthalpy/entropy, as well as a large free
energy difference between crystalline and amorphous states [26]. Fragility [28,29], which quantifies
the degree of non-Arrhenius behavior of a glass, is another parameter that can correlate with
the crystallization tendency [26,30,31]. However, it should be emphasized that the crystallization
tendency of a certain compound is frequently determined by observing its crystallization during rapid
cooling or cooling/reheating cycles using differential scanning calorimetry, which does not necessarily
reflect easiness of the isothermal crystallization, which is of interest for pharmaceutical researchers.
The difference between hot (non-isothermal) and isothermal crystallization is schematically illustrated
in Figure 1. Hot crystallization proceeds upon a decrease in free volume, and each molecule has a
relatively high conformational flexibility during the crystallization. On the other hand, isothermal
crystallization occurs under almost constant volume, and the molecular motion is more restricted.
Crystallization can only be achieved after overcoming the energetic barrier to structural transformation,
in which noncovalent “weak” interactions play an important role, unlike in inorganic glasses.
Table 1. Features of good glass formers based on small organic molecules.
Chemical-Structural Features Physicochemical Features
Large molecular weight Large melting enthalpy/entropy
Low number of benzene rings High melting temperature
Low symmetry Large crystal/amorphous energy difference
Large number of rotatable bonds Large fragility
High branching degree Large Tg/Tm
Large number of electronegative atoms Large viscosity above Tg
Tg, glass transition temperature; Tm, melting temperature.
Figure 1. Schematic representation of hot (non-isothermal) and isothermal crystallization.
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The following sections review the crystallization tendency of pharmaceutical glasses, with
emphasis on relationship with their chemical structure, remark on its evaluation process, relevance for
glass properties including the storage stability (i.e., isothermal crystallization), relevance to manufacture,
and possible correlation with the supersaturation ability. In addition to discussion on ideal glasses that
can be prepared by melt–quench procedure, the stability of real glasses, which are prepared through
formulation process such as milling, is also discussed.
2. Classification of Crystallization Tendencies
In the field of pharmaceutical sciences, many research groups have evaluated the crystallization
tendency of drug molecules by applying a cooling/reheating cycle to the melt in a differential scanning
calorimetry (DSC) [26,32]. The following classification, as proposed by Taylor et al. [26], is widely
recognized:
Class 1: Compounds that crystallize during cooling from the melt at 20 ◦C/min.
Class 2: Compounds that do not crystallize during cooling from the melt, but crystallize during
subsequent reheating at 10 ◦C/min.
Class 3: Compounds that do not crystallize during the cooling/reheating cycle mentioned above.
Examples are shown in Figure 2. Haloperidol, a Class 1 compound, always crystallizes at
100 ◦C during cooling from the melt, regardless of the cooling rate achievable by conventional DSC
(Figure 2a) [33], which means that crystallization is entirely governed by the temperature. It should be
noted that the crystallization temperature of some Class 1 compounds such as tolbutamide depends
on the cooling rate [33]. Class 1 compounds can be further divided into two groups according to their
crystallization behavior during cooling in liquid nitrogen, whereby compounds that crystallize and
remain amorphous are categorized as Class 1a and Class 1b, respectively [34]. This difference is likely
to be analogous to the dependence of the crystallization temperature on the cooling rate mentioned
above, that is, haloperidol and tolbutamide can be identified as Class 1a and Class 1b compounds,
respectively. In the case of haloperidol, crystallization is inhibited when the melt is cooled at a rate
faster than 100 ◦C/s to produce a mesophase [33]. Acetaminophen, a Class 2 compound, does not
crystallize during cooling, but crystallizes during the subsequent reheating (Figure 2b). Fenofibrate,
a Class 3 compound, does not crystallize during the cooling/reheating cycle (Figure 2c). Tables 2–4
summarizes examples of compounds belonging to each class.
(a) (b) (c) 
Figure 2. Examples of cooling/reheating differential scanning calorimetry (DSC) curves from the
melt: (a) cooling curves of haloperidol (Class 1) at various cooling rates, as indicated in the figure;
(b) cooling/reheating curves of acetaminophen (Class 2); and (c) cooling/reheating curves of fenofibrate
(Class 3).
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Table 2. Examples of Class 1 compounds.
Compounds Mw (Da) Tm (◦C) Tg (◦C) Tg/Tm ΔH (kJ/mol) m Reference
Antipyrin 188 111 −25 0.65 25.2 81 [31]
Anthranilic acid 137 147 5 0.66 22.8 - [26]
Atenolol 266 153 22 0.69 37.5 - [26]
Atovaquone 367 219 - - 33.5 - [35]
Benzamide 121 127 −10 0.66 21.7 - [26]
Benzocaine 165 89 −31 0.67 22.6 - [26]
Caffeine 194 237 72 0.68 20.8 - [26]
Carbamazepine 236 192 61 0.72 25.5 - [26]
Chlorpropamide 277 118 17 0.74 27.4 219 [31]
Chlorzoxazone 170 191 38 0.67 25.6 - [26]
Clofibric acid 215 121 - - 29.0 - [35]
Diflunisal 250 213 - - 35.6 - [35]
Felbinac 212 164 24 0.68 29.8 - [26]
Flufenamic acid 281 135 17 0.71 27.1 78 [26,36]
Griseofulvin 353 218 89 0.74 39.1 74 [26,37]
Haloperidol 376 152 33 0.72 54.3 - [26]
Indoprofen 281 212 50 0.67 36.0 - [26]
Lidocaine 234 68 −39 0.69 16.7 - [26]
Mefenamic acid 241 231 - - 39.4 - [35]
Naproxen 230 157 56 0.77 32.4 - [35,38]
Nepafenac 254 183 - - 42.8 - [35]
Phenacetin 179 136 2 0.67 31.5 - [26]
Piroxicam 331 201 - - 35.6 - [35]
Probenecid 285 199 - - 40.4 - [35]
Saccharin 183 228 - - 29.5 - [35]
Salicylic acid 138 159 - - 24.9 - [35]
Theophylline 180 272 94 0.67 29.6 - [26]
Tolbutamide 270 128 5 0.69 26.2 122 [31]
Tolfenamic acid 262 213 63 0.69 38.8 - [26]
Average 237 172 27 0.69 31.1 115 -
Mw, molecular weight; ΔH, melting enthalpy; m, fragility. Although the fragility can be determined by various
methods, the evaluation based on the temperature dependence of Tg is preferentially employed because it exhibits
the best correlation with the crystallization tendency [31].
Table 3. Examples of Class 2 compounds.
Compounds Mw (Da) Tm (◦C) Tg (◦C) Tg/Tm ΔH (kJ/mol) m Reference
Acetaminophen 151 169 23 0.67 27.2 77 [31]
Bifonazole 310 149 16 0.68 39.2 76 [31]
Celecoxib 381 163 58 0.76 37.4 85 [26]
Cinnarizine 369 120 7 0.71 40.9 84 [31]
Clofoctol 365 88 −4 0.75 35.2 70 [26]
Dibucaine 343 65 −35 0.70 29.2 132 [26]
Droperidol 379 143 29 0.73 40.0 108 [26]
Flurbiprofen 244 115 −5 0.69 27.4 88 [31]
Nifedipine 346 172 46 0.72 38.2 112 [31]
Phenobarbital 233 174 42 0.70 28.7 96 [31]
Phenylbutazone 308 106 −6 0.70 27.6 79 [36]
Tolazamide 311 172 18 0.65 43.4 18 [26]
Average 312 136 16 0.71 34.5 85 -
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Table 4. Examples of Class 3 compounds.
Compounds Mw (Da) Tm (◦C) Tg (◦C) Tg/Tm ΔH (kJ/mol) m Reference
Aceclofenac 354 153 10 0.66 42.3 25 [26]
Clotrimazole 345 141 28 0.73 33.3 63 [31]
Curcumin 368 182 62 0.74 50.1 87 -
Felodipine 384 147 45 0.76 31.0 66 [26]
Fenofibrate 361 80 −19 0.72 33.0 82 [31]
Ibuprofen 206 76 −44 0.66 26.5 75 [31]
Indomethacin 358 161 45 0.73 37.6 85 [31]
Itraconazole 706 168 58 0.75 57.6 731 [26]
Ketoconazole 531 147 44 0.75 52.9 97 [31]
Ketoprofen 254 95 −3 0.73 28.3 67 [31]
Loratadine 383 134 35 0.76 27.3 72 [31]
Miconazole 417 86 1 0.76 32.8 61 [26]
Nilutamide 317 155 33 0.72 31.0 106 [26]
Nimesulide 308 150 21 0.70 33.4 103 [26]
Pimozide 462 219 54 0.66 42.7 170 [26]
Probucol 517 126 27 0.75 39.3 138 [39]
Procaine 236 61 −39 0.70 26.2 90 [31]
Ribavirin 244 168 56 0.75 45.7 70 [40]
Ritonavir 721 122 47 0.81 65.3 86 [31]
Average 393 135 24 0.73 38.8 120 -
Average parameters are also presented in the table for each class of compounds. The molecular
weight shows an increase with increasing classification number, which reflects the importance of
the complexity of the molecular structure. The melting enthalpy also increases with increasing
classification number, which can be explained in terms of the strength of the molecular interactions.
On the other hand, the effect of the melting temperature was opposite to the expectation, while the
effect of the fragility was not clear. However, the effect of the fragility is difficult to evaluate, because
this parameter could not be calculated for most Class 1 compounds. Moreover, the fragility obtained
for chlorpropamide exhibited an unusual value, 219, which significantly influenced the overall average.
Figure 3 visualizes individual data of molecular weight and melting enthalpy of compounds
in each class. Figure 3a clearly shows that all compounds with the molecular weight larger than
400 Da are involved in Class 3, whereas the molecules smaller than 200 Da are not included in Class
3 at all. However, molecular weight was found to be the only parameter that shows some extent
of correlation with the crystallization tendency, if all the data are plotted, as presented in Figure 3.
As an example, Figure 3b shows relationship between the melting enthalpy and crystallization tendency.
Although the averaged values indicated correlation with the crystallization tendency, it is not obviously
statistically meaningful. Other structural/thermodynamic parameters did not exhibit any correlations
with the crystallization tendency, either. Special attention to molecular weight was also made by
Mahlin et al. [24], who found the molecules larger than 300 Da to be good glass formers during
formulation processes. Note that the structural feature of compounds that may be correlated with
the crystallization tendency, as shown in Table 1, has been mainly concluded by observing series of
compounds that have similarity in their chemical structure. When variety of compounds is collected for
examination, focus on single parameter does not seem to be sufficient. The combination of molecular
volume and melting enthalpy was reported to be an excellent predictor of the crystallization tendency
by Wyttenbach et al., based on theoretical considerations centered on the so-called Prigogine–Defay
ratio [35]. In their study, the trend of the Tg/Tm ratio also agreed with the expected trend; interestingly,
the Tg/Tm parameter was also shown to be correlated with the Prigogine–Defay ratio [35,41].
5
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Figure 3. Visualization of: (a) molecular weight; and (b) melting enthalpy of compounds belonging to
each class.
A common strategy to improve biopharmaceutical performance of poorly soluble candidates
includes increase in hydrophilicity, which frequently has trade-off relationship with affinity to
therapeutic targets. However, another approach may be suppression of crystallization tendency based
on the information described in Table 1 to increase applicability of ASD. As noted below, suppression
of crystallization tendency may also be related to increase in supersaturation ability after dissolution.
Further understanding on relationship between chemical structure and crystallization tendency should
increase options of chemical modification strategy of candidate compounds.
Alternatively, the critical cooling rate for achieving vitrification has also been employed for
the classification; for example, compounds that crystallize even at 750 ◦C/min were classified as
Class 1, those with moderate crystallization ability and that can be vitrified at ca. 10–20 ◦C/min
were designated as Class 2, while Class 3 compounds only require a very slow cooling rate, below
2 ◦C/min, for vitrification [38,42]. Despite the different criteria employed, the classifications based on
this methodology agreed well with those in Tables 2–4, except that tolbutamide and cinnarizine were
placed in Classes 2 and 3, respectively [38].
The different behavior of Classes 1 and 2 compounds likely reflects differences in nucleation and
crystal growth temperatures (Figure 4). For Class 1 compounds, the optimum nucleation and crystal
growth temperatures should be close to each other; hence, after reaching an optimum temperature
where both nucleation and crystal growth proceed, the melt can crystallize. This process is expected to
be based on homogeneous nucleation. In contrast, the optimum nucleation temperature for Class 2
compounds should be located far below the optimum crystal growth temperature. Thus, the melt must
be first cooled to the nucleation temperature range and then heated to the crystal growth temperature
for crystallization to proceed. However, if the cooling rate is sufficiently slow, there is a finite chance
for nucleation to occur at the optimum crystal growth temperature even though the nucleation rate is
very low, which could explain the similar classifications produced by the two methods.
Figure 4. Schematic representation of the temperature dependence of the nucleation and crystal growth
temperatures for Classes 1 and 2 compounds.
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Figure 5 shows reheating DSC curves of celecoxib melt, illustrating the dependence of the cold
crystallization on the target temperature of the cooling process [43]. When the melt was cooled down
to −20 ◦C, a crystallization exotherm was observed during the subsequent heating process. However,
no crystallization was observed when the melt was cooled down to 30 ◦C, although celecoxib is known
as a Class 2 compound. Our investigation revealed that the optimum nucleation temperature of
celecoxib was ca. −50 ◦C; thus, cooling to 30 ◦C was obviously not enough for inducing nucleation.
In the classification criteria discussed above, the minimum temperature of the cooling process is not
specified. However, a poor understanding of the nucleation process may result in the misclassification
of a particular compound.
 
Figure 5. Reheating DSC curves of celecoxib melt, illustrating the dependence of the cold crystallization
on the target temperature of the cooling process (shown in the figure).
The different behavior of Classes 2 and 3 compounds is likely due to the different strength of their
molecular interactions. Thus, the presence of neighboring molecules during the crystallization cannot
be ignored, and the crystallization is based on heterogeneous nucleation.
3. Relationship between Crystallization Tendency and Isothermal Crystallization
The crystallization tendency discussed above does not directly correlate with the physical stability
under isothermal conditions. However, these two processes do have some indirect relationships.
Figure 6 shows the time to reach 10% crystallinity (t10, expressed in minutes) for pharmaceutical
glasses as a function of Tg/T, where T is the storage temperature [44]. These data were acquired for
quenched glass pellets under dry conditions. Crystallization has frequently been observed to start at the
surface [45,46]. Since the pellets have a very small surface area, the surface effects on the crystallization
were almost eliminated in this experiment. Clearly, the data corresponding to most compounds fell on
a universal line; in particular, the compounds located on the line belonged to Classes 1 and 2. The other
compounds, which exhibited better stability especially above Tg, belonged to Class 3.
The above data were obtained by fitting the crystallinity value at each time point to the
Avrami–Erofeev equation. The obtained Avrami exponents are shown in Table 5 Smaller Avrami
exponents were obtained for higher classification numbers, which indicates that the nucleation
mechanism becomes more homogeneous with decreasing classification number. This hypothesis is
also supported by a previous in-situ analysis of the isothermal crystallization process of tolbutamide
and acetaminophen using synchrotron X-ray diffraction [44].
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Figure 6. Initiation time of crystallization (t10, min) as a function of Tg/T. The q and FD labels in
the parentheses indicate that the glass was prepared by quenching and freeze-drying, respectively.
The numbers in parentheses denote the crystallization tendency classification. The universal line is the
best fit for Classes 1 and 2 compounds (ln(t10) = 66.2Tg/T − 57.0).
Table 5. Ranges of Avrami exponents for isothermal crystallization.












The crystallization of some glasses was observed to start at the surface. In the case of indomethacin,
crystallization is enhanced with decreasing particle size, which is most likely due to the increasing
surface area [45]. Moreover, the crystallization of indomethacin glass particles is retarded by a polymer
coating of the surface [46]. Quenched ritonavir glass exhibited higher stability relative to that of the
compounds located on the universal line in Figure 6. However, the stability of freeze-dried ritonavir
glass could be explained by the universal line, which is likely due to the increase in surface area [47].
The lower packing of the glass structure might also partially contribute to eliminate the effect of
molecular interactions. The surface effects are usually explained in terms of the higher mobility of
surface molecules [48], due to a decreased number of nearest neighbor molecules [49].
The results in Figure 6 suggest that the physical stability of Classes 1 and 2 compounds was
strongly affected by the temperature. In these cases, physical stabilization of the glasses appears
difficult to achieve without adding excipients. However, as the crystallization of Class 3 compounds
is influenced by molecular interactions, physical stabilization of these systems may be achieved by
manipulating these interactions. In fact, quenched ritonavir glass had higher stability compared to
that of the freeze-dried glass, as discussed above.
Sub-Tg annealing based on this strategy was found to be an effective strategy for stabilizing
ritonavir glass [50]. For example, ritonavir glass annealed at 40 ◦C for two days was much more
8
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stable compared to fresh glass. The fresh glass reached a crystallinity of 58% after annealing at 60 ◦C
for six days, whereas the glass pre-annealed at 40 ◦C reached a crystallinity of only 8% after the
same annealing procedure at 60 ◦C. Structural analysis revealed a change in the packing volume and
hydrogen-bonding pattern during the pre-annealing at 40 ◦C, which was the most likely source of the
stabilization. Such pre-annealing strategy did not work for Classes 1 and 2 compounds [50].
4. Non-Ideal Crystallization of Practical Glasses
The discussion presented above is based on observation under well-defined conditions, where
effect of mechanical stress, moisture sorption, and surface area were minimized. Crystallization
behavior of practical glasses, especially in the case of powder samples, may not be explained in such
an ideal manner. Glasses prepared by grinding typically exhibit lower stability than the intact ones
most likely because of remaining nuclei and/or small crystals that cannot be detected by X-ray powder
diffraction. In the observation of Crowley et al. [51], crystallization behavior of indomethacin glasses
prepared by cryogenic grinding of various crystal forms depended on the initial crystal form used,
suggesting that the ground glasses remembered their original forms even after the grinding. In their
study, they also observed significant differences in the crystallization rates of ground and quenched
glasses. Thus, although grinding is a simple process to prepare amorphous form in a laboratory
scale, it is not recommended because of difficulty in transformation into the amorphous state in a
molecular level.
Even for melt–quenched glasses, application of subsequent grinding process can accelerate
crystallization [52]. Moreover, very weak stresses such as crack formation [53] and transfer to different
vessels [52] are also suspected as causes of nucleation. Figure 7 shows comparison of crystallization
behavior of melt–quenched indomethacin glasses at 30 ◦C with or without grinding process before
the storage. In the absence of the grinding process, the quenched glass remained completely in
an amorphous state for more than one month. However, if the grinding process is applied for the
melt–quenched glass, crystallization is initiated within one day. This comparison clearly indicates
significant effect of the grinding process on the crystallization behavior, which appeared to be due to
increase in the surface area and mechanical stress. It is also interesting to note that the crystal form
obtained was not identical in these examples. Since no relevance between the preparation process and
crystal form could be found, it might be because of difference in impurity profiles.
Figure 7. Isothermal crystallization of indomethacin glasses at 30 ◦C under dried condition.
() Quenched and ground for 6 min. Crystallized to form γ [51]. () Quenched and ground.
Crystallized to form α except that symbols with asterisk involves small amount of form γ [54].
() Quenched and cryoground. Crystallized to mixture of form α and γ (our data). () Quenched.
Crystallized to form γ [55]. () Quenched and stored in DSC pan (our data). Crystallized to form α
which contains small amount of form γ.
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Crystallization of nifedipine is very sensitive to various factors including moisture sorption and
mechanical stress. Thus, extensive care is required to investigate the ideal crystallization behavior as
presented in Figure 6. In our experiments, crystalline powder was dried in a vacuum oven at 50 ◦C and
stored in a desiccator with silica gel before use. Then, the dried powder was loaded in a hermetically
sealed pan under flow of dried nitrogen air, and subjected to the melt–quench procedure to initiate the
stability study. Only after such careful treatment, the data which could be explained by the universal
line were obtained.
Therefore, the data for nifedipine crystallization found in literature are usually faster than the
expectation from the universal line. Figure 8 shows onset crystallization time of nifedipine glasses
extracted from various literature sources. As already presented in Figure 6, the nifedipine data
obtained after the careful treatment mentioned above were explainable by the universal line. However,
the crystallization was much faster for the glasses loaded in normal sealed pans without pretreatment.
Observation using polarized light microscopy by Bhugra et al. was done in a very careful manner [56],
where cracked glasses were eliminated from the analysis, because it can enhance the crystallization.
However, the crystallization was much faster, presumably because the glasses could not be shielded
from outer atmosphere completely.
 
Figure 8. Onset crystallization time (to, min) of nifedipine glass as a function of Tg/T. () After the
pretreatment (see text), quenched in hermetically sealed pan (our data) [44]. () Quenched in sealed
DSC pan without pretreatment (our data). () Quenched in DSC pan [57]. () Quenched on glass slides
and crystallization was observed by polarized light microscopy [56]. Cracked glasses were excluded
from the analysis. ( ) Quenched in DSC pan [58]. All the literature data were recalculated using the Tg
value of 45.5 ◦C. Definition of onset crystallization time, which is analogous to t10, is slightly different
depending on literature, but its impact is ignorable in the analysis here.
Compression process is also recognized to affect the crystallization kinetics. Figure 9 shows
effect of compression pressure on crystallization of sucrose glass investigated by isothermal
microcalorimetry [59]. Initiation time for crystallization was rarely influenced below 0.5 MPa; however,
crystal growth was enhanced with increasing pressure. It was shortened at 2.5 MPa, suggesting
that condensation of glass structure can enhance nucleation after application of such relatively weak
compression force. Similarly, Ayenew et al. reported that cold crystallization of indomethacin glass was
enhanced by compression at ca. 43.7 MPa [60]. In their study, uncompressed glass, which was prepared
by cooling the melt at 0.2 ◦C/min, was observed to crystallize at 121.4 ◦C during subsequent reheating
at 5 ◦C/min. However, it decreased to 114.1, 113.1, and 112.7 ◦C, if the compression was applied for
1 s, 2.5 min, or 5 min, respectively. Rams-Baron et al. observed that isothermal crystallization of
etoricoxib was significantly enhanced after compression at 300 MPa; however, it could be prevented
by mixing with polyvinylpyrroridone (PVP), where investigations were done under the identical
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relaxation time conditions [61]. This result indicated that physical barrier by excipients were very
effective for inhibiting pressure-induced nucleation.
Based on the universal line, the only requirement for assuring three-year stability of pharmaceutical
glasses at 25 ◦C is the Tg higher than 48 ◦C [44]. Its applicability to practical glasses which are produced
under various mechanical stresses without protection from outer atmosphere is discussed next.
 
Figure 9. Effect of compression pressure on crystallization heat flow curves of sucrose glasses
investigated by isothermal microcalorimetry (30 ◦C). Freeze-dried sucrose was compressed at pressure
of ca. 2.5 MPa (black), 0.5 MPa (red), or 0.1 MPa (blue) for 10 s and subjected to the measurement.
5. Relevance to Formulation Research
Practical ASDs cannot be manufactured by the melt–quenching procedure. The crystallization
tendency during practical formulation processes is also of great interest to formulators. This is similar
but different phenomena from the crystallization from the melt; therefore, some attempts have been
made to find relevance between them. The tendency to crystallize from solution after drying is of
great importance for evaluating applicability of spray-drying. Eerdenbrugh et al. investigated the
crystallization of 51 compounds after removal of the solvent by spin coating, in order to identify
possible correlations between the crystallization tendencies evaluated by thermal analysis upon
cooling/reheating and during drying from solutions [62]. In their analysis, the compounds that
exhibited a tendency to crystallize immediately after spin coating were denoted as Class 1, those
that crystallized within one week were categorized as Class 2, and the remaining compounds were
regarded as Class 3. Approximately 76% of the compounds classified as Class 1 by DSC were also
assigned to Class 1 by the spin coating method, whereas 76% of the compounds classified as Class 3 by
DSC were again classified in the same group by the spin coating approach. The Tg values seemed to
break the correlation between the two classification methods.
The relevance to vitrification during milling has also been studied. Blaabjerg et al. reported
minimum milling times to achieve vitrification as 90 and 270 min for Classes 3 and 2 compounds,
respectively, whereas no vitrification was achieved for any of the Class 1 compounds [42]. It should be
noted that some Classes 2 and 3 compounds failed to form amorphous systems, most likely due to
their low Tg. This observation suggests that the crystallization tendency from the melt can be used to
guide the design of hot-melt extrusion processes, along with additional information on the Tg values.
Thus, applicability of ASD technology to poorly soluble candidates may be judged from the
crystallization tendency determined by DSC with the information on Tg. In the formulations,
polymeric excipients are used for two purposes: physical stabilization and improvement of
dissolution/supersaturation behaviors [12]. Class 3 compounds can be expected to be transformed
into the amorphous state using typical formulation processes for ASDs even without excipients. Main
purposes of addition of polymeric excipients in the ASD design are to raise Tg for ensuring storage
stability and to improve dissolution behavior. Amount of excipient may be kept small for these
compounds. Even if amount of the drug exceeds solid solubility limit, the drug is expected to remain in
the amorphous state [63]. In contrast, Class 1 compounds must be completely mixed with excipients in
11
Pharmaceutics 2019, 11, 202
a molecular level for the successful transformation to the amorphous state. The amounts of excipients
are expected to be larger compared to that for Class 3 compounds. Typically, solid solubility of drug
in polymeric matrix under ambient temperature is below 30%, sometimes below 10%, depending on
combination of drug and excipient [21–23]. Moreover, it is frequently observed that the effective polymer
for physical stabilization and dissolution improvement is different. Hydroxypropyl methylcellulose
acetate succinate frequently offers great effect for maintaining high level of supersaturation; however, its
miscibility with drug is typically low. In contrast, PVP and its derivatives have relatively high miscibility
with drug, but its supersaturation effect cannot be maintained for long duration in many cases. It must
be recognized as well that prepared ASDs are not necessarily in the equilibrium state. If ASDs are
prepared under an elevated temperature condition, as in case of hot-melt extrusion, the mixing state at
this temperature may be kinetically frozen even after cooling to ambient temperature. In spray-drying,
the drug and excipient molecules may be separated based on the difference in their molecular weights,
because diffusion rate during evaporation process is different [64,65]. This kinetically-separated
structure may also be frozen after the drying [65,66]. If solvents are used during the preparation, as in
the cases of spray-drying and coprecipitation, the mixing state of the ASDs is affected by the solvent
species [67]. In such cases, the mixing state may change with time [23].
How the universal line in Figure 6 is applicable to multi-component ASDs is of great interest.
Figure 10 shows comparison of the onset crystallization time of single phase ASDs appearing in the
literature. As an overall trend, the universal line seems to work even for the multicomponent systems.
Comparison of nifedipine/PVP ASDs from three different stuides implies that milling enhances the
nucleation. However, presence of polymeric excipients appears to stabilize the ASDs more than
expected from change in Tg (i.e., molecular mobility), most likely because of dilution effect and
interaction with drug. The result for Sanofi–Aventis compounds is the most informative from a
practical point of view, because the ASD was prepared by spray-drying. Stability of this ASD is a little
lower but roughly agrees with the universal line regardless of absence/presence of the moisture. When
each dataset is fitted with a regression line, their slopes are almost the same, suggesting that activation
energy for nucleation does not significantly depend on the type of ASDs. Design of accelerated physical
stability test may be possible for ASDs based on this information.
 
Figure 10. Onset crystallization time (to, min) of various ASDs as a function of Tg/T.
( , ,) Nifedipine/PVP ASDs prepared by melt–quench [68,69] followed by milling [58],
respectively. (, ) Phenobarbital/PVP ASDs prepared by melt–quench [68,69]. (,) Sanofi–Aventis
compound/HPMCP ASDs prepared by spray-drying stored under dried and humid conditions,
respectively [70]. Definition of onset crystallization time, which is analogous to t10, is slightly different
depending on the study, but its impact is ignorable in the analysis here. HPMCP, Hydroxypropyl
methylcellulose phthalate.
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6. Relevance to the Dissolution Benefits of ASDs
The greatest advantage of ASDs is that they can achieve supersaturation of poorly soluble drugs.
Supersaturation can be maintained unless crystallization occurs in aqueous environments [71]. Thus,
it is important to understand the controlling factors that cause crystallization of pharmaceutical glasses
in aqueous media. Our preliminary investigation revealed that crystallization proceeds immediately
above Tg of the solid [33]. Blaabjerg et al. reported that the degree of supersaturation tended to
be high for good glass formers, but no correlation was found between crystallization tendency and
supersaturation lifetime [72]. We have shown that amount of orally absorbed fenofibrate was correlated
with liquid–liquid phase separation concentration, which is analogous to degree of supersaturation, if
the oral absorption was limited by solubility [13]. Thus, suppression of the crystallization tendency can
be an option of chemical modification of the poorly soluble candidates instead of increasing aqueous
solubility. Alhalaweh analyzed the relationship between the crystallization tendencies from the melt
and those in solution, highlighting the need to consider structural factors to improve the correlation
between these tendencies [73]. From the viewpoints of physical stability and supersaturation ability,
Class 3 compounds seem to be suitable candidates for ASDs. In fact, most of the marketed ASDs
consist of Class 3 compounds [74].
7. Summary
This review provides the classification of the crystallization tendencies of pharmaceutical
compounds, focusing on its relevance for the glass properties. Possible relationships discussed in this
review are summarized in Table 6. In addition to its effectiveness for describing the physical stabilities
of ASDs, this classification provides important insights into the glass properties. The investigation of
the crystallization mechanism of small organic compounds is an attractive subject because of their
structural diversity and complicated molecular interactions, in contrast to the inorganic compounds
that have dominated the field of glass science so far. Further progress in this field can make a significant
contribution to both basic glass science and practical developmental studies of pharmaceutical products.
Table 6. Relevance of crystallization tendency classification for glass properties.
With increasing classification number:
• Nucleation becomes more heterogeneous
• The nucleation barrier becomes larger
• Surface effects become more important
• Vitrification during the formulation processes may become easier
• The supersaturation ability may increase
• The universal line in Figure 6 is applicable for Class 1 and 2 compounds, whereas the stability of Class 3
compounds may be better
• Stabilization may be achieved via thermal treatment
Preparation of practical formulations involves some procedure to enhance nucleation. Ideality of
the nucleation/crystallization behavior is destroyed by application of some activation processes such
as milling. However, presence of polymeric excipients can contribute to stabilization, presumably due
to dilution effect and its interaction with drug molecules. As a result, deviation from the ideal behavior
due to formulation processes is suppressed for enabling rough prediction of the crystallization time.
Design of accelerated physical stability test may be possible for ASDs based on this observation.
Although compounds in any classes can be formulated as ASDs, Class 3 compounds obviously
have the highest applicability. In addition to their high physical stability, they may have an advantage
in supersaturation ability that has great contribution to enhanced absorption. Therefore, chemical
modification to decrease crystallization tendency may be considered as an option for drug design
instead of increasing solubility.
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Abstract: The development of stable solid dispersion formulations that maintain desired improvement
of drug dissolution rate during the entire shelf life requires the analysis of drug-polymer solubility
and miscibility. Only if the drug concentration is below the solubility limit in the polymer, the physical
stability of solid dispersions is guaranteed without risk for drug (re)crystallization. If the drug
concentration is above the solubility, but below the miscibility limit, the system is stabilized through
intimate drug-polymer mixing, with additional kinetic stabilization if stored sufficiently below
the mixture glass transition temperature. Therefore, it is of particular importance to assess the
drug-polymer solubility and miscibility, to select suitable formulation (a type of polymer and drug
loading), manufacturing process, and storage conditions, with the aim to ensure physical stability
during the product shelf life. Drug-polymer solubility and miscibility can be assessed using analytical
methods, which can detect whether the system is single-phase or not. Thermodynamic modeling
enables a mechanistic understanding of drug-polymer solubility and miscibility and identification of
formulation compositions with the expected formation of the stable single-phase system. Advance
molecular modeling and simulation techniques enable getting insight into interactions between the
drug and polymer at the molecular level, which determine whether the single-phase system formation
will occur or not.
Keywords: solid dispersions; miscibility; solubility; thermodynamic modeling; phase diagram;
molecular dynamics simulation; thermal analysis; spectroscopic techniques
1. Introduction
Rise in the number of poorly soluble drugs is accompanied by simultaneous progress in the
development of techniques for improving solubility and bioavailability of these drugs, which include but
are not limited to: formation of salts and soluble prodrugs, particle size reduction up to nano-size range,
using of cosolvents or surfactants in the formulation, complexation with cyclodextrins, formulation
of micro or nanoemulsions, and solid dispersions. Solid dispersions, as systems where the drug
is dispersed within the polymeric matrix in the crystalline or amorphous state, or dissolved in the
polymeric matrix, have been proved to be one of the most successful approaches for overcoming drugs’
poor solubility and bioavailability [1–6]. Even though since the introduction of solid dispersions in 1961,
by Sekiguchi and Obi [7], thousands of studies have proved their benefits, both in vitro and in vivo,
only a few such formulations have appeared on the market up to date. One of the main reasons for this
is certainly the difficulty of ensuring long-term product stability due to phase separation between the
Pharmaceutics 2019, 11, 372; doi:10.3390/pharmaceutics11080372 www.mdpi.com/journal/pharmaceutics18
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drug and the polymer and/or drug recrystallization from the initial amorphous form that can cause
unacceptable variations in drug dissolution rate and oral bioavailability. It has been well established
that apart from differentiation whether the drug is present in the crystalline or amorphous form within
the polymeric matrix, it should be determined whether the drug forms single-phase system with
amorphous polymer or system separates into drug-rich and polymer-rich phases. It has been shown
that the maximum improvement of drug dissolution rate and maintenance of long-term formulation
stability are achieved if the formation of a single-phase system occurs [8,9]. Otherwise, if the phase
separation occurs, properties of pure components will dominate in the respective phases, and polymer
effect on inhibition of drug molecular mobility and reduction of driving force for crystallization will
be diminished. Additionally, separation into drug-rich and polymer-rich phases will lead to the
fast dissolution of the polymer phase leaving undissolved drug phase [10,11]. Currently available
analytical techniques can distinguish between drug and polymer domains of different size, but only at
the moment of analysis, which does not guarantee that initially single-phase system will maintain
this structure during the whole storage period. Also, direct measurement of drug-polymer miscibility
or solubility of the drug in the polymer is challenging due to the high viscosity of polymers below
glass transition temperature (Tg), which makes it difficult to achieve equilibrium in the drug-polymer
system in the glassy state [12,13]. Only in the last 10 years, it has been recognized that the evaluation of
thermodynamics of drug-polymer mixing should be included in the rational design of solid dispersion
formulations. Thermodynamic models, initially developed for polymer-polymer and polymer-solvent
systems, have been successfully adapted to drug-polymer systems and showed the good prediction of
drug-polymer miscibility and solubility of the drug in the polymeric matrix [8,11,14–20]. Although the
terms solubility and miscibility are sometimes used with confusion, they can be distinguished, since
the term solubility describes the ability of a polymer to dissolve a crystalline drug, while miscibility
describes the ability of an amorphous drug to mix with an amorphous polymer giving a single-phase
system [11,12]. Although only below the drug solubility limit in the polymer, solid dispersion systems
are stable without any concern for drug crystallization, the low solubility of most drugs in the common
polymers limits formulation of solid solutions only to very low dose drugs. Therefore, particular
efforts are invested to estimate the miscibility of the drug with the polymer, which is always greater
than the drug solubility in particular polymer, and below miscibility limit, only large temperature
and/or composition fluctuations can destabilize system toward drug crystallization. Thermodynamic
modeling allows estimation of the free energy of mixing between the drug and the polymer, with
regards to formulation composition and temperature, i.e., whether mixing between the drug and
polymer is spontaneous or not at a particular drug:polymer ratio and temperature. This approach,
based on well-known Florry-Huggins theory [21], allows construction of temperature-composition
phase diagrams, which separates stable, metastable, and unstable regions and helps formulation
scientists to choose appropriate formulation compositions and processing conditions during solid
dispersions preparation. Apart from the estimation of formulation stability, usage of thermodynamic
modeling is particularly beneficial in the early stages of formulation development, when a limited
amount of material is available, since totally immiscible formulations can be rejected at this stage,
saving both materials and time. In this review, we have given an overview of the currently available
methodology for the estimation of miscibility between the drug and polymer as well as solubility of
the drug in the polymer. Although in the text, methods are separated into analytical methods and
computational methods (based on thermodynamic modeling and molecular modeling and simulations),
one should be aware that estimation of the drug-polymer miscibility and the solubility of the drug in
the polymer is a complex problem, requiring multi-methodological approach.
2. Analytical Techniques for the Assessment of Drug-Polymer Solubility/Miscibility
Once a solid dispersion system is formed, the solid-state characterization is performed using
various techniques to estimate the physical state of the drug and/or potential interactions, which can
be attributed to the miscibility, with the selected polymers. In the case of the well-mixed system, only
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one phase exists since the system components (i.e., drug and the polymer) are intimately mixed at the
molecular level. On the other hand, the presence of at least two different phases shows that components
are immiscible. These differences are reflected in the physical properties and can be analyzed using a
variety of analytical techniques for solid-state characterization.
2.1. Thermal Techniques
Thermal characterization, using Differential Scanning Calorimetry (DSC) or
Modulated-temperature Differential Scanning Calorimetry (M-DSC), is used to determine the
solid-state of the drug and possible drug-polymer interactions in the prepared solid dispersions.
M-DSC enables determination of both the specific heat capacity and the heat flow data from a
kinetically controlled process [22]. Polymers used for the preparation of the solid dispersions are
usually amorphous and thermoplastic with specific glass transition temperatures (Tg). If the selected
drug is crystalline, it usually preserves this state in physical mixtures with the polymer, which is
evident on the DSC thermogram of the physical mixture as sharp endothermic peak(s), corresponding
to the drug melting point. However, the absence of drug-specific endothermic melting peak(s) may
suggest either that the drug is present in the solid dispersion in its amorphous state (drug forms
single-phase or multi-phase system with polymer), or it is solubilized during DSC analysis by the
polymer (or other excipients) used for the preparation of solid dispersions. Furthermore, shifts in
the polymer Tg may also occur, which is also indicative of molecular interactions between the drug
and the polymer [23]. Since solid dispersions, with miscible drug and polymer, create a single-phase
amorphous system, single Tg peak is considered as the marker of the miscible drug-polymer
system [24]. When the two components are miscible, the single Tg of the formed solid dispersion lies
between the Tgs of the individual components [25].
Melting point depression is one of the most common analytical methods for the assessment of the
drug and polymer miscibility. The changes in the onset of the melting endotherm or the drug melting
enthalpy are monitored as a function of the polymer amount in the prepared solid dispersions. In
the case of the miscible system, a decrease in the drug melting point(s) and/or enthalpies is expected
with the increase of the polymer amount. If the DSC scan represents separate glass transition points,
Tg, specific of the drug and the polymer, it is an indication that the prepared solid dispersions do not
constitute a miscible system, i.e., two individual phases are present [23]. Therefore, immiscibility is
usually manifested as the phase separation, i.e., the existence of crystalline or amorphous domains
within the polymer or two separated amorphous domains. There may also be a gradient of drug
concentrations in different regions of the dispersion [26].
Several different approaches have been established to estimate Tg of drug-polymer mixtures based
on the known mixture composition. Certainly, the most widely used equation for the estimation of
mixture Tg (Tgmix) is the Gordon-Taylor equation [27]:
Tmixg =
w1Tg1 + K w2Tg2
w1 + K w2
(1)
where w and Tg are weight fraction and glass transition temperature of each component, respectively,
while subscripts 1 and 2 represent components with the lowest and the highest Tg, respectively.
Constant K is originally defined as a parameter whose value depends on the change of thermal
expansion coefficient of the components upon their transformation from glassy to the rubbery state





where ρ1 and Tg1 are the density and the glass transition temperature of the amorphous component
with the lowest Tg, respectively, and ρ2 and Tg2 are the density and glass transition temperature of
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the amorphous component with the highest Tg, respectively. Couchman and Karasz [29] proposed a
thermodynamic model to predict the Tg of mixtures:
ln Tgmix =
w1ΔCp1ln Tg1 + w2ΔCp2ln Tg2
w1ΔCp1 + w2ΔCp2
(3)
where ΔCp is a change in heat capacity of the component between liquid-like and glassy state. Another










When using these theoretical approaches to predict mixture Tg, one should be aware of some inherent
limitations of these methods. These approaches assume the absence of specific interactions between
components (i.e., ideal mixing behavior is assumed), ideal volume additivity of the components at Tg,
and linear change in volume with temperature [31,32]. Therefore, the presence of interactions between
components will result in deviations between experimentally observed Tg of the mixture and those
predicted by previously described models. Negative deviation of experimental Tg from predicted
one can indicate that cohesive interactions between individual components are more pronounced
than adhesive drug-polymer interactions, as observed for indomethacin-polyvinylpyrrolidone
(PVP) system [33,34]. Positive deviation of experimental Tg from predicted one indicates that
drug-polymer interactions are stronger than drug-drug and polymer-polymer interactions. This
effect has been observed for numerous solid dispersion systems, such as indomethacin-Eudragit®
E [34,35], lapatinib-hydroxypropylmethylcellulose phthalate (HPMCP) [36], nimodipine-PVP [37].
However, the presence of positive or negative deviations of experimental from predicted Tg is not a
reliable indicator whether adhesive or cohesive interactions are predominant. This is demonstrated for
curcumin-hydroxypropylmethylcellulose (HPMC) solid dispersions, where the negative deviation
of experimental Tg from predicted one is observed, even though the presence of drug-polymer
intermolecular interactions is proved by FT-IR spectroscopy [38]. An additional limitation of the
presented models is that they do not take into account entropic contribution to the drug-polymer
mixing. It should be also noted that the chosen experimental conditions can influence the measured
values of Tg. Gordon-Taylor equation has been adapted for ternary solid dispersions (Equation (5));
however, above-mentioned basic assumptions of this model significantly limit its application for
ternary systems, making difficult to draw any conclusions from the obtained results:
Tmixg =
w1Tg1 + K1w2Tg2 + K2w3Tg3










It has been reported that some microstructural phase separations could not be detected by the
DSC method due to its resolution limitation (~30 nm) [39]. If the drug and the polymer have similar Tg
values, then it is also difficult to estimate their miscibility using DSC studies [26]. Another limitation of
the conventional DSC analysis is the fact that the drug may dissolve in the molten polymeric material
below its melting point, which may be mistakenly considered as solubility/miscibility [40]. If the
crystalline drug dissolves in the molten polymer during heating, it is better to use fast DSC analysis
(such as M-DSC) because higher heating rates may hinder the drug dissolution process [26]. Fule and
Amin [41] used M-DSC studies to investigate whether the absence of drug melting endotherm in the
DSC scan is a consequence of the presence of drug amorphous form, or drug dissolution within the
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molten excipients during DSC scan. They demonstrate that the endothermic peak, corresponding to
the melting of crystalline drug, broadens during the first heating cycle and disappears in the second
heating cycle of M-DSC analysis. On the other hand, melting peak of the drug is absent on the DSC
thermogram since the crystalline drug gradually dissolves in the molten polymers during conventional
DSC heating process, giving false evidence of the presence of amorphous drug [41]. Tao et al. [13]
have used slow heating rates for DSC measurements and extrapolated the temperature of the final
dissolution of the crystalline drug to zero heating rate to determine the solubility of the small molecule
crystalline drugs in the polymer. If mixture containing known composition of the crystalline drug (x) is
heated, the broad endothermic peak occurs due to the drug dissolution, and the drug solubility in the
polymer is defined as x at the end temperature of drug dissolution (Tend). Specifically, cryogenic milling
is used for sample preparation to ensure uniform mixing and facilitate determination of dissolution
endpoint. However, even at a low heating rate (0.1 ◦C/min), the available time during DSC analysis
may not be sufficient to reach equilibrium (i.e., Tend is higher than equilibrium solution temperature),
and solubility of the drug in the polymeric matrix may be underestimated. This problem is particularly
pronounced at temperatures close to Tg, due to high polymer viscosity, which causes the time for
reaching equilibrium to be much higher, compared to the timescale of the DSC scan. Therefore, this
method was further refined by Sun et al. [42] who proposed a method where the drug-polymer mixture
is annealed during 4–10 h near an equilibrium solution temperature followed by the scan at standard
scanning speed (10 ◦C/min) to detect the presence of undissolved drug crystals. If the annealing
temperature is lower than the equilibrium solution temperature, the melting endotherm will appear in
the heating scan due to the presence of undissolved crystals. By annealing at different temperatures,
boundaries of equilibrium solution temperature can be determined. Although this method enables
determination of solubility at a temperature closer to Tg and improves sensitivity to detect residual
drug crystals, it is still considerably time-consuming and requires several experiments for only one
point in the solubility plot. The method proposed by Mahieu et al. [43] is based on the generation of the
supersaturated solid solution of drug in polymer and further induction of demixing by annealing above
Tg. The equilibrium concentration of a dissolved drug is subsequently determined by measuring Tg of
the annealed mixture and further calculation from Gordon-Taylor equation (Equation (1)), which gives
the relationship between Tg of the mixture and mixture composition. This method is much faster, since
the demixing process is faster than dissolution, due to enhanced mobility in the supersaturated system
caused by plasticization effect of drug molecules, and only one experiment is required to generate one
point in the drug-polymer solubility plot. Schematic drawing of methods for the determination of
drug solubility in the polymer, described in the references [13], [42], and [43] is given in Figure 1. Tian
et al. [44] recently proposed an improved method for the determination of equilibrium drug solubility
within the polymeric matrix and the determination of the solid-liquid transition curve. In this method,
a mixture of drug and polymer is firstly undergone to hot-melt extrusion and then subject to isothermal
annealing at elevated temperatures (above Tg of polymer and below the melting temperature (Tm) of
the drug) during 24 h. High-speed DSC (Hyper DSC) analysis with a heating rate of 200 ◦C/min is used
to detect the presence of undissolved drug crystals remained after sample annealing. This method
should provide a more reliable determination of drug solubility within the polymer as long annealing
process provides sufficient time for dissolution of drug crystals and overcoming of high polymer
viscosity, which can delay completion of drug dissolution. High heating rate after sample annealing
provides greater sensitivity to detect melting endotherm of remaining drug crystals, compared to usual
DSC heating rates (1–10 ◦C/min), with the lower possibility that drug crystal will dissolve during DSC
scan, leading to overestimation of drug equilibrium solubility in the polymer [44].
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Figure 1. Schematic drawing of methods for the determination of drug solubility in polymer described
by (A) Tao et al. [13], (B) Sun et al. [42], and (C) Mahieu et al. [43] (T—temperature, Tg—glass transition
temperature, Tend—end temperature of drug dissolution, Tm—melting temperature).
Thermally stimulated depolarization current (TSDC) is a method for measurement of dielectric
properties through thermally stimulated depolarization of materials molecules. This technique can
also be used to study the miscibility of the drug and the selected polymer [45]. Shmeis et al. [46] have
compared TSDC and DSC for the assessment of the miscibility of the novel drug substance and PVP
and demonstrated the superiority of the TSDC method. At higher drug loads, the saturation level of
the drug within the polymer has been only possible to be detected by the TSDC method of analysis.
2.2. Spectroscopic Techniques
Apart from the thermal methods, miscibility within the solid dispersions is often analyzed by
spectroscopic techniques. Fourier Transform Infrared (FT-IR) Spectroscopy can be used to study
specific interactions between the polymer and the drug functional groups. Hydrogen bonding is
a predominant mechanism for the stabilization of the miscible drug-polymer systems. When such
bonds are formed, subtle changes in the FT-IR spectra are visible [23]. IR spectroscopy with principal
component analysis can be utilized to verify drug-polymer mixing at the molecular level [47].
Taylor and Zografi [33] have criticized the traditional approach where the spectra of the pure
crystalline drug and solid dispersion are compared to assess changes in the crystallinity of the drug
and potential for miscibility with the polymer. More detailed studies on the amorphous structures
should be performed, using the spectra of the amorphous form of the drug as the reference [33].
Solid-State Nuclear Magnetic Resonance (SSNMR) spectroscopy is often employed for structural
analysis and the assessment of interactions between the molecules. 1H-NMR spin-lattice relaxation
measurements can be used for the assessment of the drug-polymer miscibility [48]. The main benefit
of this technique is that it can detect phase-separated domains with size below the detection limit
of DSC. The miscibility of the drug-polymer and size of the phase-separated domains are estimated
23
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based on the spin-lattice relaxation times in the laboratory (1H T1) and rotating frames (1H T1ρ). In the
phase-separated system, protons in each phase will have their relaxation times, so individual relaxation
times of drug and polymer will be observed. On the other hand, in a single-phase system, spin diffusion
should average individual relaxations, resulting in uniform average relaxation time, different from
relaxation time measured for pure components [36,49,50]. Single 1H T1 in the drug-polymer system
indicates miscibility down to 20–50 nm domain size, while single 1H T1ρ indicates miscibility with
domain size below 5 nm [51]. Formation of single-phase solid dispersions with indomethacin and
Eudragit® E, with drug loading up to ~50%, has been shown based on similar 1H T1 and 1H T1ρ values
for the drug and polymer [50]. Miscibility of the selected drug (nifedipine) and polymers (PVP and
HPMC) is appointed by mono-exponential spin-lattice relaxation decay for measurements of solid
dispersions in the rotating frame [48]. Geppi et al. [52] have used several high-resolution solid-state
NMR techniques to confirm the miscibility of ibuprofen and Eudragit® L100 and the chemical nature
of their interactions. Phase separation, which is indicative of the immiscible system, has been also
assessed by NMR relaxometry study [26].
X-ray Photon Spectroscopy (XPS) is an advanced surface analysis technique, which can also
be used to assess the magnitude of the intermolecular interactions between the drug and polymer,
which are indicative of the miscibility within the system [24]. Due to the drug-polymer interactions
in the obtained spectra, new peaks are formed, and several bond peaks are shifted. It has been
demonstrated that drug-polymer interactions observed through XPS analysis are directly related to
their miscibility [24].
2.3. X-ray Powder Diffraction (XRPD)
X-ray Powder Diffraction (XRPD) technique, in general, can be used to assess the crystalline
state of the material. It is to be expected that solid dispersions prepared from miscible drug-polymer
systems are amorphous and lack typical crystalline patterns in an X-ray diffractogram. Newman et
al. [39] have developed the XRPD method coupled with the computation of pair distribution functions
(PDF) to analyze miscibility in the drug-polymer systems. A lack of agreement of the PDF profiles
of the solid dispersions and individual components indicates that the mixture with a unique PDF
is miscible [39]. The method proposed by Newman et al. [39] has revealed the superiority of XRPD
studies over the DSC analysis for the assessment of the drug-polymer miscibility due to an inability
of the DSC technique to detect Tg values for amorphous domains smaller than 30 nm. XRPD with
PDF and pure curve resolution method (PCRM) analysis may be used to verify drug-polymer mixing
for both completely and partially miscible systems. These techniques are especially useful for the
examination of miscibility when DSC measurements are inconclusive or yield variable results [47].
2.4. Microscopic and Imaging Techniques
Methods for the visual analysis of solid dispersion samples are also of great importance to study
the solubility/miscibility within the solid dispersion systems. Scanning electron microscopy (SEM) or
transmission electron microscopy (TEM) studies of prepared solid dispersions may be indicative of
intrinsic miscibility of the drug and polymer. The surface and cross-section morphological features
of prepared solid dispersions are studied to analyze whether the miscible system is formed, usually
in addition to DSC and XRPD analyses. An example of the assessment of the drug and polymer
miscibility using SEM demonstrates that solid dispersions appear to be agglomerated with a rough
surface, which is attributed to the miscibility of the drug and polymer [41].
3D surface Atomic Force Microscopy (AFM) imaging analysis of solid dispersions is used to
further elucidate drug-polymer surface morphology and interactions [41]. Although AFM provides
nanoscale resolution, which is desirable in miscibility evaluation, it cannot provide information
regarding chemical composition in different regions of analyzed samples. To overcome this drawback,
AFM imaging is coupled with the source of IR radiation (nanoscale infrared spectroscopy—nano IR,
AFM-IR) or heating source (nanoscale thermal analysis—nanoTA). In the AFM-IR technique, light
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from IR source is focused on the contact area between the sample and AFM tip. Absorption of IR
radiation causes thermal expansion of the sample, which induces cantilever oscillation. The spectrum
of the amplitude of cantilever oscillations as a function of IR wavelength is unique for each sample and
provides information about chemical composition in the analyzed sample. In the nanoscale thermal
analysis, AFM probe is heated and moved along the region of interest and, when the thermal event
occurs, a region of the sample softens and AFM probe penetrates the sample. By measuring thermal
properties across the sample surface, nanoscale thermal analysis enables evaluation of whether a system
is single-phased or phase separation occurred. Nanoscale infrared spectroscopy and nanoscale thermal
analysis have been successfully used to evaluate miscibility between telaprevir and three different
polymers [53]. Crystalline structures may also be visually observed by polarized light microscopy
(PLM) due to the characteristic appearance of birefringence of crystalline structures, which are formed
in immiscible systems [54]. Miscibility within the drug-polymer system can be further confirmed by
the hot stage microscopy (HSM) [55], which is often coupled with polarized light microscopy.
Raman mapping (or Raman spectral imaging) is a method whereby detailed chemical images
are generated from samples’ Raman spectra. Raman mapping may also be used to investigate the
drug crystallinity [56]. Analysis of small-size samples through micro-Raman mapping can be used to
detect the phase separation in systems in which multiple glass transition events cannot be resolved by
DSC [57]. The main benefit of using Raman mapping in the evaluation of drug-polymer miscibility
is providing information regarding the chemical composition of phase-separated domains. Qian et
al. [58] have demonstrated the superiority of a Raman mapping method over conventional DSC and
XRPD studies for analysis of the drug-polymer miscibility within the two batches of amorphous solid
dispersion systems that exhibit different physical stability against crystallization over time. They
demonstrated that single distinctive Tg might not always be a reliable indicator of homogeneity and
optimal stability since Raman maps of the less stable systems are indicative of wide distribution ranges
of the drug concentration [58].
Thermal analysis by structural characterization (TASC) is a novel thermal analysis technique that
combines image analysis with hot stage microscopy. TASC technique is based on the algorithm that
converts any change in the sample appearance during heating into a quantified signal, i.e., TASC
curve [59]. Suitability of TASC as a technique for fast screening of the drug-polymer miscibility by
evaluating the melting point depression has been demonstrated for felodipine and ten commonly used
polymers in solid dispersion formulations [60]. Fast analysis, high sensitivity, and the requirement of
a small amount of sample make this technique very attractive in the early stage of solid dispersion
formulation development; however, further studies are necessary to confirm the usefulness of
this technique.
Martinez-Marcos et al. [55] have highlighted the potential of the novel technique, micro-computed
tomography (μ-CT), to be used for the characterization of internal materials properties. This technique
enables X-ray imaging in three dimensions. X-ray micro-computed tomography and TASC technique
are used in conjunction with conventional thermal, microscopic, and spectroscopic techniques to
analyze the miscibility of felodipine with several excipients [61].
2.5. Other Techniques
Crowley and Zografi [62] have estimated the miscibility of PVP and three hydrophobic drugs
through water vapor absorption studies. They demonstrated that interactions in amorphous dispersions
affect the water uptake properties of the individual components [62]. Liu et al. [35] have reported on
the potential for application of rheological measurements to accompany thermal and spectroscopic
analysis for the assessment of the drug and polymer miscibility. Gupta et al. [63] have proposed that
if the viscosity versus temperature plots for different drug concentrations are parallel to each other
(without observable drug melting transition), it is indicative of complete drug-polymer miscibility.
25
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2.6. Techniques Used in Combination
It might be of great interest to use several analytical techniques for investigation of the miscibility
of the selected drug-polymer system. Rumondor et al. [47] have demonstrated that DSC, FT-IR
spectroscopy, and XRPD analysis provide complementary results to each other. Marsac et al. [64]
have used DSC, AFM, and TEM techniques to study the effect of temperature and moisture on
the miscibility within the drug-polymer solid dispersions. It is also of great interest to study
ternary systems, i.e., to estimate the solubility/miscibility of the drug within the polymer mixtures.
Janssens et al. [65] have analyzed the miscibility in ternary systems of itraconazole with polyethylene
glycol (PEG) and HPMC polymer blends, of different molecular weights, using M-DSC and XRPD.
Miscibility in ternary polymer-drug-surfactant systems hydroxypropylmethylcellulose acetate succinate
(HPMCAS)-itraconazole-Soluplus® has been also analyzed using DSC, XRPD, and PLM [66]. Parikh et
al. [67] have proposed the preparation of the film-casted samples to investigate miscibility of the drug
and the polymer using techniques, such as DSC, XRPD, and PLM. Several analytical techniques are
also used to investigate miscibility of felodipine with polymer blends used for the fused deposition
modeling 3D printing [68]. Examples of usage of different analytical methods for the estimation of
drug-polymer solubility/miscibility are given in Table 1.
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3. Computational Methods for the Assessment of Drug-Polymer Solubility/Miscibility
3.1. Solubility Parameters
The early phase of formulation development requires fast screening methods capable of making
rough differentiation between the drug-polymer immiscible systems and the drug-polymer systems
that are likely to be miscible. The usage of solubility parameters, as a purely theoretical-based approach,
perfectly fits this description since it enables evaluation of the drug-polymer miscibility based on only
drug’s and polymer’s chemical structures and without the need for performing even single experiment.
The concept of solubility parameters has been introduced by Hildebrand [76,77] and Scatchard [78]
who have linked solubility of the solute in different solvents with cohesion energy density.
Cohesion energy is defined as the increase in internal energy per mole of a substance if all of the
intermolecular forces are eliminated, i.e., cohesion energy represents the strength of attractive forces of
constituent molecules in the substance. For low molecular weight molecules, cohesion energy (Ecoh) can
be calculated from experimentally determined heat of vaporization using the following equation [79]:
Ecoh = ΔHvap − pΔV ≈ ΔHvap −RT (8)
where ΔHvap is molar heat of evaporation, p is pressure, ΔV is the volume change, R is the universal
gas constant, and T is temperature.







Since it is not possible to determine the heat of vaporization for polymers, δ for these high
molecular weight molecules can be determined by indirect methods, such as dissolving or swelling of
polymers in series of solvents of known δ [80,81], measurements of polymers viscosity in the solvents
of known δ [82], or using inverse gas chromatography [83]. Because these methods are time and
material consuming, several group contribution methods are developed, which enable calculation of
solubility parameters from the knowledge of the molecule’s chemical structure. The basic postulate of
group contribution methods is that properties of the polymer can be estimated by summation of the
contributions of its structural fragments. Although there are several group contribution methods for
the estimation of the cohesion energy of the polymers, in the following text we have given an overview
of the few of them, which are the most commonly used. One of the earliest group contribution methods
for the estimation of Hildebrand solubility parameters has been proposed by Small [84] who defined
parameter F = (EcohV)1/2, called molecular attraction constant, and provided values of this parameter
for numerous structural groups. According to Small’s group contribution method, the Hildebrand
solubility parameter can be estimated by summation of F for structural fragments of the molecule,






This system has been further refined by Hoy [85] and Hoftyzer and Van Krevelen [86] who
provided refined and updated tables for group contributions to the overall F value of the molecule.
Fedors [87] proposed a slightly different concept that provides contributions of a much larger number
of structural groups to both Ecoh and volume of the molecule. According to Fedors’ method, the
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where Δei and Δvi are the additive atomic and group contribution for the energy of vaporization and
molar volume, respectively.
The specificity of this approach is that it offers the way for estimating not only Ecoh but also
volume from group contributions and allows estimation of the temperature dependence of δ from the
knowledge of density-temperature dependence.
Although the introduction of the Hildebrand solubility parameter resulted in huge progress
in studying solute-solvent interactions, its application is limited to the systems with predominant
dispersion force between molecules (non-polar molecules). Therefore, this concept was further
extended by Hansen [88], who defined three-dimensional Hansen solubility parameter, which applies
to substances that, in addition to dispersion forces, also interact by hydrogen bonding and polar forces.
Total cohesion energy (Ecoh) is redefined as the sum of the contributions from dispersion forces (Ed),
polar forces (Ep), and hydrogen bonding (Eh):
Ecoh = Ed + Ep + Eh (12)
Accordingly, the three-dimensional solubility parameter can be expressed as follows:





where δd, δp, and δh are dispersion, polar, and hydrogen bonding partial solubility
parameters, respectively.
Several group contribution methods have been developed to estimate the Hansen solubility
parameter. Two most widely used group contribution methods have been developed by Hoftyzer and
Van Krevelen [86] and Hoy [89]. According to the method proposed by Hoftyzer and Van Krevelen [86],
partial solubility parameters are estimated using the following equations, and the total solubility
















where Fdi is molar attraction constant due to dispersion component, Fpi is molar attraction constant
due to the polar component, Ehi is hydrogen bonding energy, and V is molar volume.
If the two identical polar groups are presented in the symmetrical positions, δp is reduced by
multiplying value obtained using Equation (15) with one of the following correction factors: 0.5 for
one plane of symmetry, 0.25 for two planes of symmetry, or 0 for more than two planes of symmetry.
Besides, for molecules with several planes of symmetry, δh is 0. The method developed by Hoy [89,90]
is more complex and requires the usage of four additive functions and several auxiliary equations to
estimate values of partial solubility parameters and the total solubility parameter. Equations that are
used for calculations in Hoy’s method are given in Table 2 [79]. Although presented group contribution
methods up to now have been enriched and provide a huge collection of group contributions for
solubility parameters estimation with reasonable accuracy, further research in this field pointed out
some drawbacks of this concept and provided its further refinement. It has been recognized that
presented group contribution methods are quite simplified and neglected how groups are connected as
well as interactions between adjacent groups and electron delocalization. Therefore, these methods are
unable to distinguish between different isomers and estimate the same δ values for those molecules [91].
To overcome these drawbacks, Stefanis and co-workers developed a new group contribution system
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for the estimation of solubility parameters, through the division of molecules into the first order and
second order groups. The first order groups describe the basic structure of the molecule, similar to the
previously described group contribution methods. Additional second-order groups consist of two or
three adjacent first-order groups, and they are based on the conjugation theory [92–94]. Conjugation
is considered as one of the important stabilization mechanisms, whereby compounds with a higher
number of conjugates are considered as more energetically stable. This theory, known as ABC approach
(ABC-contribution of Atoms and Bonds to the properties of Conjugates), considers chemical compounds
not as single structures but as hybrids of different conjugates formed by a different arrangement of
valence electrons. Therefore, this method can capture intramolecular interactions between adjacent
atoms as well as atoms separated by several bonds [91]. Second-order groups are formed from the two
or three adjacent first-order groups and ranked based on their contribution to the standard enthalpy of
formation. Structures that exhibit the highest contribution to the enthalpy of formation are considered
as second-order groups for further calculations [92,93]. The basic equation for the estimation of Hansen









where Ci is the contribution of the first-order group of type i that appears Ni times in the compound and
Dj is the contribution of the second-order group of type j that appears Mj times in the compound. The
constant W is equal to 0 for compounds without second-order groups and equal to one for compounds,
which have second-order groups.

















































Stefanis and Panayiotou further proposed subdivision of δh into acidic and basic components δa and
δb, respectively, and extended the three-parameter Hansen solubility parameter to the four-parameter
solubility parameter. The donor and acceptor parameters of the hydrogen bonds have been obtained by
evaluation of third moments of sigma profiles of charge density distribution on the surface of molecules.
These profiles for a large number of compounds are available in the software databases (COSMObase
or VT Sigma Profile Databases) or can be calculated using suitable software (Dmol3 or TURBOMOLE).
Therefore, calculations do not require so many computational resources. The main benefit of this
concept is that it takes into account acid-base interactions that favor solubility and miscibility [94]. Just
et al. [95] for the first time developed group contribution set based exclusively only on pharmaceutical
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relevant solids to predict the solubility of the drug in polymer for solid dispersion systems prepared by
hot-melt extrusion. Although in the initial study, this group contribution system showed improved
prediction ability of drug solubility compared to existing methods, further experiments are necessary to
enrich group contribution tables with more data as well as to validate obtained methods on additional
experimental data.
Table 2. The equations used for the estimation of the solubility parameter and its components in Hoy’s
(1985) group contribution system [79].























3.39 log(Tb/Tcr) − 0.1585− log V α(P) = 777ΔT
(P)/V
Tb/Tcr = 0.567 + ΔT − (ΔT)2 n = 0.5/ΔT(P)
Calculation of total and partial
solubility parameters




















2 − δp2 − δh2)1/2
Ft—total molar attraction constant for each group; Fp—polar molar attraction constant; Fi—sum of molar attraction
constants of constituent groups; V—molar volume of the molecule or repeated unit in the polymer; ΔT—Lydersen
correction for non-ideality (values for low molecular substances have been provided by Lydersen [96], while values
for polymers ΔT(P) have been derived by Hoy; Tb—boiling point; Tcr—critical temperature; B—base value (B = 277).
Solubility parameters are used as a simple screening tool for miscibility evaluation in the early
solid dispersion formulations development. Simply, values of the solubility parameters of drug
and polymer should be close to each other, if the drug and polymer are miscible. This means that
energy released due to cohesive interactions between like molecules is counterbalanced by adhesive
interactions between unlike molecules [97,98]. While the difference in the solubility parameters (Δδ) in
the case of Hildebrand solubility parameters is easily calculated by subtracting δ of the drug from δ of
polymer, for Hansen solubility parameters difference is calculated as the Euclidean distance according
to the following equation:
Δδ =
√




+ (δh1 − δh2)2 (23)
where subscripts 1 and 2 denote drug and polymer, respectively.
Bagley et al. [99] considered the effects of δd and δp as similar and combined them into single
parameter δv, while the effect of δh is considered as different. After applying this transformation,
the difference between Hansen solubility parameters of drug and polymer can be evaluated on a
two-dimensional plot with δv and δh on the axes. Since Bagley’s plot shows superior performances
over three-dimensional Hansen plot in locating regions where the polymer is soluble in solvents, this
plot should be preferably used in evaluating miscibility between drug and polymer. Although the
difference between solubility parameters of drug and polymer should be small if components are
miscible, it is difficult to establish a threshold for Δδ value below which components are considered as
miscible. According to Greenhalgh et al. [100], if Δδ < 7.0 MPa1/2, components are likely to be miscible,
while if Δδ > 10.0 MPa1/2, components are like to be immiscible. In their study, Forster et al. [101]
suggested more rigorous criteria, which predict the formation of solid solution in the cases where
Δδ < 2.0 MPa1/2, while immiscibility is predicted for systems with Δδ > 10.0 MPa1/2. For drug-polymer
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systems with Δδ between 5.0 and 10.0 MPa1/2, it is difficult to make a reliable conclusion of whether
the system is miscible or immiscible. Further melt extrusion experiments showed that this system
successfully predicts whether a system is miscible or not in the cases where Δδ < 2.0 MPa1/2 and
Δδ > 10.0 MPa1/2.
Solubility parameters have been extensively used as the screening tool to get some information
regarding drug-polymer miscibility, alone or more commonly in conjunction with thermodynamic
modeling [20,38,98,102–105]. Although this method is more or less successful to distinguish between
drug-polymer miscible pairs from those pairs where miscibility problems may occur, the application of
this method alone is not highly reliable and can give misleading results. When applying solubility
parameters for the evaluation of drug-polymer miscibility, one should be aware of some limitations of
this concept. This is a purely theoretical concept, wherein drug-polymer interactions are based on
chemical similarity, and it takes into account only enthalpic contribution to drug-polymer mixing. For
further thermodynamic interpretation of the drug-polymer mixing, this method is used in conjunction
with Florry-Huggins thermodynamic modeling, which has been explained in the further text. One of the
main limitations of this method is that it is qualitative and does not provide any quantitative information
regarding drug-polymer miscibility as well as the physical state of the API (active pharmaceutical
ingredient) after mixing with the polymer [98]. It should also bear in mind that the application of
different group contribution methods will inevitably give different values of solubility parameters and
even the same group contribution method will give a different result if the structure of the molecule
is divided in different ways. However, solubility parameters can still be considered as a useful
screening tool in the early formulation development, wherein bringing of any conclusions regarding
drug-polymer miscibility/immiscibility requires further application of experimental techniques and
thermodynamic modeling.
3.2. Thermodynamic Modeling
Although analytical methods, described in Section 2, are capable of more or less accurate
determination whether the drug and polymer form single-phase system or not, obtained results are
valid only at the moment of analysis. It is more important to get insight into thermodynamics of the
drug-polymer mixing since this will enable identification of drug and polymer composition ranges,
where the formation of single-phase system is more likely to occur as well as identification of potential
destabilization mechanisms. Additionally, miscibility or solubility of the drug in the polymeric matrix,
below polymer’s Tg, can be only estimated by model prediction due to very slow system equilibration,
which gives more significance to this approach.
It has been recognized that thermodynamic models describing the mixing of small molecules with
a solvent are not suitable to describe mixing between the drug and polymer since they do not take
into account large volume differences between polymer and drug molecules [11]. The suitable model
should relate free energy change upon mixing to volume fractions, rather than mole fractions of the
components since entropic contribution to the free energy change is significantly reduced by mixing a
large molecular weight molecule with a small molecular weight molecule. Flory-Huggins lattice theory
that has been originally developed to describe mixing in the polymer-polymer and polymer-solvent
blends is further applied to describe mixing between the drug and polymer by considering drug
molecule analogous to the solvent molecule. According to this theory, free energy change upon mixing
(ΔGmix) of the drug and polymer is given by the following equation [11]:
ΔGmix
RT
= ndruglnΦdrug + npolymerlnΦpolymer + ndrugΦpolymerχ (24)
where ndrug is the number of moles of the drug, npolymer is the number of moles of polymer, Φdrug is the
volume fraction of the drug, Φpolymer is the volume fraction of the polymer, R is the gas constant, T is
the absolute temperature, and χ is Flory-Huggins interaction parameter.
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The first two terms on the right side of the Equation (24) describe entropic contribution to the
free energy of mixing, which always favors mixing, since mixing of two components increases system
disorder. Since entropic contribution to the free energy of mixing in drug-polymer systems is much
lower compared to the small molecule-solvent system, enthalpy of mixing will mainly determine
whether drug-polymer mixing will occur spontaneously (ΔGmix < 0) or not (ΔGmix > 0). The contribution
of the enthalpy of mixing to the overall free energy of mixing is determined by the sign and magnitude
of the Flory-Huggins interaction parameter χ, which reflects the strength of drug-polymer adhesive
interactions relative to cohesive interactions between drug-drug and polymer-polymer pairs. Negative
values of χ indicate stronger adhesive interactions, which facilitate drug-polymer mixing, as a result of
negative ΔGmix. In the case of positive χ, which indicates stronger cohesive interactions, drug-polymer
mixing will be thermodynamically favored only if the entropic contribution to ΔGmix overcomes
unfavorable enthalpy of mixing and gives negative overall free energy of mixing [11,106,107]. Since
the strength of adhesive interactions between the drug and polymer is determined by their chemical
structures, shifting from one to other chemical class of polymers is a better approach to achieve
miscibility than shifting from higher to lower molecular weight grade of the same polymer [11].
Although values of χ can be determined by different approaches, the most common way to determine
χ in drug-polymer systems is a melting point depression method. In this method, physical mixtures of
drug and polymer of various compositions are subjected to DSC scan and, if the system is miscible,
drug melting point should be reduced in the mixture compared to the melting point of the pure drug.
Melting of the drug occurs at a temperature where the chemical potential of the crystalline drug
becomes equal to the chemical potential of the molten drug. Mixing of drug with polymer will reduce
drug chemical potential and, therefore, the melting of the drug will occur at a lower temperature,
compared to the pure drug. If the drug and polymer are immiscible, the melting of the drug will be
unaltered in the presence of polymer [14,15,20]. The relationship between the melting point depression
















where TmixM is the melting temperature of the drug in the presence of the polymer, T
pure
M is the melting
temperature of the pure drug, ΔHfus is the heat of fusion of the pure drug, and m is the ratio of the
volume of the polymer to that of the lattice site (defined as the volume of the drug molecule). This

















Φpolymer vs. Φ2polymer (26)
which exhibits linear relationship within the low polymer concentrations with the slope equal to χ.
When using melting point depression method to estimate χ, one should be aware of some limitations
of this approach. Firstly, Tg of polymer should be sufficiently below drug melting temperature because
the crystalline drug should interact with the polymer in a supercooled liquid state sufficiently long
before it starts to melt. Additionally, linearity in the plot used to calculate χ is limited to low polymer
concentrations. Although markedly different values of χ are obtained if used onset, midpoint, or offset
of drug melting peak in the DSC scan as a drug melting temperature [14], there is no consensus in the
literature regarding which value should be used. Marsac et al. [14] and Paudel et al. [15] proposed that
offset of melting endotherm should be used since it represents the melting of the final composition after
the occurrence of mixing. However, in most of the studies, onset values have been used [17,19,20,104],
where the low heating rate is used to facilitate mixing within the experimental time scale. Calculated χ
enables estimation of the free energy changes upon drug-polymer mixing (ΔGmix) as a function of the
drug weight fraction, according to the Equation (24). However, values of χ obtained by the melting
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point depression method are valid only at drug melting temperature and cannot be used to predict
drug-polymer miscibility at lower temperatures. It has been shown that χ varies with temperatures
and composition. Since the effect of the composition on χ is considered as negligible, compared to the
effect of temperature, the temperature dependence of χ can be expressed using the following simplified
equation [12,18]:




where A is referred to as the non-combinatorial entropic contribution to χ, while B/T is the enthalpic
contribution [108]. By measuring melting points of the drug in mixtures of different compositions,
different values of χ can be obtained, and by plotting these values as a function of corresponding
temperatures, parameters A and B can be obtained. This enables calculation of χ at any temperature
and prediction of ΔGmix as a function of temperature and composition. Solubility parameters can be




(δdrug − δpolymer)2 (28)
where Vsite is the volume of the hypothetical lattice (approximated as the volume of the drug).
Since χ calculated in this way reflects drug-polymer interactions at 25 ◦C, this value can be
additionally used to estimate temperature dependence of χ, according to Equation (27) [17,20].
Although the calculation of χ using solubility parameters is the simplest approach and does not require
any experiment, it has been shown that obtained χ can fail to predict drug-polymer miscibility [11].
This probably comes from the inherent limitation of solubility parameters approach in systems with
pronounced specific intermolecular interactions. An additional limitation of this approach is that it
does not take into account possible exothermic mixing since calculated χ is always positive [15].
Besides the estimation of the drug-polymer miscibility, thermodynamic modeling is used to
estimate drug solubility in polymers used for solid dispersions preparation. Only if drug concentration
in solid dispersion is below the solubility limit, physical stability of this system is guaranteed without
the tendency of drug toward crystallization. Therefore, estimation of the drug solubility in the
polymeric matrix is of particular importance since it is an indicator of the degree of supersaturation,
which determines driving force for drug crystallization. If the amount of drug in solid dispersion
is above its solubility in the polymer, but below the miscibility limit, the system is considered as
metastable and is stabilized against crystallization through intimate mixing with polymer, unless
large fluctuations of temperature and/or composition occur, which makes favorable conditions for
crystallization [12]. Marsac et al. [14] developed a model for the estimation of the solubility of the drug
in polymers by using the measured drug solubility in low molecular weight analog of the polymer.






















where γdrug is the activity coefficient of the drug in the mixture at the solubility limit, xdrug is the mole
fraction of dissolved drug, ΔGfus is the free energy difference between supercooled liquid and crystal,
T is the temperature of interest, Tm is melting temperature, R is universal gas constant, ΔHfus is heat of
fusion, and ΔCp is the capacity difference between the liquid and crystal.
By considering that ΔCp does not change significantly in the temperature range of interest,
Equation (29) can be rewritten into the following form [109]:
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Since all parameters in the Equations (29) and (30) can be easily experimentally determined,
except activity coefficient (γdrug), calculation of γdrug is a necessary prerequisite to determine drug
solubility. By considering ideal mixing (γdrug = 1), ideal solubility of the drug in the low molecular
weight analog can be calculated from Equation (30). The ratio of ideal solubility to experimentally
determined the solubility of the drug in the low molecular weight analog of polymer gives γdrug in
low molecular weight analog of the polymer (γdrugLMW). The activity coefficient of the drug in the
polymer (γdrugpolymer) is considered equal to γdrugLMW after the addition of correction factor to reduce



















+ ln γLMWdrug (31)
where MVlattice is lattice molecular volume (in this case, defined as volume of low molecular weight
analog of polymer), MVdrug is drug molecular volume, mpolymer is the ratio of the volume of the polymer
to that of the lattice site, mdrug is the ratio of the volume of the drug to the lattice site [14].
Calculated γdrugpolymer can be further used to calculate χ, as an alternative approach compared to






















Marsac et al. [14] calculated the solubility of several drugs in different grades of PVP using
solubility data in the 1-ethyl-2-pyrrolidone as the low molecular weight analog of PVP. Obtained
results show significantly reduced solubility in polymer due to reduced entropy of mixing up to the
certain molecular weight of the polymer after which solubility is only slightly changed. Additionally,
χ calculated using this approach is in agreement with those obtained by melting point depression
method. The same method has been successfully used by Paudel et al. [15] to predict the solubility of
naproxen in different grades of PVP using measured solubility of naproxen in N-methylpyrrolidone as
a low molecular weight analog of PVP. Although this approach is quite simple and does not require
so many experimental resources, it assumes that interactions between the drug and polymer are the
same as between the drug and the low molecular weight analog (i.e., χ is the same in both cases) and is
applicable only for polymers with available low molecular weight analog in the liquid state. Djuris
et al. [19], in their study, used Hansen solubility parameters to calculate the activity coefficient of
carabamazepine in polyethyleneglycol-polyvinylcaprolactam-polyvinyl acetate grafted copolymer































where δ is the molar volume-weighted solubility parameter, and V is the mixture volume, where the
subscript k denotes the different components of the mixture.
Obtained activity coefficient shows strong composition dependence and can be used to estimate
mole fraction of dissolved drug within the polymeric matrix using either Equation (30) or Equation (32).
Results obtained via both ways are in close agreement and show that the amount of carbamazepine
that can be molecularly dispersed in the Soluplus® matrix is limited to below 5% (w/w) [19].
Prudic et al. used thermodynamic modeling based on perturbed-chain statistical associating fluid
theory (PC-SAFT) to estimate drug solubility in polymer. According to this theory, each molecule is
described as a chain composed of spherical segments that can interact with segments of other molecules
through different types of interactions. In PC-SAFT model, the residual Helmholtz energy ares of a
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system containing drug and polymer is calculated as the sum of reference hard-chain contribution
accounting for repulsive interactions between molecules (ahc), a dispersion contribution accounting for
van der Waals attraction forces (adisp), and a contribution caused by association via hydrogen bonds
(aassoc) [110]:
ares = ahc + adisp + aassoc (35)
Segment number miseg and segment diameter σi are used to calculate hard-chain contribution, while
the contribution from the van der Waals attraction forces between segments (adisp) is calculated using
dispersion-energy parameter ui/kb (ui—dispersion energy, kb—the Boltzmann constant). Additionally,
for drugs and polymers capable of hydrogen bonds formation, it is necessary to calculate a contribution
caused by association via hydrogen bonds (aassoc). The calculation of this term requires definition of
the number of association sites (electron acceptors and donors) Niassoc, defined based on the molecule’s
chemical structure, the association-energy parameter εAiBi/kB (related to the strength of association),
and the association-volume parameter κAiBi (related to the distance between two molecules necessary
to form a hydrogen bond). These pure-component parameters of drugs and polymers, required for
the calculation of the residual Helmholtz energy, are usually determined by fitting to experimental
solubility data of these components in organic solvents. The calculation of the residual Helmholtz
energy of the system is described in detail elsewhere [110].
The activity coefficient of the drug in the liquid drug/polymer phase (γiL), required for the
calculation of solid-liquid equilibrium curve (Equation (30)), can be calculated by PC-SAFT method
































where φLi is fugacity coefficient of component i in the mixture, φ
L
0i is fugacity coefficient of the pure
component, μresi is residual chemical potential, Z is compressibility factor, p is system pressure, and NA
is the Avogadro number.
PC-SAFT is successfully used to predict the solubility of artemisinin and indomethacin in PEGs of
different molecular weights as a function of temperature and predicted results are in close agreement
with experimentally obtained data [110]. This approach is also used to predict long-term stability of
the drug in both binary and ternary solid dispersions and evaluate the impact of relative humidity
on drug recrystallization and amorphous-amorphous phase separation [110–114]. The solubility of
acetaminophen in PVP K25 and PVP VA64 and the impact of relative humidity on the solubility are
predicted by PC-SAFT and Flory-Huggins modeling and further used as an indicator of long-term
stability of acetaminophen solid dispersions in these two polymers. Obtained results show that the
PC-SAFT method gives more accurate prediction and can better differentiate whether solid dispersions
remain stable or undergo recrystallization under elevated humidity [111]. Advantage of PC-SAFT
method is that each component is characterized with parameters that are physically meaningful and
do not depend on the temperature, component molecular weight, concentration, etc. Additionally, this
method takes into account different types of interactions in the system, such as association (hydrogen
bonding) and ionic and polar interactions between the compounds [115]. It has been also demonstrated
that the PC-SAFT method enables accurate prediction of the drug solubility in copolymers if the drug
solubility in the respective homopolymers is known [115]. Although the PC-SAFT method requires less
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experimental work than Flory-Huggins method, it requires more complicated calculations. However,
once determined, parameters of the pure component can be further used for other systems, which
contains that component, so it is expected that this method will be more frequently used in the future
upon an increase in the availability of necessary component parameters in the literature.
Construction of the Phase Diagram
As stated above, the calculation of χ at different temperatures, using Equation (27), enables
prediction of the free energy change upon drug-polymer mixing as a function of both temperature
and composition. As long as ΔGmix < 0 and ΔGmix vs. composition curve is concave up, the formation
of the single-phase system occurs since free energy of the mixture is lower than the free energy of
the two-phase system. Phase separation can occur only if the single-phase system can lower its
free energy by separating into two phases [104]. Determination of ΔGmix vs. composition curve at
different temperatures is a necessary prerequisite to constructing temperature vs. composition phase
diagram, which shows phase behavior of drug-polymer mixture, and differentiate regions of stability,
metastability, and instability. Phase behavior has not been studied for so many drug-polymer systems,
and available studies describe the different methodology to construct a drug-polymer phase diagram.
Phase diagrams have been described for solid dispersions of dipyridamole and cinnarizine in PVP and
polyacrylic acid (PAA) [20], cinarizine in Soluplus® [8], indomethacin in polyvinylpyrrolidone-vinyl
acetate (PVP VA) copolymer [17], itraconazole in HPMC [106], felodipine in HPMCAS HF grade
and Soluplus® [18], PAA [16] and different grades of PVP [103], aceclofenac in Soluplus® [104],
naproxen and acetaminophen in HPMCAS, PVP K25 and PVP VA64 [112], and binary polymeric
blends containing HPMCAS and either PVP K25 or PVP VA64 [113]. Typical phase diagram includes a
solid-liquid phase transition curve, amorphous phase separation curve, and glass transition curve. In
their work, Tian et al. [8] calculated drug solubility curve for cinarizine in Soluplus® using solid-liquid








− ln γdrug (40)
Lehmkemper et al. suggested that solubility of the drug in polymer should be assessed using
Equation (30), which includes ΔCp term and, therefore, should give more accurate results [111]. Activity
coefficient, required for the calculation of the solubility curve, can be calculated using Hansen solubility
parameters, according to above-mentioned Equation (33). Solid-liquid phase transition curve can be
also calculated using melting point depression approach (Equation (25)), considering Flory-Huggins
interaction parameter calculated at different temperatures, as described by Lin et al. [16] and Tian et
al. [18]. The PC-SAFT method also enables the prediction of the solid-liquid phase transition curve in
the drug-polymer systems and, in some cases, gives more accurate results compared to Flory-Huggins
modeling [110,111].
While the solid-liquid phase transition curve describes the solubility limit of the drug in the
polymer, miscibility limit of two phases, i.e., the tendency towards amorphous-amorphous phase
separation is described by binodal and spinodal curves. The binodal curve is determined by the
common tangent rule to free energy vs. composition curve, where the first derivative of this curve
is set to zero [17,108]. Above this curve, single-phase amorphous system is formed, while in the
region below binodal and above the spinodal curve, the system is metastable, i.e., large composition
fluctuation is necessary to induce phase separation [8]. Phase separation process between binodal and
spinodal curves can occur via nucleation and growth mechanisms, only if the significant energetic
barrier is overcome [18]. The spinodal curve is obtained by setting the second derivative of free energy







(1−Φdrug) − 2χdrug−polymer = 0 (41)
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After the determination of the temperature dependence of χ, Equation (41) can be transformed
in the following form, which enables the construction of the spinodal curve on the temperature vs.





+ 1m (1−Φdrug) − 2A
(42)
The spinodal curve represents phase boundary between metastable and unstable region, and,
below this curve, spontaneous (barrier-free) phase separation into drug-rich and polymer-rich regions
occurs, which is often denoted as spinodal decomposition. The glass transition curve is an important
part of the temperature composition phase diagram as an indicator of system kinetic stabilization.
Although solubility and miscibility limits can be exceeded, phase separation and crystallization can
be avoided, through kinetic stabilization of the system below Tg of the mixture. Polymers with high
Tg are preferred in the formulation of solid dispersions due to increasing Tg of the mixture, which is
denoted as an antiplasticization effect. Below Tg, viscosity drastically increases and molecular mobility
decreases, which altogether hinders crystallization of drug molecules. It is often reported that molecular
mobility can be neglected at temperatures more than 50 ◦C below the mixture Tg [116]. Therefore,
although the system is thermodynamically not stable, it can be kinetically stabilized during product
shelf life. Kinetic stabilization is particularly important when using techniques for solid dispersions
preparation where materials are processed under non-ambient conditions, such as hot-melt extrusion.
In this technique, mixing of the molten drug and polymer above polymer Tg and/or dissolving of the
crystalline drug within the polymer above its Tg is facilitated by high processing temperature and high
shear stress applied by mixing elements. During cooling to room temperature, homogeneously mixed
or dissolved drug can be kinetically frozen in that state for a sufficiently long time, although above
solubility and miscibility limit for a particular temperature. After construction, the phase diagram
should be validated. This is commonly performed by preparing the solid dispersions of different
composition and evaluating drug crystallinity by XRPD as well as the presence of phase separation
and/or drug recrystallization by DSC or similar thermal analysis techniques [17,18,104].
Due to simplicity and not a straightforward calculation of binodal curve, the phase diagram is
often represented with solid-liquid phase transition curve (solubility curve), spinodal (miscibility)
curve, and glass transition curve, as shown in Figure 2 [18]. Above the solubility curve (Zone A and B),
the drug is dissolved in the polymer and is stable to temperature and concentration fluctuations. Even
if crystallization starts, the thermodynamic driving force in this region is to dissolve the crystalline
drug in the polymer. Although this should be the most desired region in the development of solid
dispersions formulations, the solubility of the drug is usually too low and limits practical formulation
development only to very low dose drugs. Since the amorphous drug has a higher chemical potential
compared to the crystalline drug, the miscibility of the amorphous drug with the corresponding
polymer is much higher than the solubility of the crystalline drug in the polymer. Therefore, the
miscibility boundary is more relevant to the solid dispersion formulation development. Below this
boundary line (zones E and F), the system is thermodynamically unstable, and spontaneous phase
separation will occur. Only within the zone F, the system can be stabilized kinetically, if stored at
temperatures sufficiently below Tg. Above miscibility and below solubility curve (zones C and D), the
system is supersaturated with respect to drug solubility but is stabilized through mixing with polymer,
and phase separation requires certain activation energy. In the zone D, the system is additionally
kinetically stabilized due to reduced molecular mobility below Tg.
39
Pharmaceutics 2019, 11, 372
 
Figure 2. Typical temperature vs. composition phase diagram for the binary drug-polymer system
(Reproduced with permission from Tian et al., 2013). [18]. Copyright (2013) American Chemical Society.
3.3. Computational Modeling and Simulations
Following the advances in informatics technologies, which led to increased computing power and
speed, together with the high availability of reliable free or affordable proprietary molecular modeling
software capable of handling large systems, the simulation of the solid-state has become possible to
a very satisfactory degree of precision and time scale. Recent applications of molecular modeling
relevant to the formulation of poorly soluble drugs are numerous and focusing on various aspects of
the solid-state.
Specifically, molecular dynamics (MD) simulations, a highly powerful molecular modeling
technique for the study of physical movement of atoms and molecules by numerically solving
Newton’s equation of motion, is gaining increased attention in the recent years. In MD simulations,
interatomic potentials or molecular mechanics force fields are used to calculate the potential energies
and forces occurring between the simulated atom particles [117,118]. In brief, during an MD simulation,
the components are initially identified (molecules and concentrations), and the interaction functions
(or else “force fields”) are set. Then, after setting the desired thermodynamic conditions (i.e., density,
pressure, and temperature), the initial positions of molecules are defined, and the velocities of atoms are
randomly assigned. Finally, the simulation starts, and, depending on the property under investigation,
the thermodynamic parameters may change or fluctuate until the whole system equilibrates in a given
set of conditions, i.e., mimicking the procedure of macroscopic equilibration process in a real laboratory
experiment [119].
Based on the satisfactory degree of precision and the rather simple and easy to interpret theoretical
background, MD simulations have gained increased attention regarding the in-depth evaluation of
pharmaceutical solid-state processes. In recent years, such attempts include the simulation of API
amorphous state [120], API crystallization processes from supersaturated solutions [121], API—water
interactions [122], and API—matrix carrier interactions [123]. Based on the required level of detail,
simulations may be performed from picoseconds up to several hundred nanoseconds.
As noted from a recent expert review published by Edueng et al. [124], although the use of MD
simulations exhibits extremely promising results in characterizing both pure API amorphous state and
API—carrier molecular interactions, this methodology is still only used relatively sporadically. This
may be attributed probably to the improper realization or training of the scientists working in the field.
Therefore, to alleviate the poor perception of scientists on the subject, it is attempted in the following
section, to present a detailed overview of the currently available advanced computational models,
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used specifically for the estimation of miscibility and molecular interactions (an indirect indication of
miscibility) occurring between solid dispersion components.
In this direction, Gupta et al. have performed MD simulations to predict the miscibility of
pharmaceutical compounds [120]. Specifically, the authors developed a computational model (verified
experimentally via thermoanalytical techniques), which can predict the miscibility of indomethacin
in several carriers (polyethylene oxide, glucose, and sucrose). In all applied MD simulations, the
COMPASS (Condensed-phase Optimized Molecular Potentials for Atomistic Simulation Studies) force
field is used, which is parameterized based on ab initio quantum mechanics calculations. According to
the authors, after an initial energy minimization step, the MD simulations are carried out in two phases:
(1) the equilibration run, where the amorphous cells are allowed to relax for 2 ns under isothermal
(NVT) or isobaric-isothermal conditions (NPT-NVT) at 298 K and (2) the production run where the
equilibrated structure is processed via the NVT ensemble for 200 to 500 ps at 298 K with a time step
of 1 fs. The Andersen thermostat and barostat are used to maintain the temperature and pressure
stable, respectively. The non-bonded van der Waals and electrostatic interactions are truncated using
the group-based cut-off distance of 1.25 nm. Trajectory frames are captured during the production
run, and the data from the final 50 ps are used for computing the Cohesive Energy Density (CED) and
solubility parameter (δ). Results show that the employed MD simulations can predict successfully
indomethacin miscibility with polyethylene oxide and immiscibility with sucrose and glucose.
In another paper, the same group of authors used MD simulations for predicting glass transition
temperature and plasticization effect in amorphous pharmaceuticals [122]. Amorphous sucrose (widely
used as a carrier in the preparation of solid dispersions) and water are selected as model compound
and plasticizer, respectively. As in their previous work, MD simulations are performed using the
COMPASS force field and isothermal-isobaric ensembles in two steps (equilibration and production
phase). In this study, to predict Tg, the authors allowed the system to stepwise cooling from 440 K
to 265 K at 5 K intervals by using the final structure from each MD run as the starting structure for
the subsequent run. The density is measured at every picosecond interval during the last 50 ps run
at each temperature step of the production run, and the average density values are used to calculate
the specific volume. Specific volume vs. temperature plots is used to estimate MD-based Tg value
for amorphous sucrose containing 0%, 3%, and 5% w/w water, respectively, which are in reasonable
agreement with the experimental values reported in the literature. Additionally, radial distribution
function analysis of the MD trajectories reveals strong hydrogen bond interactions between sucrose
hydroxyl oxygen and water oxygen.
In another study, Maus et al. used MD simulations to predict miscibility and Tg for pharmaceutical
solid dispersion systems prepared by a melt-based method, such as hot-melt extrusion [125].
Different mixtures containing theophylline or ibuprofen and water-soluble (triethyl citrate) or
water-insoluble (acetyl tributyl citrate or dibutyl sebacate) plasticizers dissolved or dispersed in
a cationic polymethacrylate matrix carrier have been evaluated. Initially, for the MD simulations, cubic
simulation boxes (with periodic boundary conditions in all directions) are constructed (side length of
ca. 4 nm). Then, after appropriate energy minimization, the structures are left to relax for 2 ns under
NPT conditions at ambient conditions, to obtain a well-relaxed start structure with the correct density
using the Andersen thermostat and barostat, at a time step of 1 fs. Afterward, a 200 ps run at constant
volume and temperature (NVT) is carried out (100 ps for equilibration and 100 ps for data sampling).
The cohesive energy (Ecoh) is averaged over this latter period, and the corresponding cohesive energy
density is calculated by dividing it through the volume (V) of the simulation cell (Ecoh/V). In all MD
simulations, a cut-off distance of 1.25 nm with a spline switching function is applied for the Coulomb
and van der Waals interactions using charge groups to prevent dipoles from being artificially split.
Atomic charges and interactions between atoms and molecules are accounted for by the use of the
COMPASS force field. For Tg evaluation, the specific volume vs temperature diagrams are constructed
by relaxing the systems for 2 ns under NPT conditions at a temperature of approximately 100 K
above the supposed Tg, followed by a cooling process with a stepwise of 10 K until the temperature is
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~100 K below Tg. Results show that the use of Hilderbrand’s solubility parameter estimated via MD
calculations leads to an incomplete picture of the system’s miscibility, while better results are obtained
when MD-based Gibbs free energy is used. Additionally, the correlation of the simulated Tg with the
experimentally determined values reflects the different solubility behaviors of the plasticizers studied
(less miscible plasticizers show a higher deviation from the experimental Tg).
In a similar work, published by Macháčková et al. [126], MD simulations are employed evaluate
miscibility of cyclosporine-A in six biodegradable polymers, namely l-polylactide, d-polylactide,
chitosan, polyglycolic acid, PEG, and cellulose [126]. All prepared models are optimized using PCFF
(Polymer Consistent Force Field) force field, while smart algorithm (a cascade of steepest descent,
conjugate gradient, and quasi-Newton methods) with 50,000 steps is used for geometry optimization,
while atomic charges are assigned by a PCFF force field. For MD simulations, periodic boundary
conditions are employed under NPT dynamics with Nose thermostat and Berendsen barostat for
1.5 ns. The Flory-Huggins interaction parameter, χ, describing API-polymer miscibility is calculated
based on the mixing energy (Emix) representing the difference in free energy between the mixture and
the sum of pure state energy of both components (API and polymer). With the present work, the
author revealed that MD-simulations could be a powerful tool for predicting component miscibility.
Specifically, results show that miscibility is dependent on chain length and this dependence is more
noticeable for flexible chains, while the best miscibility is strongly correlated with the polymer-drug
interaction energy and with the number of hydrogen bonds between polymer and drug molecule.
Additionally, MD simulations can show that the two polymers (polycellulose and polychitosan), with
the best miscibility and the highest polymer-drug adhesion, exhibit surprisingly higher rigidity.
Barmpalexis et al. [127] have also used MD simulations to study the miscibility of three commonly
used plasticizers (namely, citric acid, triethyl citrate, and PEG) with Soluplus®, a widely used polymeric
matrix in hot-melt extrusion processes [127]. MD simulations are performed using pcff_d force field
under NPT with a cut-off radius of 7 Å, spline distance of 1 Å, Berendsen thermostat, variable volume
and shape option, and 1 fs time step. The cohesive energy (Ecoh, i.e., the measure of the intermolecular
forces acting between molecules) is calculated after 2 ns structure relaxation process and another 400 ps
run under NVT, to calculate the Hildebrand solubility parameter by dividing the square root of Ecoh
with square root of simulation volume (V) (Equation (9)). Simulations show miscibility only in the case
of Soluplus® and PEG, a result that is verified experimentally by the presence of significant molecular
interactions between the two components.
In another paper, the same group of authors tried to expand their previously developed molecular
model (polymer-plasticizer matrix system) by including two BCS (Biopharmaceutics Classification
System) class II model drugs (namely ibuprofen and carbamazepine) having substantially different
thermal properties and glass-forming ability [123]. The same set of MD simulation parameters, as
the once selected previously, are used in this attempt. Simulations results suggest that both APIs
are miscible in the selected solid dispersion matrix (Soluplus®-PEG) verified experimentally by
thermoanalytical analysis (DSC).
MD simulations (using AMBER 11 force field) are also utilized to evaluate the molecular
structures of solid dispersions by the simulated annealing method, mimicking the hot-melt preparation
method [128]. During the minimization procedure, the structures are subjected to 1000 steps of steepest
descent minimization followed by 1000 steps of conjugate gradient minimization. After minimization,
a 1 ns simulated annealing simulation, with a Langevin dynamics is used in a 2 fs time step and a
cut-off of 12 Å for non-bonded interactions. During the simulated annealing procedure, the system
is initially heated from 0 to 500 K in 200 ps and then is kept at temperature for 300 ps to equilibrate.
Next, the system is quickly cooled down from 500 to 300 K in 100 ps and is kept at that temperature for
400 ps. The simulated annealing procedure is repeated 10 times (10 ns) for complete convergence of
the systems. Based on the presented results, the authors have succeeded in developing an all-atomic
MD model for the formation of solid dispersions prepared by hot-melt method and the molecular
mechanisms involved during such preparations.
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Finally, in a similar attempt, Xiang and Anderson [129] have also used a simulated annealing
method, mimicking the hot-melt preparation in an attempt to investigate the molecular interactions
occurring between indomethacin and PVP. All MD simulations are performed via Amber-ff02 force
field. The prepared initial structures after energy minimization are left to equilibrate at 600 K for
approximately 10 ns and then subjected to cooling dynamic runs to a final temperature of 200 K at a
cooling rate of 0.03 K/ps. The newly formed glasses are used as starting configurations for prolonged
aging dynamic runs (~100 ns) at 298 K and 1 bar. MD simulations suggest that the two components are
miscible, a result that is verified by the formation of strong specific interactions (hydrogen bonds).
4. Conclusions
Evaluation of the drug-polymer miscibility and solubility of the drug in the selected polymer
has become an unavoidable part in the rational design of solid dispersion formulations. There
are numerous approaches to estimate the drug-polymer solubility/miscibility, which we grouped
into analytical and computational methods, although this classification is rather arbitrary since
computational methods in most cases use data obtained by analytical methods. However, one should
be aware that each analytical technique alone has its limitations to differentiate between the drug
and polymer domains, whereas computational methods have some inherent assumptions since they
have not been developed specifically for the drug-polymer systems. Since the application of any of
either computational or analytical methods alone provides only one part of the complete picture,
the evaluation of the drug-polymer miscibility and solubility of the drug in polymer requires a
multimethodological approach. Future research in this field should enable the development of a
standardized methodology for the estimation of drug-polymer solubility/miscibility, which is of the
utmost importance for the development of solid dispersion formulations, as well as the final dosage
forms, in the pharmaceutical industry. We propose that standardized methodology should be based on
the thermodynamic modeling, a coupled computational-analytical method, as this approach enables
straightforward construction of temperature vs. composition phase diagram, which further serves as a
guidance for formulation scientists to choose suitable polymer, drug loading, processing conditions,
and storage conditions to ensure long-term stability of solid dispersion systems. Certainly, analytical
methods are an inevitable part of this methodology, as it is necessary to provide experimental data for
thermodynamic modeling and validation of the phase diagrams. The time-consuming calculations
required for the thermodynamic modeling hinder its implementation in the pharmaceutical industry,
so the development of user-friendly software solutions for thermodynamic modeling should certainly
facilitate the wider application of this approach in the formulation development. Additionally, it is of
particular importance to refine currently used thermodynamic models to adjust them to drug-polymer
systems and to include specific drug-polymer interactions with the overall aim to improve the
prediction accuracy of the models. Thorough implementation of a methodology for the assessment
of drug-polymer solubility/miscibility in the development of solid dispersion formulations should
bridge the gap between the great success in solid dispersion technology on the laboratory scale and
difficulties for such products to reach the market.
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Abbreviations
AFM Atomic Force Microscopy;
AFM-IR (nano IR) Nanoscale Infrared Spectroscopy;
BCS Biopharmaceutics Classification System
COMPASS Condensed-phase Optimized Molecular Potentials for Atomistic Simulation Studies




HPMCAS Hydroxypropylmethyl Cellulose Acetate Succinate;
HPMCP Hydroxypropylmethyl Cellulose Phthalate;
HSM Hot Stage Microscopy;
MD Molecular Dynamics;
M-DSC Modulated-temperature Differential Scanning Calorimetry;
μ-CT Micro-computed Tomography;
Na CMC Sodium Carboxymethyl Cellulose;
nanoTA Nanoscale Thermal Analysis;
NMR Nuclear Magnetic Resonance;
PAA Polyacrylic Acid;
PCFF Polymer Consistent Force Field
PCRM Pure Curve Resolution Method;
PC-SAFT Perturbed-Chain Statistical Associating Fluid Theory;
PDF Pair Distribution Functions;
PEG Polyethylene Glycol;
PHPA α,β-poly(N-5-hydroxypentyl)-l-aspartamide;
PLM Polarized Light Microscopy;
PVA Poly(vinyl alcohol);
PVP Polyvinylpyrrolidone;
PVPVA Polyvinylpyrrolidone Vinyl Acetate;
SEM Scanning Electron Microscopy;
SSNMR Solid State Nuclear Magnetic Resonance;
TASC Thermal Analysis by Structural Characterization;
TEM Transmission Electron Microscopy;
Tg Glass Transition Temperature;
TPGS d-α-Tocopheryl Polyethylene Glycol 1000 Succinate;
TSDC Thermally stimulated depolarization current
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Abstract: Approximately 40% of new chemical entities (NCEs), including anticancer drugs, have
been reported as poorly water-soluble compounds. Anticancer drugs are classified into biologic
drugs (monoclonal antibodies) and small molecule drugs (nonbiologic anticancer drugs) based on
effectiveness and safety profile. Biologic drugs are administered by intravenous (IV) injection due
to their large molecular weight, while small molecule drugs are preferentially administered by
gastrointestinal route. Even though IV injection is the fastest route of administration and ensures
complete bioavailability, this route of administration causes patient inconvenience to visit a hospital
for anticancer treatments. In addition, IV administration can cause several side effects such as
severe hypersensitivity, myelosuppression, neutropenia, and neurotoxicity. Oral administration is
the preferred route for drug delivery due to several advantages such as low cost, pain avoidance,
and safety. The main problem of NCEs is a limited aqueous solubility, resulting in poor absorption
and low bioavailability. Therefore, improving oral bioavailability of poorly water-soluble drugs is
a great challenge in the development of pharmaceutical dosage forms. Several methods such as
solid dispersion, complexation, lipid-based systems, micronization, nanonization, and co-crystals
were developed to improve the solubility of hydrophobic drugs. Recently, solid dispersion is one of
the most widely used and successful techniques in formulation development. This review mainly
discusses classification, methods for preparation of solid dispersions, and use of solid dispersion for
improving solubility of poorly soluble anticancer drugs.
Keywords: solid dispersion; classification; manufacturing methods; bioavailability; anticancer drugs
1. Introduction
Cancer is one of the leading causes of death worldwide, and treatment remains a great
challenge. Currently, there are three major cancer treatment strategies of surgery (performed by
a surgical oncologist), chemotherapy (use of anticancer drugs), and radiotherapy (delivered by a
radiooncologist) [1]. The objective of any treatment is to kill as many cancer cells as possible and
minimize death of normal cells. Patients can receive monotherapy or combination therapy. For example,
Hwang et al. [2] reported a combination of photodynamic therapy (PDT) and anti-tumor immunity
in cancer therapy. Among the three major therapeutic strategies, surgery has been the first line
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of treatment for many solid tumors. This strategy involves removal of solid tumors by a surgical
oncologist under anesthesia. However, patients have to be hospitalized, the entire tumor cannot
always be removed, damage can occur to nearby normal tissues, and complications can arise from
surgery. Radiotherapy is focused on the tumor and is designed to kill a large proportion of cancer cells
within the tumor. As with surgery, this therapy has disadvantages such as damage to surrounding
tissues (e.g., lung, heart) and inconvenience for patients (e.g., in some cases, it must be delivered daily,
5 days per week, for 1–2 months). In addition, radiotherapy causes hair loss. As such, use of anticancer
drugs (chemotherapy) is currently preferred for treatment of both localized and metastasized cancers.
Chemotherapy can kill many cancer cells throughout the body, eradicate microscopic disease at the
edges of tumors that may not be seen by a surgeon, and be used in combination with other therapies.
Tumor-targeted delivery and controlled release of drugs are two important strategies for improving
therapeutic efficacy and reducing side effects.
Cancer-targeting strategies for drug delivery include passive and active targeting strategies [3].
Active targeting focuses anticancer drugs to ligands or receptors in the target region. For example, folic
acid (FA) has been used as a targeting ligand to the folate receptor in various tumor sites including
lung, ovarian, breast, and colon cancers [4]. Vinothini et al. [5] developed a graphene oxide-methyl
acrylate-FA/paclitaxel (GO-MA-FA/PTX) nanocarrier for targeted anticancer drug delivery to breast
cancer cells, resulting in reduction of 39% of typical cytotoxic effects. Voeikov et al. [6] prepared
dioxadet-loaded nanogels using a block copolymer of polyethylene glycol and polymethacrylic acid
(PEG-b-PMAA) as a high-loading capacity (>35% w/w) and high-loading efficiency (>75%) drug
delivery system. In another study, trastuzumab, a monoclonal antibody with specific targeting to
human epidermal growth factor receptor 2 (HER2) protein, was used in combination with cisplatin for
treatment of HER2-overexpressing breast cancer [7]. Passive targeting occurs through interactions with
the reticuloendothelial system, allowing for entry into the blood, which is dependent on particle size
and surface characteristics. Development of nanoparticle anticancer drugs has improved therapeutic
efficacy because the drug can be directly and selectively targeted to cancer cells [8–10]. For example,
Kirtane et al. [11] developed a polymer-surfactant nanoparticle composed of a sodium alginate core
complexed with doxorubicin and the surfactant aerosol OT for stability. The relative BA of the
nanoparticle formulation was higher than that of the pure drug. In another study by Valicherla el
al. [12], docetaxel nanoparticles were prepared in a self-emulsifying drug delivery system (SEDDS) to
enhance BA and anti-tumor activity. The BA of docetaxel-SEDDS was 3.19-fold higher than that of the
pure drug. Furthermore, docetaxel-SEDDS showed 25-fold higher cytotoxic activity than the free drug
in vitro.
Intravenous (IV) and oral are the two most popular routes of drug administration. Paclitaxel is
an anticancer drug used to treat many types of cancers such as breast, ovarian, lung, and pancreatic
cancer. Paclitaxel is administered by IV infusion and sold under the marketed name Taxol 30 mg
(5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) [13]. Tamoxifen, an anticancer drug used to treat
breast cancer, is sold under the brand name Nolvadex (10 mg and 20 mg tablets) and is formulated
for oral administration [14]. IV infusion is the best route of administration for most anticancer drugs
because this route leads to 100% BA. However, IV administration is associated with several side
effects, short duration of effectiveness, and inconvenience due to hospitalization. Taxol is prepared by
solubilizing paclitaxel in ethanol: Cremophor EL (1:1, v/v). This formulation is then diluted 5–20-fold
in normal saline, resulting in a final concentration of 0.03–0.60 mg/mL [15]. However, several side
effects result from administration of Cremophor EL such as hypersensitivity, nephrotoxicity, and
neurotoxicity [16–18]. Despite the continuing interest on anticancer drugs in recent years, their use in
clinical anticancer therapy is limited due to nonspecific biodistribution, low therapeutic indices, and
poor aqueous solubility. As such, oral administration has received increasing attention, leading to
increased numbers of anticancer drugs being developed for oral dosing. Oral drugs can be administered
at home, do not induce the same discomfort as IV infusion, and the drug concentration can be
maintained for long time periods in cancerous cells. Oral dosage forms rely on drug solubility
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to achieve the desired concentrations in the systemic circulation. Drugs have to dissolve in the
gastrointestinal (GI) fluid and then permeate the membrane of the GI tract into the blood to be effective.
However approximately 40% of new chemical entities (NCEs), including anticancer drugs, are poorly
water-soluble [19–21]. Due to poor aqueous solubility, the drug cannot completely absorb in the GI tract,
resulting in poor bioavailability (BA) and high intra- and inter-individual pharmacokinetic variability.
The Biopharmaceutics Classification System (BCS) divides drugs into four groups as follows:
Class I (high solubility, high permeability), Class II (low solubility, high permeability), Class III (high
solubility, low permeability), and Class IV (low solubility, low permeability) (Figure 1) [22]. A drug
substance is considered highly soluble when the highest single therapeutic dose is soluble in 250 mL
or less of aqueous media over the pH range of 1.2–6.8 at 37 ± 1 ◦C. Permeability is evaluated on
the basis of the extent of absorption of a drug from human pharmacokinetic studies. Alternatively,
in vitro culture methods can also be used to predict drug absorption in humans. A drug is considered
highly permeable when the absolute BA is ≥85%. High permeability can also be concluded if ≥85%
of the administered dose is recovered in urine as unchanged (parent drug) or as the sum of the
parent drug, Phase 1 oxidative, and Phase 2 conjugative metabolites. Among four groups, drugs
belonging to Class II and IV exhibit poor aqueous solubility, resulting in poor BA. Therefore, enhancing
solubility and BA of poorly water-soluble drugs in BCS Classes II and IV is a significant challenge in
the pharmaceutical industry.
In the clinic, there are many insoluble drugs with small dose administration such as risperidone
(0.25–4 mg), lorazepam (0.5–2 mg), diazepam (2–10 mg), and clonazepam (0.5–2 mg), which do not
require increased solubility. However, the solubility of these drugs is usually affected by pH due to
physicochemical properties resulting in a decrease in the effective treatment. For example, risperidone
is indicated for treatment of schizophrenia at a small dose (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, or 4 mg)
in oral administration. It is a weak base that is practically insoluble in water. Its solubility is pH
dependent, with high solubility in acidic pH, and decreasing solubility as pH increases (range from
>200 mg/mL at pH 2.1 down to 0.29 mg/mL at pH 7.6 and reaches 0.08 mg/mL at pH 8). After oral
administration, risperidone is rapidly absorbed, and approximately 80% of drugs will be absorbed in
the GI tract, where the solubility significantly drops. Moreover, risperidone is a metabolized drug, in
which approximately 70% and 14% of the dose is excreted in urine and feces, respectively. Therefore,
enhancing solubility in simulated intestinal pH to ensure higher drug concentrations at the main
absorption site and improve BA is a challenge in drug development.
To improve the solubility and BA of poorly water-soluble drugs, several methods have been
developed such as solid dispersion (SD) [23–25], complexation [26], lipid-based systems [27,28],
micronization [29,30], nanonization [31–33], and co-crystals [34,35]. Among these, SD is one of the most
potent and successful methods. SD is defined as a group of solid products consisting of a hydrophobic
drug dispersed in at least one hydrophilic carrier, resulting in enhanced surface area, leading to
higher drug solubility and dissolution rate. Improving wettability and dispersibility and reducing
aggregation and agglomeration of drug particles result in enhanced drug BA. An SD is typically
characterized on the molecular level using Fourier-transform infrared spectroscopy (FTIR), Raman
spectroscopy, near-infrared spectroscopy (NIR), and solid-state nuclear magnetic resonance (SSNMR)
at the particulate level using powder X-Ray diffraction (PXRD), differential scanning calorimetry (DSC),
scanning electron microscopy (SEM), and transmission electron microscopy (TEM) and at the bulk
level using density, contact angle, flowability, and Karl Fischer titration [36]. SD can be accomplished
by several methods such as solvent evaporation [23], hot-melt extrusion [37], and spray drying [38].
In this review, we mainly discuss classification of drugs, methods for preparation of SD, and use of SD
for improving solubility of poorly soluble anticancer drugs.
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Figure 1. Biopharmaceutics classification system (BCS).
2. Solid Dispersions
An SD is defined as a group of solid products consisting of a hydrophobic drug dispersed in at
least one hydrophilic carrier, resulting in increased surface area and, enhanced drug solubility and
dissolution rate. They are classified as follows.
2.1. Carrier-Based Class of Solid Dispersion
Many carriers are used in SD. These carriers determine the final formulation properties and can
be categorized into first, second, and third classes (Figure 2).
Figure 2. Classification of solid dispersions.
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2.1.1. First Class of SD
The first study of SD was conducted by Sekiguchi and Obi in 1961 [39]. They studied absorption
of a eutectic mixture of sulfathiazole [39] and chloramphenicol [40] compared with that of the original
formulations of the same drugs. The results showed that the use of urea as a hydrophilic carrier
increased the absorption of sulfathiazole and chloramphenicol in the eutectic mixture compared
to that of the conventional formulations, thereby improving BA. Sugars and their derivatives are
carriers with high solubility in water and low toxicity. Levy [41] and Kaning [42] used mannitol as
a carrier to develop SD as a solid mixture instead of as a eutectic mixture. The formulation using
mannitol as a carrier showed higher dissolution compared to the original formulation of the drug.
To enhance the dissolution profile of clotrimazole, Madgulkar et al. [43] prepared an SD by a fusion
method using various sugars such as D-mannitol, D-fructose, D-dextrose, and D-maltose as carriers at a
different weight ratios to the drug. The results showed that a 100% solution of mannitol showed an
806-fold increase in solubility compared to the conventional drug in water. The dissolution profile
of clotrimazole SD was improved at 1:3 drug to mannitol ratio. In conclusion, urea and sugars were
first used as crystalline carriers for production of SD. These formulations were thermodynamically
unstable, resulting in slow drug release.
2.1.2. Second Class of SD
Because of thermodynamic instability of first class SD [44], second class SDs were introduced
using amorphous polymeric carriers [45] instead of urea or sugars. The polymeric carriers can be
synthetic or natural polymers. Synthetic polymers include povidone (PVP) [46–50], PEG [51–54],
and polymethacrylates [55,56], and natural polymers include hydroxypropylmethylcellulose
(HPMC) [57–61], ethyl cellulose [62–64], and starch derivatives such as cyclodextrins (CDs) [65].
A study by Franco et al. [66] showed that using PVP as a carrier in ketoprofen SD increased the
dissolution rate of ketoprofen 4.2-fold compared to that of the conventional drug. In a study by
Dhandapani and El-gied [67], β-CD was used as a carrier in cefixime SD to improve solubility.
The dissolution rate of cefixime SD was 6.77-fold higher than that of the pure drug. In another
study, an SD of diclofenac sodium was prepared by solvent evaporation using Eudragit E 100 as the
carrier [68]. Solubility of diclofenac sodium from the SD (0.823 mg/mL) was approximately 58.8-fold
higher compared with the pure drug (0.014 mg/mL). In dissolution studies, diclofenac sodium released
from SD was approximately 60% after 2 h at pH 1.2, while the pure drug release was less than 10% after
2 h. Second class SDs are dispersed in polymeric carriers and achieve a supersaturated state. These
formulations have smaller particle sizes and enhanced wettability thereby increasing the aqueous
solubility of drugs.
2.1.3. Third Class of SD
The third class of SD was recently developed. In this class, surfactant can be used alone or
in the combination with other hydrophilic carriers in the preparation of SD (Figure 2). Surfactants
were widely used to improve the solubility and BA of poorly water-soluble drugs and play a crucial
role in the pharmaceutical industry. Adsorption of a surfactant on a solid surface can modify the
hydrophobicity of the drug, thereby reducing surface tension between two liquids or between a
liquid and a solid. In addition, surfactants can also act as wetting agents, detergents, emulsifiers,
foaming agents, and dispersants. Several surfactants such as Inulin [69,70], inutec [70], poloxamer
407 [71], Gelucire 44/14 [72], and Compritol 888 ATO [73] are used in preparation of SD. In a study
by Panda et al. [74], Gelucire 50/13 and poloxamer 188 were used in the development of a bosentan
SD formulation to improve the solubility and dissolution of this drug. The results showed that the
solubility of bosentan from the SD formulation increased 8- and 10-fold when using Gelucire 50/13-
and poloxamer 188-based SDs, respectively, in comparison with that of the pure drug. Furthermore,
over 90% of the drug was released from SD after 1-h in vitro dissolution studies. Karolewicz et al. [75]
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prepared an SD of fenofibrate with poloxamer 407 as the carrier at ratios of 10/90, 20/80, 30/70, 40/60,
50/50, 60/40, 70/30, 80/20, and 90/10 using the fusion method. The results showed a 134-fold increase
in dissolution rate for SD containing 30/70 w/w fenofibrate/ poloxamer 407. Surfactants are also used
in preparation of SD of poorly soluble anticancer drugs such as docetaxel [76], flutamide [77], and
lapatinib [78].
2.2. Structure-Based Class of Solid Dispersion
2.2.1. Eutectic Mixtures
A eutectic mixture is a mixture of two components that melt at a single temperature. Components
A and B were co-melted at the eutectic point (E) (Figure 3), where the melting point of the mixture was
lower than that of component A or B alone. In 1961, Sekiguchi and Obi [39] were the first to prepare a
eutectic mixture of sulfathiazole and urea. The results showed that the absorption of sulfathiazole in
the eutectic mixture was improved compared to that of the conventional drug.
Figure 3. Phase diagram of a eutectic mixture. A, B (drug, carrier), E (eutectic point).
2.2.2. Solid Solution
Herein, SD is a mixture of the drug and a carrier [79]. Solid solution is categorized on the basis
of miscibility and molecular size of the components as continuous and discontinuous solid solutions.
In continuous solid solutions, the two components can be mixed in all proportions at which the
bonding strength between the two components is greater that of the individual components [80].
In discontinuous solid solutions, the solubility of each component is limited in solid solvents [81]. Solid
solutions are classified as substitutional (Figure 4A) and interstitial (Figure 4B) based on molecular
size. In substitutional solid solutions, solute molecules substitute for solvent molecules in the crystal
lattice. In interstitial solid solutions, the dissolved molecules occupy the interstitial spaces between the
solvent molecules in the crystal lattice [82].
Figure 4. Schematic structure of the solid solution.
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2.2.3. Glass Solution/Glass Suspension
A glass solution is a homogeneous system in which the drug molecule is dissolved in a glassy
solvent [81,82]. Glass suspension is a homogeneous system in which the drug molecule is suspended
in a glassy solvent [83]. The glassy state is characterized by transparency and brittleness below the
glass transition temperature for both glass solutions and glass suspensions.
2.3. Advantages of Solid Dispersions
SD was widely used for enhancing dissolvability in water of poorly water-soluble drugs with
several advantages as follows:
• One of the most important advantages of SD is drugs interacting with hydrophilic carriers can
decrease agglomeration and release in a supersaturation state, resulting in rapid absorption and
improved BA [84].
• SD can improve drug wettability and increase the surface area, resulting in enhanced aqueous
solubility of drugs.
• SD can be produced as a solid oral dosage form, which is more convenient for patients than other
forms like liquid products.
• In addition, SD showed an advantage compared to salt formulation, cocrystallization, and other
methods. For example, salt formulations use ionized active pharmaceutical ingredients (APIs)
(cationic or anionic form) and are widely used in the pharmaceutical industry due to the broad
capacity of design according to desired drug properties. However, not all drugs can ionize
with all cations/anions, and phase dissociation or stability issue is inherent in salt formation or
cocrystallization. Salt formulation showed several disadvantages such as reduced solubility
and dissolution rate, resulting in decreased relative BA (common ion effect for HCl salts);
greater regulatory scrutiny for strong acid salts isolated from alkyl alcohols; and increased
hygroscopicity, e.g., for Na and, K salts, spray-drying/lyophilization can dissociate strong acid
salts. The disadvantages of salt formulation can be resolved when the formulation is produced
using an SD.
• Practically, dissolution of drugs is a prerequisite for complete absorption to have the desired
therapeutic effect of anticancer drugs after oral administration. Most of the anticancer drugs
exhibit poor aqueous solubility causes of dissolution limit resulting low BA and high variability
in blood concentration. The limitation of drug dissolution can improve by SD, a technique that
induces supersaturated drug dissolution and with that it enhances in vivo absorption.
2.4. Disadvantages of Solid Dispersions
SD is a good technique for improving solubility and BA of hydrophobic drugs. However, some
disadvantages are as follows:
• Physical instability.
• SDs show changes in crystallinity and decreased dissolution rate with aging.
• Due to their thermodynamic instability, SD is sensitive to temperature and humidity during
storage. These factors can promote phase separation and crystallization of SD by increasing
the overall molecular mobility, decreasing the glass transition temperature (Tg) or disrupting
interactions between the drug and carrier, resulting in a decreased solubility and dissolution rate
of the drug.
• Patients suffering from cancer should continue to use anticancer drugs during treatment. However,
the instability of SD during the period of storage can affect drug quality and the effectiveness
of treatment.
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2.5. Preparation Methods for Solid Dispersions
SD can be prepared by several methods such as solvent evaporation, melting, and supercritical
fluid (SCF) technology (Figure 5). The list of drugs investigated for SDs is shown in Table 1, and a list
of commercial SDs is shown in Table 2.
Figure 5. Manufacturing methods of solid dispersion.
2.5.1. Melting Method/Fusion Method
The melting method was first used in 1961 by Sekiguchi and Obi [39]. The basic principle of the
melting method is that a physical mixture of a drug and hydrophilic carrier is heated directly until
they melt at a temperature slightly above their eutectic point. Then, the melt is cooled and solidified
rapidly in an ice bath with stirring. The final solid mass is crushed and sieved. The advantages of this
method are simplicity and economy. Several drug SDs have been prepared using this method such
as sulfathiazole [39], fenofibrate [75], furosemide [85], albendazole [54], and paclitaxel [86] (Table 1).
The melting method has also been used to improve solubility of poorly soluble anticancer drugs.
For example, to improve solubility of prednisolone, an SD was prepared by the melting method using
PEG 4000 and mannitol as the carriers [87]. The results showed that, at weight ratios of drug: PEG
4000 (1:4) and drug: mannitol (1:7), release of drug from the SD (~85%) increased in comparison
with the pure drug (~50%). In a study for improving release of paclitaxel from poly(ε-caprolactone)
(PCL)-based-film, an SD of paclitaxel was prepared by the melting method using poloxamer 188 and
PEG as the carriers and was then incorporated into PCL films. Drug released from SD was higher than
that from the pure drug, with over 90% of drug released from the SD after 1 h at a weight ratio of drug:
poloxamer 188 (1:3).
Table 1. List of drugs investigated for solid dispersions.
Methods Drugs
Melting/fusion method
Sulfathiazole [39], clotrimazole [43], albendazole [54], tacrolimus [61],
fenofibrate [75], furosemide [85], paclitaxel [86], manidipine [88],
olanzapine [89], diacerein [90]
Solvent evaporation method
Dutasteride [23], tadalafil [50], glimepiride [53], nimodipine [59],
diclofenac [68], azithromycin [91], tectorigenin [92], flurbiprofen [93],
cilostazol [94], ticagrelor [95], piroxicam [96], indomethacin [97],
loratadine [98], abietic acid [99], efavirenz [100], repagnilide [101],
prednisolone [102]
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Ritonavir [37], naproxen [46], oleanolic acid [103], efavirenz [104],
tamoxifen [105], lafutidine [106], disulfiram [107], bicalutamide [108],
itraconazole [109], miconazole [110], glyburide [111]
Lyophilization/Freeze-drying Nifedipine and sulfamethoxazole [112], celecoxib [113],meloxicam [114], docetaxel [115]
Co-precipitation method Silymarin [116], celecoxib [117], GDC-0810 [118]
Supercritical fluid method Ketoprofen [66], irbesartan [119], apigenin [120], carbamazepine [121],glibenclamide [122], carvedilol [123]
Spray-drying method Nilotinib [124], spironolactone [125], valsartan [126], rebamipide [127],artemether [128], naproxen [129]
Kneading method Cefixime [67], efavirenz [100], domperidone [130]
Table 2. List of commercial solid dispersions.
Products Drugs Polymers Company
Afeditab® Nifedipine Poloxamer or PVP Elan Corp, Ireland
Cesamet® Nabilone PVP Lilly, USA
Cesamet® Nabilone PVP Valeant Pharmaceuticals, Canada
Certican® Everolimus HPMC Novartis, Switzweland
Gris-PEG® Griseofulvin PEG Novartis, Switzweland
Gris-PEG® Griseofulvin PVP VIP Pharma, Denmark
Fenoglide® Fenofibrate PEG LifeCycle Pharma, Denmark
Nivadil® Nivaldipine HPC/HPMC Fujisawa Pharmaceuticals Co., Ltd
Nimotop® Nimodipine PEG Bayer
Torcetrapib® Torcetrapib HPMC AS Pfizer, USA
Ibuprofen® Ibuprofen Various Soliqs, Germany
Incivek® Telaprevir HPMC AS Vertex
Sporanox® Itraconazole HPMC Janssen Pharmaceutica, Belgium
Onmel® Itraconazole HPMC Stiefel
Prograf® Tacrolimus HPMC Fujisawa Pharmaceuticals Co., Ltd
Cymbalta® Duloxetine HPMC AS Lilly, USA
Noxafil® Posaconazole HPMC AS Merck
LCP-Tacro® Tacrolimus HPMC LifeCycle Pharma, Denmark
Intelence® Etravirine HPMC Tibotec, Yardley, PA
Incivo® Etravirine HPMC Janssen Pharmaceutica, Belgium
Rezulin® Troglitazone PVP Pfizer, USA
Isoptin SRE-240® Verapamil Various Soliqs, Germany
Isoptin SR-E® Verapamil HPC/HPMC Abbott Laboratories, USA
Crestor® Rosuvastatin HPMC AstraZeneca
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Table 2. Cont.
Products Drugs Polymers Company
Zelboraf® Vemurafenib HPMC AS Roche
Zortress® Everolimus HPMC Novartis, Switzweland
Kalydeco® Ivacaflor HPMC AS Vertex
Kaletra® Lopinavir and Ritonavir PVP/polyvinyl acetate Abbott Laboratories,
USA
PVP: polyvinylpyrrolidone; HPMC: hydroxypropylmethylcellulose; PEG: polyethyleneglycol; HPC:
hydroxypropylcellulose; HMPC AS: hydroxypropylmethylcellulose acetylsuccinate.
2.5.2. Solvent Evaporation Method
The solvent evaporation method is one of the most commonly used methods in the pharmaceutical
industry for improving solubility of poorly water-soluble drugs. This method was developed mainly
for heat unstable components because drug and carrier are mixed by a solvent instead of heat as
in melting method. Therefore, this method allows use of carriers with an excessively high melting
point. The basic principle of this method is that drug and carrier are dissolved in a volatile solvent
for homogeneous mixing. SD is obtained by evaporating the solvent under constant agitation. Then,
the solid SD is crushed and sieved. This method was first applied by Tachibana and Nakamura
in 1965 [131]. The formulation was prepared by dissolving a drug (β-carotene) and a carrier (PVP)
in an organic solvent (chloroform). After that, the solvent was completely evaporated to form a
solid mass, which was then sieved and dried. The main advantage of this method is avoidance of
decomposition of drug and carrier because the required temperature for evaporation is low. In 1966,
Mayersohn and Gibaldi developed an SD of griseofulvin using PVP as the carrier and chloroform as
the solvent [132]. Dissolution of griseofulvin from the SD was 11-times greater than that of the pure
drug at a ratio of griseofulvin: PVP (1:20). This method has been used to improve solubility of many
drugs such as azithromycin [91], tectorigenin [92], flurbiprofen [93], cilostazol [94], ticagrelor [95],
piroxicam [96], indomethacin [97], loratadine [98], diclofenac [68], abietic acid [99], efavirenz [100], and
repaglinide [101] (Table 1). An SD of tectorigenin, PVP, and PEG 4000 at a weight ratio of 7:54:9 was
prepared using solvent evaporation to increase dissolution and BA [92]. In vitro release of the drug
from the SD was 4.35-fold greater than that of the pure drug after 2.5 h. In addition, the oral BA of
the drug from the SD was higher than that of the conventional drug as determined by AUC (4.8-fold)
and Cmax (13.1-fold). The solvent evaporation method has often been used to improve solubility of
poorly water-soluble anticancer drugs such as paclitaxel [133], docetaxel [76], and others (Table 3).
For example, the solubility and dissolution of emulsified SD of docetaxel at 2 h were 34.2- and 12.7-fold
greater, respectively, compared to those of the conventional drug [76]. In the study by Adeli [91],
azithromycin SD was prepared by the solvent evaporation method using various PEG such as PEG
4000, PEG 6000, PEG 8000, PEG 12,000, and PEG 20,000 as the carriers at different ratios. Using PEG as
the hydrophilic carrier in SD, the solubility of drug is improved compared to the pure conventional
drug. The best result was obtained from SD containing azithromycin: PEG 6000 (1:7). After 1 h,
the amount of azithromycin released from SD was more than 49%.
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Bicalutamide PVP K30 Solventevaporation
Using PVP K30 as carrier, SD
showed the highest cumulative
released percentage (about 98%
during the initial 10 min) and
stability after 6 months
[134] 2006
Docetaxel HPMC, PEG Solventevaporation
The solubility and dissolution of
emulsified SD of docetaxel at 2
h were 34.2- and 12.7-fold
higher, respectively, compared
to the pure conventional drug
[76] 2011
Docetaxel PoloxamerF68/P85 Freeze-drying
A combination of poloxamer
F68 and P85 in the preparation
of docetaxel SD not only
enhanced solubility, but also
improved intestinal permeation
[135] 2016
Etoposide PEG Fusion method
The solubility and dissolution of





At a ratio of drug to HPMC
(1:15), drug release from SD was
75% after 30 min, thereby








The exemestane SD showed
4-6-fold increase in absorptive
transport compared to the pure
drug. In addition, AUC0-72h of
exemestane SD was 2.3-fold
higher in comparison with that
of drug alone
[138] 2017
Flutamide PVP K30, PEG,Pluronic F127 Lyophilization
The dissolution of flutamide
was higher (81.64%) than the
drug alone (13.45%) using







Solubility and dissolution of
lapatinib SD were enhanced
compared to the drug alone.
After 15 min, the drug in SD
was released at 92%compared to





Solubility of letrozole SD using
supercritical fluid is 7.1 times










The SD with drug: HPMC:
Ryoto sugar ester L1695 ratio of
1:2:1 showed over 95% rapid
dissolution within 30 min. In
addition, AUC and Cmax (0-24h)
of drug in SD were 4.0- and
5.5-fold higher, respectively,
compared to those in pure drug
[140] 2015
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Oridonin PVP K17 Supercriticalfluid
The dissolution of oridonin SD
significantly increased
compared to the original drug.
In addition, the absorption of
oridonin in SD showed 26.4-fold
improvement in BA
[141] 2011
Paclitaxel Poloxamer 188,PEG Fusion method
Paclitaxel SD was successfully
prepared, and the drug release
from SD was higher than that of
the drug alone
[86] 2013
Paclitaxel HPMC AS Solvent method
The solubility and permeability















The in vitro dissolution of
prednisolone SD was improved
compared with the pure drug
[87] 2011
Raloxifene PVP K30 Spray-drying
The absorption of raloxifene
from SD showed 2.6-fold
enhanced BA in comparison
with the conventional drug
[142] 2013
Sorafenib Soluplus Spray-drying
The Cmax and AUC0-48h of
sorafenib in SD formulation
increased 1.5- and 1.8-fold,




The dissolution and BA of
tamoxifen in SD were improved
compared with the drug alone
[105] 2018
Vemurafenib HPMC AS Solvent-controlledprecipitation
The BA of vemurafenib in SD
was improved 4~5-fold
compared to the conventional
drug
[144] 2013
HP-β-CD: hydroxypropyl-β-cyclodextrin, MNT: mannitol, SMP: skimmed milk powder.
2.5.3. Melting Solvent Method (Melt Evaporation)
The melting solvent method was first studied by Goldberg el al. [145]. In their study, an SD was
prepared to improve dissolution of griseofulvin using succinic acid as the carrier and methanol as
the solvent. The melting solvent method combines melting method and solvent evaporation method.
The drug is first dissolved in a suitable solvent and incorporated into the melt of the carrier, and
the mixture is then evaporated to dryness. Practically, this method is very useful for drugs with a
high melting point. Chen el al. [146] showed a novel monolithic osmotic tablet composed of an SD
of 10-hydroxycamptothecin (HCPT) prepared by the melting solvent method with PEG 6000 as the
carrier and methanol as the solvent. At 12 h, the cumulative release of drug was over 90%, and the
optimized formulation was able to deliver HCPT at a constant rate of 1.21 mg/h for 12 h in simulated
intestinal fluid (SIF; pH 6.8).
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2.5.4. Melt Agglomeration Process
Melt agglomeration is a process in which a binder acts as a carrier. In this method, the drug, binder,
and other excipients are heated to above the melting point of the binder. Alternatively, a dispersion
of the drug is sprayed onto the heated binder [147–150]. A diazepam SD was prepared by melt
agglomeration method in a high shear mixer to improve the dissolution rate. In this preparation,
lactose monohydrate was used as the binder and was melt agglomerated with PEG 3000 or Gelucire
50/13. The binder was added by either pump-on or melt-in procedures. Use of melt agglomeration
resulted in a high dissolution rate at a lower drug concentration. The dissolution rates were similar
between pump-on and melt-in procedures. In addition, the SD of diazepam containing Gelucire 50/13
showed higher dissolution compared with the SD containing PEG 3000.
2.5.5. Hot-Melt Extrusion Method
Hot-melt extrusion is a common method for improving solubility and oral BA of poorly
water-soluble drugs, in which the amorphous SD is formed without solvent, thereby avoiding residual
solvents in the formulation [151]. This method is conducted by a combination of the melting method
and an extruder, in which a homogeneous mixture of drug, polymer, and plasticizer is melted and then
extruded through the equipment. The shapes of products at the outlet of extruder can be controlled and
do not require grinding in the final step. For example, the melt extrusion method was used to increase
dissolution and oral BA of oleanolic acid [103]. Using PVP VA 64 as the carrier, an SD of oleanolic acid
was successfully prepared. Dissolution of this SD was better (about 90% of drug from SD released in
the 10 min) in comparison with those of a physical mixture (45% after 2 h) and pure drug (37% after
2 h). In addition, the AUC0–24h (1840 ± 381.8 ng·h/mL) and Cmax (498.7 ng/mL) of the drug from the
SD were enhanced 2.4 times and 5.6 times compared with those of pure drug (761.8 ± 272.2 ng·h/mL
and 89.1 ± 33.1 ng/mL, respectively). In another study by Sathigari el al., [104], efavirenz SD was
prepared via hot-melt extrusion method using Eudragit EPO or Plasdone S-630 as carriers to improve
the dissolution rate of efavirenz. In the dissolution test, because of very low aqueous solubility
(3–9 μg/mL), sodium lauryl sulfate (SLS) was added in the dissolution medium. The results showed
that the solubility of efavirenz increased substantially (197 μg/mL) in comparison with that of the
pure drug. After 30 min, about 96% and 82% of drug was released from SD using Eudragit EPO
and Plasdone S-630 as carriers, approximately 2-fold and 1.7-fold higher compared with drug alone,
respectively. In addition, the SD was stable after 9 months.
2.5.6. Lyophilization Techniques/Freeze-Drying
Lyophilization is an alternative process to the solvent evaporation method in which the drug
and carrier are dissolved in a solvent and then the solution is frozen in liquid nitrogen to form a
lyophilized molecular dispersion [152]. This method is typically used for thermolabile products that
are unstable in aqueous solutions but stable in the dry state for prolonged storage periods. In a
previous study, nifedipine and sulfamethoxazole SD were prepared by Soluplus and PEG 6000 as
carriers to evaluate physicochemical and in vitro characteristics [112]. SDs of the two drugs were
successfully prepared, and drug dissolution rate were increased. In a study of the anticancer drug
exemestane [138], an exemestane-loaded phospholipid/sodium deoxycholate SD was prepared to
improve the solubility and oral BA of the drug. The solubility and dissolution rate of exemestane from
SD were increased compared to those of the pure drug. The absorptive transport of the SD was 4.6-fold
greater in comparison with that of the conventional drug. Furthermore, the AUC0–72h of the drug in
the SD was 2.3-fold greater than that of the drug alone. In another study on a flutamide SD prepared
by lyophilization to enhance the dissolution rate [77], PVP K30, PEG 6000, and poloxamer 407 were
used as the carriers. Among these carriers, dissolution of SD when using poloxamer 407 as the carrier
(81.6%) was higher compared with that using other carriers (PVP K30 66.5% and PEG 6000 78.2%) after
30 min and higher compared with that of the pure drug (13.5%).
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2.5.7. Electrospinning Method
The electrospinning method is a combination of SD technology and nanotechnology. In this
method, solid fibers are produced from a polymeric fluid stream or melt delivered through a
millimeter-scale nozzle [153]. The advantage of this method is that the process is simple and
inexpensive. This method is suitable for preparing nanofibers and controlling release of biomedicine.
A nanofiber of polyvinyl alcohol (PVA):ketoprofen (1:1, w/w) was prepared by the electrospinning
method [154]. Dissolution of this nanofiber was significantly (p < 0.05) greater than that of ketoprofen
alone. In another study, an amorphous formulation of indomethacin and griseofulvin was prepared by
the electrospinning method using PVP as the carrier. This formulation was stable for 8 months in a
desiccator [155].
2.5.8. Co-Precipitation
In this method, the carrier is first dissolved in solvent to prepare a solution, and the drug is
incorporated into the solution with stirring to form a homogeneous mixture. Then, water is added
dropwise to the homogenous mixture to induce precipitation. Finally, the precipitate is filtered and
dried. In a study by Sonali et al. [116], a silymarin SD was prepared with HPMC E15LV as the
carrier with various methods such as kneading, spray-drying, and co-precipitation. The silymarin SD
prepared by co-precipitation showed significantly (p < 0.05) enhanced dissolution compared with the
other two methods. Furthermore, the solubility of silymarin from the SD prepared by co-precipitation
improved 2.5-fold in comparison with that of the conventional drug.
2.5.9. Supercritical Fluid (SCF) Technology
SCF was introduced in late 1980s and early 1990s. SCF produces a formulation with a narrow
particle size range (microparticles or nanoparticles) without solvent and was reported by Hannay
and Hogarth in 1897 as a medium for particle production [156]. A substance is in the supercritical
state when the temperature and pressure are above its critical point. SCF can act as solvent or
antisolvent in SD. The basic principle of SCF is that the drug and carrier are dissolved in a supercritical
solvent (e.g., CO2) and sprayed through a nozzle into an expansion vessel with lower pressure.
The rapid expansion induces rapid nucleation of the dissolved drugs and carriers, leading to the
formation of SD particles with a desirable size distribution in a very short time. To date, SCF can
be performed by several methods such as rapid expansion from supercritical solution (RESS) [157],
gas antisolvent (GAS) [141], supercritical antisolvent (SAS) [119], and solution enhanced dispersion
by SCF (SEDS) [158]. The RESS process is conducted as follows: Drug and carrier are dissolved in
SCF, then sprayed through an atomizer in an expansion vessel maintained at low pressure, resulting
in formation of an SD. The advantage of this method is that it can minimize use of organic solvents
for preparation of SD. In SCF technology, CO2 is a suitable solvent for preparation of SD of insoluble
drugs, primarily due to its low critical temperature (31.04 ◦C) and low critical pressure (7.38 MPa), lack
of toxicity, lack of inflammability, and environmental safety [159]. To improve dissolution of irbesartan,
Adeli [119] prepared an SD by the SAS method using poloxamer 407 as the carrier. The optimal ratio
of drug and carrier was 1:1. As a result, dissolution of the irbesartan-SAS sample was 13 times higher
than that of the pure drug. In another study, to enhance the BA of apigenin, apigenin nanocrystals were
prepared by the SAS method [120]. The results showed that the Cmax and AUC of the final formulation
increased 3.6-fold and 3.4-fold, respectively, in comparison with that of the drug alone, demonstrating
improved BA. In drug development, SCF technology is a potential method for enhancing solubility
and BA of poorly water-soluble drugs. One limitation of this method is that most drugs are not soluble
in CO2.
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2.5.10. Spray-Drying Method
Spray-drying is one of the oldest methods for drying materials, especially thermally-sensitive
materials such as foods and pharmaceuticals. In this method, the drug is dissolved in a suitable solvent,
and the carrier is dissolved in water to prepare the feed solution. Then, the two solutions are mixed by
sonication or other suitable methods until the solution is clear. In the procedure, the feed solutions
were firstly sprayed in a drying chamber via a high-pressure nozzle to form fine droplets. The formed
droplets are composed of drying fluid (hot gas) and form particles of nano or micro size [160].
Clinically, the spray-drying method has been widely used for preparation of SD for improving solubility
and BA of poorly water-soluble drugs such as nilotinib [124], spironolactone [125], valsartan [126],
rebamipide [127], and artemether [128] (Table 1). For example, in a study by Herbrink et al. [124],
an SD of nilotinib was prepared by spray-drying to enhance solubility. Soluplus was selected as
the best carrier based on in vitro dissolution studies. At a drug: Soluplus (1:7) ratio, the solubility
of nilotinib was improved 630-fold in comparison with the pure drug. In another study by Pawar
et al. [128], an artemether SD was prepared by spray-drying to improve solubility and dissolution.
The results showed that the optimal ratio of drug: carrier (artemether: Soluplus) was 1:3. After 1 h,
artemether release from SD was 82%, 4.1-fold higher than the conventional drug (20%). Spray-drying
is an efficient technology for preparation of SD for improving solubility and BA of hydrophobic drugs.
2.5.11. Kneading Method
In this method, the carrier is dispersed in water and processed into a paste. Then, the drug is
added and kneaded thoroughly. The final kneaded formulation is dried and passed through a sieve if
necessary. In a previous study by Dhandapani and El-gied [67], cefixime SD was prepared with β-CD
as the carrier using the kneading method. The result showed that the dissolution rate of cefixime from
the SD was 6.77-fold greater than that of the pure drug, suggesting a possible improvement in BA. In
another study [130], the HP-β-CD was used as the carrier in a domperidone SD. Saturation solubility
and in vitro dissolution of domperidone from SD were considerably higher (3-fold) in comparison
with the pure drug.
2.5.12. Suitable Methods for Production of SDs of Anticancer Drugs
Anticancer drugs are classified into biologic drugs (monoclonal antibodies) and small molecule
drugs (nonbiologic anticancer drugs) based on effectiveness and safety profile. Biologic drugs are
administered by intravenous (IV) injection due to their large molecular weight, while small molecule
drugs are preferentially administered by gastrointestinal route. Oral administration is currently
preferred for treatment of cancer in comparison with IV route because it is convenient, painless, safe,
and economic. Oral drugs can be administered at home, do not induce the same discomfort as an
IV infusion, and the drug concentration can be maintained for long time periods in cancerous cells.
In addition, oral dosage forms are easy to store and transport. Therefore, oral administration has
received increasing attention, leading to increased numbers of anticancer drugs being developed for
oral dosing.
To date, SD technology is widely used to improve the solubility and BA of anticancer drugs due
to its simplicity, economy, and high effectiveness. Most methods are suitable for making SD, in which
melting method, solvent evaporation method, SCF technology, and freeze-drying are common for
production of SD formulation of anticancer drugs in comparison with other methods. The selected
method will be based on physicochemical properties of anticancer drugs.
2.5.13. Lab Scale and Industrial Scale Manufacturing Processes
Several manufacturing methods were used to produce SD. However, not all methods are available
for commercial processes. Practically, the melting method and solvent evaporation method are two
distinct processes that are widely used on lab and industrial scale.
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On the lab scale, for the solvent evaporation method, a rotary evaporator was mostly used to
produce SD. Recently, SCF and freeze-drying are also employed. Due to its simplicity and economy, the
melting method is popularly used. Currently, several types of equipment from many manufacturers
such as Brabender Technologies, Coperion GmbH, Thermo Fisher Scientific, and Leistritz Advanced
Technologies Corp are available in the laboratory, in which SD amount can be produced from a few
grams to a kilogram.
On the industrial scale, production of SD is not as simple as at the lab scale because it involves
a large amount of product from a few to several hundred kilograms. In addition, processes need
to be robust, reproducible, and follow good manufacturing practices (GMP). These are difficult to
ensure for processes such as solvent cast evaporation or water bath melting process. Spray-drying and
freeze-drying are the most representative of the solvent evaporation methods used for manufacturing
SD. Moreover, the spray-drying process is easy to scale up from lab scale to industrial scale. Melt
agglomeration and hot-melt extrusion are two types of melting processes available on the industrial
scale. For instance, hot-melt extrusion is one of the most common methods used on an industrial scale
to produce SD using twin-screw extruder with a large diameter of the screw (16–50 mm) compared
with small diameter of the screw at lab scale (11–16 mm).
In summary, the selected method for manufacturing process plays an important role in the success
of a formulation. On the lab scale, the criteria for selecting the melting method are based on the melting
point and thermal stability. For selecting the solvent evaporation method, important factors to consider
are properties of the drug, carrier, and an organic solvent. On the industrial scale, the production of
SD is limited to only a few manufacturing processes. Hot-melt extrusion is the most common among
the melting processes to produce SD. For the evaporation method, the selection criteria are based on
solvent toxicity and loading capacity.
2.6. Use of SD for Improving Poorly Soluble Anticancer Drugs
Cancer is one of the leading causes of death worldwide and is defined as a group of diseases
involving abnormal cell growth with potential to invade or spread to other parts of the body. The World
Health Organization predicted that the burden of cancer will increase to 23.6 million new cases each
year by 2030 [161]. In 2018, among 1,735,350 new cancer cases, an estimated 609,640 Americans
will die from cancer, corresponding to almost 1,700 deaths per day [162]. Therefore, treatment of
cancer is one of the most important issues studied during the past several decades. For anticancer
drugs to induce a therapeutic effect, they must first be absorbed and enter the circulation. To ensure
complete BA, most anticancer drugs are preferably administered by IV infusion because the entire
dose of the drug will directly enter into the circulatory system and instantaneously distribute to its
sites of action. However, IV administration inconveniences the patients because they have to visit the
hospital to receive treatment. In addition, several side effects may occur during the treatment period.
For example, the commercial product paclitaxel (Taxol), which is prepared with Cremophor EL and
ethanol as solvents (50:50, v/v), is associated with serious side effects due to Cremophor EL such as
severe hypersensitivity, myelosuppression, neutropenia, and neurotoxicity [16–18]. To avoid these
side effects, Park et al. [163] prepared paclitaxel SD without Cremophor EL using the supercritical
antisolvent method. The solubility of paclitaxel in SD is 10 mg/mL, an almost 10 000-fold increase
compared to the conventional drug at a weight ratio of 1/20/40 of paclitaxel/HP-β-CD/HCO-40.
In addition, the SD is stable over 6 months.
In the past few decades, many oral formulations of anticancer drugs have been developed. Oral
administration is currently the desired route for treatment of cancer because it is convenient, painless,
safe, and economic. In addition, oral dosage forms are easy to store and transport. The prerequisite for
oral administration is complete and predictable absorption. To achieve this, drugs have to dissolve
in water to absorb in GI tract to be effectively taken up in the circulatory system. However, nearly
all anticancer drugs are poorly water-soluble, which can lead to incomplete absorption and poor BA,
resulting in large inter- and intra-individual variability in drug concentrations in vivo. Thus, improving
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the solubility of anticancer drugs is a great challenge in development of improved cancer therapies in
the pharmaceutical industry [164]. Among several methods such as complexation, lipid-based systems,
micronization, nanonization, and co-crystals, SD is the most successful for improving solubility and BA
of anticancer drugs. Vemurafenib (Zelboraf® Roche), regorafenib (Stivarga®, Bayer), and everolimus
(Afinitor®, Votubia®, Certican®, Novartis) are three commercial anticancer drugs that were prepared
by SD [165]. Zelboraf® was prepared from vemurafenib and hypromellose acetate succinate carrier at
a weight ratio of 30/70 (w/w). Dissolution of the SD formulation was approximately 30 times higher
compared to the crude powder. Stivarga, which contains regorafenib and PVP-25 as the carrier, showed
a 4.5-fold increase in dissolution rate compared to that of the drug mixture. In addition, the BA of the
drug from the SD was approximately 7 times higher than that of the conventional drug. Afinitor is an
SD prepared with drug and HPMC at a weight ratio of 1:40 in which the dissolution rate from the SD
was improved about 4-fold in comparison with the pure drug. The anticancer drugs investigated for SD
are shown in Table 3. To enhance the solubility and dissolution rate of docetaxel, an SD was prepared
and the solubility and dissolution rate at 2 h were 34.2- and 12.7-fold higher in comparison with the
crude powder, respectively [76]. In another study by Ren et al. [134], dissolution of bicalutamide was
improved by preparing an SD using PVP K30 as the carrier at a weight ratio of drug: PVP K30 (1:5).
At this ratio, about 98% of bicalutamide was dissolved during the first 10 min. Recently, mixtures
of surfactants were used to prepare SD, resulting in increased solubility and improved permeability
of BCS Class IV drugs. Song et al. [135] prepared a docetaxel SD using poloxamer F68 alone or a
poloxamer SD using a combination of poloxamer F68 and poloxamer P85. Performance of the two SDs
was compared, showing that the SD prepared with only poloxamer F68 increase in solubility (1.39-fold
increases in BA), while the SD prepared with a combination of poloxamer F68 and poloxamer P85
showed enhanced solubility and permeability (2.97-fold increase in BA). Thus, SD is a promising
technique for improving solubility and BA of poorly water-soluble anticancer drugs.
2.7. Future Prospects
SD is currently considered one of the most effective methods for enhancing the solubility and BA
of poorly water-soluble drugs. Even though the issues related to preparation, stability, and storage
formulation of drugs may limit the numbers of commercial SD products on the market, SD products
are still steadily increasing in clinical settings based on improved manufacturing methods and carriers
to solve the above problems.
In recent years, carriers used in the preparation of SD have been developed. Some studies used
new carriers, while other studies used more than one carrier for production of SD formulation. Using
more than one carrier in the formulation of SD, many effective methods were designed, recrystallization
was decreased, and the stability of SD was improved. Some carriers used recently are Inulin®,
Gelucire®, Pluronic®, and Soluplus®.
In the manufacturing process, Kinetisol Dispersing (KSD) [166–168] is a novel high-energy mixing
process for preparation of SD, in which the drug and carrier are processed by utilizing a series of
rapidly rotating blades through a combination of kinetic and thermal energy without the aid of external
heating sources. This brings new hope for development of more SD products in the future.
3. Conclusions
In this review, we focused on classification of SD, methods for preparation of SD, and current
trends in SD for improving the solubility of poorly water-soluble drugs, including anticancer drugs.
IV administration is preferred for anticancer treatment. However, patients are inconvenienced by this
route because they have to visit a hospital to receive treatment. Therefore, scientists are working to
develop oral dosage forms of anticancer drugs. Oral administration is currently the most common route
of administration of drugs because it is convenient for patients. A prerequisite for oral administration
is dissolution of the drug in water to allow absorption in the GI tract; however, approximately 40% of
NCEs including anticancer drugs are insoluble in water which leads to poor absorption, poor BA, and
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high intra- and inter-individual variability in blood concentrations. Therefore, improving the solubility
of poorly water-soluble drugs is a large challenge in the pharmaceutical industry. To overcome this
problem, various methods such as complexation, lipid-based systems, SD, micronization, nanonization,
and cocrystallization were developed for clinical use. Among these, SD is one of the most successful
methods and is widely used for development of drugs. It is considered a promising technique to
overcome problems related to poor aqueous solubility and poor BA. By improving wettability of
drugs and surface area, drug solubility and dissolution were increased. In the preparation of SD,
understanding the properties of the carrier and drug, and selecting a suitable method play crucial
roles in the success of the formulation.
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4000 solid dispersions with supercritical carbon dioxide: Preparation, characterisation, and in vitro
dissolution. Int. J. Pharm. 2001, 222, 129–138. [CrossRef]
122. Tabbakhian, M.; Hasanzadeh, F.; Tavakoli, N.; Jamshidian, Z. Dissolution enhancement of glibenclamide
by solid dispersion: Solvent evaporation versus a supercritical fluid-based solvent -antisolvent technique.
Res. Pharm. Sci. 2014, 9, 337–350.
123. Djuris, J.; Milovanovic, S.; Medarevic, D.; Dobricic, V.; Dapčević, A.; Ibric, S. Selection of the suitable polymer
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Abstract: Solid dispersions are important supersaturating formulations to orally deliver poorly
water-soluble drugs. A most important process technique is hot melt extrusion but process
requirements limit the choice of suitable polymers. One way around this limitation is to synthesize
new polymers. However, their disadvantage is that they require toxicological qualification and
present regulatory hurdles for their market authorization. Therefore, this study follows an alternative
approach, where new polymeric matrices are created by combining a known polymer, small molecular
additives, and an initial solvent-based process step. The polyelectrolyte, carboxymethylcellulose
sodium (NaCMC), was tested in combination with different additives such as amino acids,
meglumine, trometamol, and urea. It was possible to obtain a new polyelectrolyte matrix that
was viable for manufacturing by hot melt extrusion. The amount of additives had to be carefully
tuned to obtain an amorphous polymer matrix. This was achieved by probing the matrix using
several analytical techniques, such as Fourier transform infrared spectroscopy, differential scanning
calorimetry, hot stage microscopy, and X-ray powder diffraction. Next, the obtained matrices had to
be examined to ensure the homogeneous distribution of the components and the possible residual
crystallinity. As this analysis requires probing a sample on several points and relies on high quality
data, X-ray diffraction and starring techniques at a synchrotron source had to be used. Particularly
promising with NaCMC was the addition of lysine as well as meglumine. Further research is needed
to harness the novel matrix with drugs in amorphous formulations.
Keywords: polyelectrolytes; amorphous solid dispersions; hot melt extrusion; polyelectrolyte
excipient matrix
1. Introduction
The rising number of poorly water-soluble drugs in the development pipelines as well as on the
market encouraged the pharmaceutical industry to develop new formulation techniques. One strategy
is the formulation of a drug in an amorphous form as a solid dispersion, which normally leads to
drug supersaturation upon oral administration to promote absorption [1–5]. Among the different
process techniques for the manufacturing of amorphous solid dispersions, hot melt extrusion (HME)
and spray drying are the most common methods [5,6]. These two process techniques mostly use a
combination of drug and polymeric compound. However, HME formulations currently available
on the market utilize only about six of the pharmaceutically accepted polymers or a combination of
Pharmaceutics 2019, 11, 174; doi:10.3390/pharmaceutics11040174 www.mdpi.com/journal/pharmaceutics7
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these [6]. Contemporary research is primarily focused on finding new combinations of well-established
polymers with plasticizers and surfactants [7], or even on designing new monomers for novel
synthetic polymers that come with the aforementioned multiple development hurdles to reach
the pharmaceutical market [8]. Another approach is the fine tuning of the extrusion process by
changing screw configuration, temperature profiles or by employing different downstream processing
steps [9,10].
Recently, we introduced the approach to molecularly modify a polymeric matrix by interacting
excipients [11]. The difference to a classical mixture approach with excipients is that molecular
interactions are specifically targeted by design and cannot be facilitated in an extrusion of the physical
mixture. In line with this idea, the current study explores the possibility to use selected additives that
can interact ionically or via hydrogen bonding to enable HME of a matrix based on the polyelectrolyte
carboxymethylcellulose sodium (NaCMC) for the first time.
NaCMC was recently extruded with polydimethylsiloxane as a polymeric mixture to form material
for 3D printing [12] or it is occasionally used in spray drying [13]. The polymer shows good water
solubility and extensive swelling behavior, which are both interesting properties for a new modified
matrix produced by HME.
The concept of formulating ionic substances to produce a semi-solid or even liquid with a
lower melting point is a well-known technique of “ionic liquids” and an important pharmaceutical
application in the field of lipid-based formulations [14,15]. Recent publications highlighted the positive
implications of salt formation on HME [16,17], but primarily for keeping the drug in amorphous form
through the formation of ionic interactions [18,19]. Such an approach is of particular interest, since
the direct extrusion of neat unprocessed NaCMC is not applicable, because it decomposes at 252 ◦C
instead of having a melting point [20].
Therefore, this paper studies polymeric films of NaCMC in combination with six interacting small
molecular additives that were first transformed into a solid excipient dispersion through solvent
evaporation. In a second processing step, HME was performed. The solvent evaporation step
(involving a medium with a high dielectric constant) enabled targeted ionic interactions between
polyelectrolyte NaCMC and the ionizable additive [18]. The main reason, why a solvent evaporation
step was conducted prior to extrusion was that the compounds used would not be feasible for extrusion
as otherwise neat powders because of their high melting points.
As the first group of coformers to be studied with NaCMC, the basic amino acids, histidine,
lysine, and arginine, were chosen, as they have been proven to interact with acidic groups of mostly
drugs in various studies and consequently improved formulation properties such as amorphous
stability, miscibility and plasticizing effects [21–29]. The second group of substances consisted of
water-soluble inactive substances, which were also hypothesized to likely form an interaction with
NaCMC after solvent evaporation and extrusion. The chosen coformers were urea, meglumine and
trometamol (TRIS).
Powder X-ray diffraction (PXRD) was applied to determine the maximum amount of additive
that is still feasible for successful miscibility and an extrusion process to form an amorphous product.
Two limiting factors had to be considered during the described processing: on the one hand, the
unfavorable extrusion properties of NaCMC, which required a high amount of additive to enable
the extrusion and on the other hand, the crystalline structure of the additives, which would lead to a
crystalline product in high concentrations because of insufficient miscibility. While the preliminary
measurements could be carried out using the laboratory diffractometer, conclusive results could only
be obtained by using the data collected at a synchrotron source. Namely, to ensure the amorphous
formulation, it was necessary to collect high quality PXRD data that is sensitive to extremely low
amounts of crystalline phases in the sample. Secondly, to examine the distribution of the additive in
the sample, the sample had to be probed on several points, which again required a specific sample
stage at a synchrotron source.
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Further assessment included thermal analysis by differential scanning calorimetry, which was
complemented by hot stage microscopy and hot stage attenuated total reflectance Fourier transform
infrared spectroscopy (ATR-FTIR) to show crystallinity and form changes upon heating [18]. The HSM
images were used as a complimentary analysis of the thermal miscibility and melting behavior of the
evaporates during the extrusion [10,30].
This paper highlights the capability of different small molecular additives to enable the
formulation of a polymeric compound, which would otherwise not be suitable for extrusion. Such a
combination resulted in the development of a new modified excipient matrix for HME that formulators
will find helpful to cope with challenging pharmaceutical compounds.
2. Materials and Methods
2.1. Materials
Carboxymethylcellulose sodium salt (low viscosity), urea, meglumine, TRIS, L-lysine, L-aspartic
acid, and L-histidine were bought from Sigma Aldrich (St. Louis, MO, USA). Purified water, which
was used for the solvent evaporation, was taken from a MilliQ Millipore filter system (Millipore Co.,
Bedford, MA, USA).
2.2. Methods
2.2.1. Preparation of Hot Melt Extrudates
Binary mixtures of NaCMC and the additive (according to the composition given in Sections 3.1.1
and 3.2.1) were mixed in a mortar and dissolved in MilliQ water in a round bottom flask. Afterwards,
the water was removed by a rotary evaporator (Rotavapor Büchi, Flawil, Switzerland), which resulted
in a transparent film. This film was cut into smaller pieces and extruded on co-rotating screws with
a 9-mm diameter and 180 mm in length in a ZE9 ECO twin screw extruder by ThreeTec (Birren,
Switzerland). A screw speed of 80 rpm was applied at a temperature of 130 ◦C through all three
heating zones. The final extrudates were cooled to room temperature and stored in falcon tubes.
2.2.2. Laboratory Powder X-ray Diffraction (PXRD)
Mixtures were studied for their potential amorphous form by PXRD on a D2 Phaser diffractometer
(Bruker AXS GmbH, Karlsruhe, Germany) with a 1-D Lynxeye detector. The instrument was equipped
with a Ge-monochromator (Cu Kα radiation) providing X-ray radiation at a wavelength of 1.541 Å.
During the measurements, a voltage of 30 kV and a current of 10 mA were used. The increment and
time per step were set to 0.020 ◦ and 1 s, respectively. The measurements were scanning a range of 5◦
to 40◦ (2θ).
2.2.3. Differential Scanning Calorimetry (DSC)
Samples were further assessed by a differential scanning calorimeter on a DSC 3 (Mettler Toledo,
Greifensee, Switzerland). The samples were cut in small pieces and 5 to 9 mg was placed in a 40 μL
aluminum pan with a pierced lid. A heating rate of 10 ◦C/min from −10 ◦C to 140 ◦C was applied,
while the surrounding sample cell was purged with nitrogen 200 mL/min. Moreover, the combination
of heating, cooling and heating cycles was used to fully evaluate the samples. For the assessment of the
initial form, the first heating was used. The thermograms and glass transition temperatures (Tgs) were
analyzed with the STARe Evaluation-Software Version 16 (Mettler Toledo, Greifensee, Switzerland).
All thermograms show exothermic events as upward peaks.
2.2.4. Hot Stage Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR)
A Cary 680 Series FTIR spectrometer (Agilent Technologies, Santa Clara, CA, USA) was used,
which was equipped with a heatable attenuated total reflectance accessory (Specac Limited, Orprington,
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UK) and the control panel 6100+ by WEST (West Control Solutions, Gurnee, IL, USA). The scanning
range of 4000–600 cm−1 was selected with 1500 scans over a period of 30 min and a resolution of
4 cm−1. The heating rate was set to 5 ◦C/min going from 30 ◦C to 130 ◦C. For the evaluation, a
spectrum was extracted and evaluated by the software ACD/Spectrus Processor 2016.1.1 (Advanced
Chemistry Development, Canada) every minute (i.e., every 5 ◦C). Every spectrum shows a 5 ◦C
temperature increase going from the front to the back of the figures. The increase of peaks towards
higher temperatures in the area of 2000 cm−1 is related to the heat implications on the ATR crystal. For
the hot stage FTIR analysis, the solvent evaporated films were used, whereas the FTIR spectra at room
temperature were recorded from the physical mixture, solvent evaporates, and extrudates.
2.2.5. Synchrotron Powder X-ray Diffraction
X-ray powder diffraction data were recorded at the ID22 beamline at the European Synchrotron
Radiation Facility (ESRF, France) using a two-dimensional detector (PerkinElmer XRD 1611CP3) and
an incident X-ray energy of 60 keV (λ = 0.20678 Å, Qmax = 24 Å−1). A beam size of about 0.5 mm × 0.5
mm was used. Reference samples were packed in 0.7-mm diameter borosilicate capillaries. Extrudate
samples were mounted directly on capillary supports and measured as is. In order to minimize
any possible radiation damage, samples were cooled down to 100 K using an Oxford Cryosystem
Cryostream. To improve the overall statistics, 200 two-dimensional images were recorded (2 s per
frame) and averaged. The one-dimensional diffraction patterns were retrieved after integration using
the PyFAI software [31]. Five diffraction patterns on five different locations were recorded on each
extrudate sample in order to check for heterogeneity.
2.2.6. Hot Stage Microscopy (HSM)
The HSM analysis employed a Leica DMRM at magnifications of 100×, which is also displayed
as a scale bar in the images. The microscope was equipped with a temperature-controlled microscope
stage from Linkram. This analysis was used for the evaluation of the behavior of the formulation
upon heating in the extruder and to complement the DSC analysis [9,17,32]. For a close relation to the
extrusion process, the temperature ramp was set from room temperature (RT) to 130 ◦C. During this
ramp, the temperature was kept steady and images were taken at RT, 90 ◦C, and 130 ◦C. The obtained
images were converted into black and white to highlight the melting process.
3. Results and Discussion
3.1. Amino Acids as Additives
3.1.1. Characterization of the Formulations
Formulations containing the additives arginine and lysine were found to be amorphous after
evaporation as well as extrusion. In contrary, it was not possible to convert histidine to an amorphous
form neither with evaporation nor with extrusion. Table 1 highlights the different aspects, which were
essential during processing of the formulation such as a qualitative evaluation of technical feasibility
during HME. The extrusion was evaluated compared to a standard extrusion of the polymer, PVPVA
64, which is considered arbitrarily as ideal for extrusion. Such extrusion behavior is influenced by melt
viscosity, thermoplasticity, and degradation [10].
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Amino Acid + NaCMC
Lysine 50% (w/w) 0.64 30.27 ◦C 30.62 ◦C ++
Arginine 33% (w/w) 0.43 35.36 ◦C 33.15 ◦C +
Histidine 20% (w/w) 0.30 36.59 ◦C - - -
* For the calculation, the molar weight of the NaCMC monomer was used. ** Technical feasibility was qualitatively
assessed and details are given in the text.
The optimal amounts of additives necessary to produce an amorphous polymer matrix are
presented in Table 1, expressed as loadings in weight/weight as well as the calculated molar fractions of
the formulation components. Lysine resulted in the highest amount of additive, which was formulated
in an amorphous form in combination with NaCMC, whereas histidine being less feasible for the
evaporation and the later extrusion could only be incorporated in the lowest molar ratio used in this
study. This is also reflected by very poor extrusion behavior as well as the disappearance of the Tg in
the DSC measurements of the corresponding extrudates, which may be explained by recrystallization
from amorphous state as crystallinity was found in the extruded histidine formulation (Figure 1).
For the above-mentioned table, it has to be mentioned that lower amounts of additive during a
previous formulation development were leading to worse extrusion performances, which underlines
the insufficient extrusion performance of neat NaCMC.
 
Figure 1. The solid lines represent the differential scanning calorimetry (DSC) thermograms of the
extrudates and the dotted lines represent the evaporates which were used for the later extrusion. The
amino acids added to sodium carboxymethylcellulose (NaCMC) are arginine (cyan), lysine (orange),
and histidine (green).
In detail, the dotted lines in Figure 1, representing the solvent evaporates, show only slight
indications of a Tg in all samples. Whereas only the thermograms of extrudates containing lysine and
arginine show the presence of a clear Tg in the extrudates (see Table 1). This can be associated with an
amorphous form of the additive in the formulation [33] and gives a first indication of formed molecular
interactions [22,26]. These two additives also formed more prominent Tgs during the extrusion, which
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entails a higher amount of amorphous additive in the formulation. Consequently, such a processing
was beneficial for the formation of an amorphous modified matrix of NaCMC. However, this still
needed further measurements for confirmation.
As mentioned before, the Tg in the histidine extrudates disappeared after extrusion, which
suggested that the amorphous form changed during extrusion, leading to a crystalline fraction as
indicated by the diffraction peaks in the corresponding PXRD analysis (Figure S3). Although a Tg was
detectable for lysine and arginine after the extrusion in the DSC, it has to be kept in mind that the
substances used show rather high individual melting points, which would have led to degradation
during the thermal measurement.
Therefore, to obtain high quality data that is sensitive to extremely low amounts of crystalline
phase in the sample, it was necessary to perform the diffraction and scattering experiments at a
synchrotron source.
Thus, synchrotron X-ray diffraction offered a more thorough assessment of the amorphous form
to complement the DSC and benchtop PXRD data, which indicated that the raw substances were
crystalline except for the polyelectrolyte NaCMC (Figure S1). PXRD data collected at the synchrotron
source featured Bragg peaks that could be related directly to the crystallinity of the respective additive.
Pronounced crystallinity evidenced in the histidine evaporate was in accordance with the initial
X-ray and DSC assessment and was still detectable after extrusion, which is pointed out by the
peaks at 1.07 A−1, 1.71 A−1, 2.11 A−1, 2.60 A−1, 2.81 A−1, 3.06 A−1, 3.61 A−1 (Figure 2). Moreover,
the measurement at five different locations throughout the extrudate showed the inhomogeneous
distribution of the crystalline additive in the extrudate (Figure 2), which can potentially lead to more
recrystallization. The diffraction pattern of the arginine extrudate indicated a more homogeneous
distribution of the additive compared to histidine, although peaks at 3.05 A−1 still underline some
partial crystallinity of the extrudate, which was detectable neither in the initial benchtop PXRD
assessment nor by DSC.
Figure 2. X-ray synchrotron results (i.e., arbitrary counts versus Q vector, Q = 4πsin(θ)/λ) are displayed
from the extrudates with amino acid coformers. The amino acids added to NaCMC are from left to
right: arginine (cyan), lysine (orange), and histidine (green). Each diffraction pattern corresponds to a
measured area in the extrudate.
The FTIR spectra of arginine/NaCMC in Figure 3B exhibit reduced guanidyl vibrations of arginine
at 1675 cm−1 and 1614 cm−1, which can be associated with the interaction between the ionized arginine
side chain and the negatively charged NaCMC [22].
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Figure 3. Fourier transform infrared spectroscopy (FTIR) spectrograms of NaCMC and histidine (A,
green), arginine (B, cyan) and lysine (C, orange). Dotted lines represent the physical mixture, dashed
lines represent the solvent evaporates and the extrudates are shown in solid lines.
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For the coformer lysine, only smaller shifts in the FTIR spectrum are present in the evaporate and
the extrudate including the shoulder of the COO− bond at 1607 cm−1, which is less pronounced in the
extrudate than in the physical mixture [12,34]. In addition, a slight shift and a pronounced broadening
of the peaks at 1570 cm−1 and 1540 cm−1 [35] both highlight the interaction of the carboxylic group of
NaCMC (Figure 3C). The analysis of histidine/NaCMC in Figure 3A shows pronounced similarities of
the physical mixture and extrudate. This supported the previous findings of the extrusion leading to a
change in the solvent evaporate with recrystallization of histidine [21].
As mentioned in the previous section, the NaCMC was completely amorphous prior to processing.
Therefore, the observed peak broadening and shifts are related to the amorphization of the additive.
3.1.2. Heat Assisted Characterization
The hot stage microscopy was applied to better understand the processes occurring during the
extrusion of the evaporated films and to complement the results of extrusion performance using the
different additives. It should be noted that bright structures in the HSM images are not necessarily
related to crystallinity as they can also highlight an increase in capillarity of the samples.
Thus, Figure 4 top shows an increasing number of capillaries building up in the polyelectrolyte
film containing arginine, which can be directly associated with the positive extrusion performance.
In this case, even though the HSM suggests a successful extrusion, as highlighted in the previous
section, the arginine extrudate still contained crystallinity. This could be explained by the insufficient
mixing behavior of the two excipients, which is underlined by the minimal changes visible in the
heat-resolved FTIR. In Figure 4 bottom, only minor changes in the FTIR are visible during the heating.
 
Figure 4. Hot stage microscopy (HSM) images at the top and temperature-resolved FTIR of 33%
arginine in NaCMC at the bottom. The images show HSM images taken at RT, 90 ◦C and 130 ◦C (from
left to right). The displayed scale bar refers to 500 μm. Each spectrum was measured at temperatures
from 30 ◦C (measured first in the front) to 130 ◦C (in the back) by increasing steps of 5 ◦C.
The evaporated film containing lysine showed no crystals in the microscopic images and small
indications of melting in the images taken at 130 ◦C in comparison to RT (Figure S4). Even in case
of minor melting events, the torque in the extruder facilitates the plasticizing and melting of the
84
Pharmaceutics 2019, 11, 174
evaporate during the extrusion. Therefore, the analysis of films represents a kind of “worst case
scenario” regarding shear forces. It is still possible to successfully obtain an extrudable amorphous
formulation as in the given case of lysine. The heat-resolved FTIR spectra in Figure S4 at the bottom
show an increase in the peak at 1560 cm−1 and 1516 cm−1, which are related to the carboxylic groups
of NaCMC [35]. Such an observation can be interpreted as an increase of the interaction between
NaCMC and lysine.
The HSM images of the histidine evaporate at RT showed pronounced crystallinity, which was in
accordance with the PXRD diffraction patterns (Figure S2). Moreover, the images taken at the operating
temperature of the extruder (130 ◦C) did not show any reduction in crystallinity or a phase transition,
which could be associated with a glass transition. This is supported by the measurable crystallinity
and immiscibility in the extrudate (Figure 5 in green) [18].
 
Figure 5. The images at the top show HSM images of histidine/NaCMC evaporated films taken at RT,
90 ◦C and 130 ◦C (from left to right). At the bottom, a temperature-resolved FTIR spectrum is shown.
The displayed scale bar refers to 500 μm. Each spectrum was measured at temperatures from 30 ◦C
(measured first in the front) to 130 ◦C (in the back) by increasing steps of 5 ◦C.
The thermal evaluation of the evaporated films aligned the prior solid-state characterization as
well as the actual behavior in the extruder, meaning the formulations containing arginine and lysine,
which were successfully incorporated in a concentration of 33% and 50%, respectively, performed
well in the extruder and could only be differentiated by a synchrotron X-ray measurement showing
slight crystallinity in the arginine formulation. By contrast, the histidine formulations demonstrated
poor melting behavior as well as pronounced crystallinity after extrusion. Moreover, the distribution
of histidine was insufficient throughout the extrudate, which leads to differences in the diffraction
pattern evidenced by the synchrotron X-ray measurement.
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3.2. Additives Other than Amino Acids
3.2.1. Characterization of the Formulations
Analogous to previous results, it was necessary to combine solvent evaporation and HME in the
mixtures of NaCMC and the further tested coformers. This was suggested by the X-ray diffraction
patterns of the formulations following solvent evaporation. The X-ray diffraction pattern of the
TRIS/NaCMC solvent evaporates showed Bragg peaks that indicated the presence of TRIS in a
crystalline form (Figure S2). However, TRIS was completely transferred into an amorphous form
following a subsequent HME step (Figure S3). The urea and meglumine formulations were amorphous
after the solvent evaporation and did not recrystallize to a detectable extent based on the benchtop
PXRD results (Figure S3).
Table 2 presents a comparison of the maximal amount of additives for which the polymer matrix
was kept in an amorphous state. The differences in molar weight have to be taken into account for such
an evaluation, leading to a comparable molar fraction of meglumine and urea and a lower loading as
well as molar fraction of TRIS (Table 2). This observation was a first indicator of the different technical
feasibility of the various additives to obtain suitable modified matrices of NaCMC. A higher loading
of TRIS led to crystallinity after evaporation as well as extrusion. Therefore, a lower loading had to
be chosen, which resulted in non-ideal extrusion performance as described in the introduction. The
additives meglumine and urea could be incorporated at much higher molar ratios and positively
influenced the extrusion process.












Other Additive + NaCMC
Meglumine 50% (w/w) 0.57 5.58 ◦C 9.18 ◦C +
Urea 20% (w/w) 0.52 37.99 ◦C 40.36 ◦C 0
TRIS 25% (w/w) 0.42 - 39.18 ◦C -
* For the calculation, the molar weight of the NaCMC monomer was used. ** Technical feasibility was qualitatively
assessed and details are given in the text.
The thermograms in Figure 6 indicate the presence of remaining water after the solvent
evaporation, given as a broad peak around 100 ◦C. The Tg of urea can be hardly detected because of
small difference in heat capacity at the glass transition and for the TRIS formulation, no Tg could be
detected. On the other hand, the extrudate of meglumine shows a rather pronounced Tg and also a
shift towards a lower temperature in comparison to all other extrudates, which can be associated with
the good miscibility of meglumine and NaCMC [36,37].
All samples were measured at five different areas. However, differences in the patterns can be
seen only for the case where TRIS was used as the additive, particularly for differences in scattered
intensity and the emergence of Bragg peaks at Q values of 3.03 A−1, 3.50 A−1, 4.95 A−1 and 5.81 A−1.
By contrast, the patterns of the extrudates containing meglumine and urea present no observable
differences in their X-ray synchrotron results (Figure 7). The absence of Bragg peaks in the patterns
collected on samples containing meglumine and urea prove that the obtained polymer matrices were
fully amorphous at the molar fractions of 0.57 and 0.52, respectively. The PXRD patterns, collected on
the sample containing TRIS at the synchrotron source, showed indications of crystallinity, which were
not detectable in the patterns of the laboratory diffractometer. Such crystallinity could be a sign of
recrystallization after the extrusion as well as residual crystallinity. Both sources of crystallinity are
related to the instability of an amorphous form [38].
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Figure 6. The solid lines represent the thermograms of the extrudate and the dotted lines represent the
evaporates, which were used for the later extrusion. The additives used in addition to NaCMC are
meglumine (black), TRIS (red) and urea (blue).
 
Figure 7. X-ray synchrotron results (i.e., arbitrary counts versus Q vector) of coformers other than
amino acids. The additives in addition to NaCMC are: urea (blue), meglumine (black), and TRIS (red).
Each diffraction pattern corresponds to a measured area in the extrudate.
In the FTIR spectra, the combination of NaCMC and meglumine shows the previously discussed
broadening due to the amorphization [39,40]. It can be seen how following solvent evaporation,
distinct peaks are observed, which are broadened in one peak at 1000 cm−1 and 1400 cm−1. Moreover,
the previous discussed carboxylic peak at 1570 cm−1 of NaCMC is more pronounced and broader,
which indicates a change in the intermolecular binding of the polyelectrolyte [34,35].
The FTIR spectrum of urea in line with the spectrum of NaCMC/meglumine shows an increase
of the peak at 1580 cm−1, which indicates the same interaction with the carboxylic group as
meglumine [35].
The spectrum of TRIS showed specific peak broadening as a result of the amorphous formulation
(Figure 8). However, this broadening is overlapping a lot with the peaks formed because of a potential
interaction. The increase of broader peak between 1400 cm−1 and 1600 cm−1 can be interpreted as an
indication of an interaction [12,16,41]. However, a further, more sensitive analysis is required for a
precise statement about the interaction.
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Figure 8. FTIR spectrograms of NaCMC and TRIS (A, red), meglumine (B, black), and urea (C, blue).
Dotted lines represent the physical mixture, dashed lines represent the solvent evaporates and the
extrudates are shown in solid lines.
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Interestingly, the observed changes in the FTIR spectra indicate a likely change in the hydrogen
bonding structure because of the processing rather than the formation of a distinct salt.
3.2.2. Heat Assisted Characterization
The microscopic images at the top of Figure 9 present the melting process of the meglumine
formulation, which can be connected to the thermoplastic behavior in the extruder. The prominent peak
broadening around 90 ◦C in the area above 3000 cm−1 is an indicator of a successful amorphization
because of differences in the molecular arrangement as well as the near range order [22,40]. This
finding is in line with the start of a melting process in the HSM image at 90 ◦C. Moreover, these findings
are in accordance with the performance observed during extrusion of the meglumine formulation.
Figure 9. The images at the top show HSM images of 50% meglumine/NaCMC solvent evaporates
taken at RT, 90 ◦C and 130 ◦C (from left to right). At the bottom, a temperature-resolved FTIR spectrum
is shown. The displayed scale bar refers to 500 μm. Each spectrum was measured at temperatures from
30 ◦C (measured first in the front) to 130 ◦C (in the back) by increasing steps of 5 ◦C.
HSM images of the TRIS formulation show only minor changes. Although, an indication of
minor “bubble-shaped” features was recorded that may be associated with small melting events taken
place in the formulation (Figure 10). The FTIR spectrum supports the observation of a change with
higher temperatures. The broadening of the peaks above 3000 cm−1 can not only be associated with
the successful amorphization in the TRIS sample [40], as discussed before (Table 1), it furthermore
shows the decrease of hydrogen bonding throughout the heating process [35,42], leading to a lack of
intramolecular interaction in the NaCMC, thereby resulting in more available interaction sites for TRIS.
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Figure 10. The images at the top show HSM images of 25% TRIS/NaCMC evaporated films taken
at RT, 90 ◦C and 130 ◦C (from left to right). At the bottom, a temperature-resolved FTIR spectrum is
shown. The displayed scale bar refers to 500 μm. Each spectrum was measured at temperatures from
30 ◦C (measured first in the front) to 130 ◦C (in the back) by increasing steps of 5 ◦C.
As described before, the urea formulation formed an amorphous stable formulation after
evaporation and extrusion (Figure S5). The HSM images show a melting process over the temperature
range recorded. However, in the heat-resolved FTIR, only minor changes in peak intensity can be
observed. In line with Figure 9, this suggests that urea has a plasticizing effect without showing a
pronounced interaction with NaCMC. A possible reason for that is the lack of ionizable groups in the
urea molecule.
4. Conclusions
The application of additives and targeted molecular interactions together with an initial solvent
step enabled the extrusion of the polyelectrolyte, NaCMC. Differences in melting behavior and loading
highlighted the suitability of the investigated additives to form as a fully amorphous polyelectrolyte
matrix after extrusion. The additives, lysine and meglumine, in a concentration of 50% (w/w), have
proven to be beneficial for extrusion and formation of a fully amorphous polymer matrix. Moreover, the
application of synchrotron X-ray diffraction helped to further differentiate between the formulations
by examining the distribution of the additive throughout the matrix and residual crystallinity in the
sample. PXRD data collected at the synchrotron source proved the amorphous state of the lysine,
meglumine, and urea formulations compared to arginine and TRIS, for which crystallinity was not
detectable by means of benchtop PXRD or DSC.
While recent work has shown that the formulation of an amorphous ionic interaction is possible
by hot melt extrusion [17], the current concept presented a not extrudable polymer, which was altered
by interacting additives in a modified matrix feasible for HME. We refrained from naming the obtained
systems as ionic liquids because this would suggest exclusively ionic coformer interactions with the
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polymer. Moreover, ionic liquids have an arbitrary defined melting characteristic of <100 ◦C, which
is not required for pharmaceutical application as solid dispersions. However, it is expected that
the modified matrices share much of the molecular attractiveness of ionic liquids. Further studies
may harness the potential benefits of the solvent evaporates for pharmaceutical HME, reaching from
new systems for amorphous drug stabilization over the generation of drug supersaturation to the
precipitation inhibition of poorly water-soluble compounds.
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Abstract: A continuous-spray granulator (CTS-SGR) is a one-step granulation technology capable of
using solutions or suspensions. The present research objectives were, (1) to reduce the manufacturing
operations for solid dosage formulations, (2) to make amorphous solid dispersion (ASD) granules
without pre-preparation of amorphous solids of active pharmaceutical ingredients (API), and (3) to
characterize the obtained SGR granules by comprehensive pharmaceutical analysis. Rebamipide
(RBM), a biopharmaceutical classification system class IV drug, that has low solubility or permeability
in the stomach, was selected as a model compound. Five kind of granules with different concentrations
of polyvinylpyrrolidone/vinyl acetate copolymer (PVP-VA) were prepared using a one-step SGR
process. All of the SGR granules could be produced in amorphous or ASD form and their
thermodynamic stability was very high because of high glass transition temperatures (>178 ◦C).
They were unstable in 20 ◦C/75%RH; however, their stability was improved according to the
proportion of polymer. The carboxy group of RBM was ionized in the granules and interactions
appeared between RBM and PVP-VA, with the formation of an ASD confirmed and the solubility
was enhanced compared with bulk RBM crystals. The SGR methodology has the possibility of
contributing to process development in the pharmaceutical industry.
Keywords: amorphous; solid dispersion; molecular complex; rebamipide; polymer; interaction;
stability; characterization; continuous processing; granulation; process development
1. Introduction
Among recently developed pharmaceuticals, many synthesized candidate drug compounds
have a low bioavailability, due to their low aqueous solubility and/or permeability [1]. These issues
influence discovery stage studies and lead to delays in the development of new drugs. According to
the biopharmaceutical classification system (BCS), the drug dissolution profile and solubility of the
solid-state form are major factors and they influence gastrointestinal permeability, bioavailability,
and clinical response [2]. Hence, it is necessary to improve bioavailability by enhancing the
solubility of poorly water-soluble drug compounds by making the most of pharmaceutical
technology [3,4]. The main methodologies reported to achieve this include alteration of the solid-state
Pharmaceutics 2019, 11, 159; doi:10.3390/pharmaceutics11040159 www.mdpi.com/journal/pharmaceutics94
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by amorphization [5], increasing the particle surface area by size reduction [6], and the formation of
pharmaceutical molecular complexes [7,8].
Among these, amorphous solid dispersion (ASD) is a representative of amorphous molecular
complexes [9,10]. Generally, ASD is a solid of a polymer-based material involving a homogeneously
dispersed active pharmaceutical ingredient (API) molecules in a disordered state. In some cases,
a complex between more than two APIs is dispersed in a polymer material [11,12]. The amorphous
state of a compound is more unstable without long-range order, compared with the crystal state [13].
The use of amorphization or disruption of the crystal lattice increases the solubility and, consequently,
leads to improved bioavailability. As an advantage of the ASD system, the presence of a polymer
can stabilize an amorphous API. Some studies on ASDs have investigated API-polymer interactions
and relationships [14,15], manufacturing process development [16,17], and other factors [18–20].
The preparation of an ASD can be chosen dependent on the nature of the drug, for example,
the melting method [21,22] and the solvent method [23,24]. These preparations are necessary to
provide the final product of ASD formulations, but the manufacturing unit operation cutbacks are
ideal from the viewpoint of high-level quality control and cost saving in the recent pharmaceutical
industry. In addition, an accomplishment for high drug loading granules or tablets is difficult with
ASD formulations because of the necessity for high concentrations, such as 70−80%, of polymer
carriers to enhance the solubility, stability, and drug-polymer interaction [25,26]. Polymers have
been used extensively to fabricate ASDs; however, the formation of stable ASDs requires high
polymer concentrations, limiting their use with low-dose APIs. Therefore, considering an alternative
methodology for solid dosage formulations, ASD granules with high drug loading, using restricted
manufacturing processes, may be suitable.
A continuous-spray granulator (CTS-SGR) provides a one-step granulation method from solution
or suspension. The SGR method can be divided into the following three processes (Figure 1): Granule
nucleation by spray drying, layering granulation by continuous spray, and product collection using a
size classification system. A two-fluid spray nozzle is placed vertically at the bottom. The SGR also
has side air nozzles, which act to brush the adhered powder off the face of the wall, to maintain a
continuous flowable state in the SGR. The SGR system resembles an ordinary spray drier and fluid
bed granulation, which together result in layering granulation [27,28]. The granule size of spray
drying and fluid bed granulation depends on the particle size in the suspension sample, the nozzle
orifice diameter, and the airflow. However, spray drying granulation may have technical problems,
such as the homogeneity of the product [29]. Additionally, layering granulation requires core particles
as a seed for the granule in order to obtain the comparatively large size granules in general. Thus,
the formation a granule with high drug loading is difficult because of the concentration of the seed in
the granule [30]. On the other hand, SGR provides enhanced handling, such as the flowability of bulk
powder by layering granulation without core particles, and can prepare uniformly spherical granules
until the desired granule size and shape is reached.
Figure 1. The circulation system of a continuous-spray granulator (CTS-SGR).
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Rebamipide (RBM), a gastroprotective agent prescribed for gastric ulcer and gastritis patients,
is a weakly acidic BCS class IV drug that is insoluble in acid conditions. However, dissolution
in a low pH environment is needed because the precise mechanisms of RBM involve increasing
gastric mucosal prostaglandin and gastric mucus production and the site of action of RBM is the
stomach [31]. Commercial RBM tablets contain 100 mg of the API and the prescribed dosage is three
times per day. The current study aimed to combine a high API loading formulation and enhancement
of the solubility of RBM by specific manufacturing processes. For the purpose of achieving this,
ASD granules were prepared using SGR as a one-step method for producing high drug loading
granules. Five types of granules with different concentrations of polymers (0%, 5%, 10%, 20%, and 30%
as weight ratio) were prepared by SGR. The physical properties, stability, thermal behavior, molecular
state, and solubility of the obtained SGR samples were investigated. Comprehensive identification
was performed to understand the characteristics of the granules and expand the possibility of SGR as
a process development.
2. Materials and Methods
2.1. Materials
RBM of pharmaceutical grade was kindly provided by Ohara Pharmaceutical (Shiga, Japan,
Figure 2). Sodium hydroxide (NaOH) as an alkylating agent was purchased from Fujifilm Wako Pure
Chemical (Osaka, Japan). Polyvinylpyrrolidone/vinyl acetate copolymer (PVP-VA; Kollidon® VA64,
Figure 2) as a carrier was a generous gift from BASF (Ludwigshafen, Germany). As the additives for
the tablets, magnesium aluminometa silicates (MAS; Neusilin® NS2N) was a gift from Fuji Chemical
Industry (Wakayama, Japan) and croscarmellose sodium (CCS; KiccolateTM) and magnesium stearate
(Mg-St) were purchased from Asahi Kasei Chemicals (Tokyo, Japan) and Fujifilm Wako Pure Chemical,
respectively. All other chemicals were commercially available products of analytical grade.
Figure 2. Chemical structures of rebamipide with atom numbering and polyvinylpyrrolidone/vinyl
acetate copolymer (Kollidon® VA64).
2.2. Granule Preparation Using a Continuous-Spray Granulator
Table 1 shows the summarized liquid formulation for spraying using SGR. Firstly, RBM, PVP-VA,
and NaOH totaling 200 g were dissolved in 1800 g of purified water at 80 ◦C, with stirring. At this time,
the molar ratio of REB and NaOH was fixed at 1:1 and PVP-VA in Runs 1−5 accounted for 0%, 5%,
10%, 20%, and 30% as the weight ratio. Then, the sample solutions were fed into the SGR (CST-SGR-01
without size classification system; Powrex, Hyogo, Japan) at a rate of 10−15 mg/min and sprayed
using a two-fluid nozzle with the following conditions: Atomizing air rate was 40–80 NL/min, inlet air
temperature was 75 ◦C, and running time was 120–150 min.
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1 179.65 0 20.35 1800 2000
2 170.67 10 19.33 1800 2000
3 161.68 20 18.32 1800 2000
4 143.72 40 16.28 1800 2000
5 125.75 60 14.25 1800 2000
1 Rebamipide, 2 Polyvinylpyrrolidone/vinyl acetate copolymer, 3 Sodium hydroxide, 4 Water.
2.3. Physical Property Measurements
A scanning electron microscope (SEM; JSM-6510LV, JEOL, Tokyo, Japan) was used to characterize
the particle state and morphology. Granule samples were sprinkled onto a carbon tape and coated
with carbon by a JEC-560 (JEOL). The acceleration voltage, magnification, and working distance were
1.0 kV, ×500, and 8 mm, respectively.
Dried particle size distribution was investigated using a laser light scattering particle analyzer
(Mastersizer 3000E with Aero M, Malvern Panalytical, Malvern, UK). Data analysis was done based on
algorithms utilizing Mie scattering theory for non-spherical materials. The results were represented as
mass median diameter (D50) with a standard deviation of (n = 5).
The angle of repose (AR) was evaluated using a modified tilting method [32]. Approximately
30 mg of the granule sample was fed into a sample holder. Then, the holder was slowly tilted until the
sample began to slide and the angle of the tilt was measured. The results were described as the mean
angle of repose with a standard deviation of (n = 30).
The bulk density 1 (ρB) was measured by filling a graduated cylinder (50 mL) with a certain
amount of each sample, the height of sample was approximately 10 mm. Additionally, the tapped
density (ρT) was evaluated by tapping down each sample in the cylinder, the tapping was repeated












where B and T are bulk and tapped samples, respectively [33,34]. The results were shown as mean
values with a standard deviation of (n = 3).
2.4. Stability Testing at Different Humidities by X-Ray Diffractometry
In order to compare the stability of the amorphous state of RBM in each granule type, 4 g of each
sample was placed into containers at 30% RH or 75% RH, with an ambient temperature ca. 20 ◦C,
for the specified time periods (6 months at maximum). The samples were promptly measured by X-ray
diffraction (XRD) upon removal of the lid at each time point.
The XRD pattern of each sample was collected using RINT-Ultima III (Rigaku, Tokyo, Japan) with
Cu Kα radiation (40 kV × 40 mA). The diffraction angle range was from 5◦ to 45◦ in 2-theta, with a
step of 0.02◦ and scanned at 15◦/min. Relatively large granules were ground using manual grinding
in an agate mortar for adequate XRD analysis.
2.5. Thermal Analysis
A differential scanning calorimeter (DSC7000X, Hitachi, Tokyo, Japan) was used for investigating
the thermal behavior of granule samples. An approximately 5 mg sample was placed in an aluminum
DSC pan. All the measurements were done under a dry nitrogen purge at 30 mL/min and heated
from 25 ◦C to 350 ◦C at a rate of 5 ◦C/min. For the purpose of identification of the glass
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transition temperature (Tg), DSC was operated in the modulated mode with the following conditions:
Temperature modulation was ±3 ◦C, the repetition rate was 0.2 Hz, and the heating rate was










where Tg calc is the theoretical glass transition (◦C), w1 and w2 are the weight fractions of each
component, Tg1 and Tg2 are their glass transitions, and ΔCp1 and ΔCp2 are the change in specific
heat capacity at the glass transition [35,36]. Additionally, a positive difference between the measured
and calculated glass transition temperatures was obtained as the characteristic parameter of interaction.
2.6. Fourier Transformed Infrared Spectroscopy
Infrared (IR) spectra were accumulated using a Fourier-transform IR spectrometer (FT/IR-4100,
Jasco, Tokyo, Japan). The spectral data were collected by powder diffuse reflectance using KBr powder,
with 64 scans at 8 cm−1 resolution.
2.7. Tablet Preparation and Dissolution Testing
A mixture of resulting granules with specific amounts of PVP-VA, 7.2 mg of MAS (3.6%),
and 10.0 mg of CCS (5.0%) was blended with 1.0 mg of Mg-St (0.5%) just before tableting.
Each formulation ratio of RBM per tablet was adjusted to the same amount as commercial Mucosta®
(114.2 mg as a total API). Additionally, the PVP-VA amount depended on each batch (54.5 mg as total
PVP-VA). Specifically, the amounts in batch No. 1−5 granules and additional PVP-VAs in tablets
were 127.2 mg (63.6%) and 54.6 mg (27.3%), 136.4 mg (68.2%) and 45.4 mg (22.7%), 145.4 mg (72.7%)
and 36.4 mg (18.2%), 163.6 mg (81.8%) and 18.2 mg (9.1%), and 181.8 mg (90.9%) and 0 mg (0.0%),
respectively. The mixture was compressed using 8 mm flat-faced punches in a single stroke tablet
press (Handtab-100, Ichihashi Seiki, Kyoto, Japan). The tablet weight and hardness were 200 mg and
40 N (60–80 MPa compression pressure), respectively.
Dissolution testing of tablets was carried out in 900 mL water as the test medium (37.5 ± 0.5 ◦C)
using an NTR-3000 apparatus with a paddle speed of 50 rpm (Toyama Sangyo, Osaka, Japan) and
a S-2450 spectrophotometer (Shimadzu, Kyoto, Japan). In addition, granule dissolution testing was
demonstrated in 900 mL of acidic aqueous solution (pH 1.2 buffer; 37.5 ± 0.5 ◦C) using a DT-610
apparatus with 100 rpm (Jasco) and a V-530 spectrophotometer (Jasco) because of the low solubility
of RBM in an acidic medium. The concentration of API during these tests was determined using a
UV/VIS spectrophotometer at 327 nm. The mean values and standard deviations with time were
calculated (n = 3).
3. Results and Discussion
3.1. Morphology and Physical Properties
RBM granules, in a dry state, were prepared by SGR. Figure 3 shows SEM images of the obtained
samples, which provided insights into the morphology and approximate particle size. The particle size
of the 0% PVP-VA sample was the smallest and formed microspheres similar to a spray dried sample,
whose size would become the nuclei of the granule. Proportionally to the concentration of PVP-VA,
the size of granules increased and the surface became smoother because of the high concentration
of polymeric carrier presence as a binder. The 30% PVP-VA sample appeared as heavy and dense
granules and the surface rarely had pores, because layering granulation was carried out by continuous
spraying of the polymer. In addition, the repeating side airs broke the surface roughness of granules
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and the spray fluid was extended at the granule surface with drying. Therefore, granule spheroidizing
was performed. Table 2 shows a summary of the physical properties of the samples. The bulk
density (ρB) and tapped density (ρT) increased with layering and the flowability was also enhanced.
These prepared granules tended to become denser with SGR and a drastic change in density was
observed at >10% concentration in the polymer granules. The granule particle size, size distribution,
and particle configuration can be controlled by the concentration of the polymeric binder and the
processing time of SGR.
 
Figure 3. SEM images of the 0−30% PVP-VA granules at the same magnification (×500). The scale bar
indicates 50 μm.





3 (g/cm3) AR 4 (◦) HR 5 CI 6 (%) D50 7 (μm)
0 0.27 ± 0.02 0.51 ± 0.03 43.9 ± 4.99 1.88 ± 0.02 46.9 ± 0.65 4.18 ± 0.03
5 0.33 ± 0.01 0.55 ± 0.04 40.3 ± 4.59 1.67 ± 0.14 40.0 ± 5.23 11.2 ± 0.12
10 0.52 ± 0.01 0.67 ± 0.00 39.5 ± 3.98 1.29 ± 0.03 22.7 ± 1.76 44.2 ± 0.17
20 0.51 ± 0.02 0.71 ± 0.01 36.3 ± 4.54 1.39 ± 0.05 27.8 ± 2.79 32.5 ± 0.21
30 0.61 ± 0.00 0.76 ± 0.00 27.9 ± 4.16 1.26 ± 0.00 20.4 ± 0.14 72.7 ± 2.99
1 Weight parentage of polyvinylpyrrolidone/vinyl acetate copolymer in the granule, 2 bulk density, 3 tapped density,
4 angle of repose, 5 Hausner ratio, 6 Carr index, 7 mass median diameter.
3.2. Stability of Amorphous Solid Dispersion
In efforts to gain an insight into the crystallization properties, amorphous state stability testing
was performed in conditions of high and low humidity and the thermal analysis investigated the
thermodynamic and phase behavior. The SGR granules had been confirmed to have no moisture
content, such as free and crystal water, by thermal analysis, then the stability testing was carried
out. Figures 4 and 5 show the compiled XRD patterns of storage at the conditions of 20 ◦C/30%
RH and 20 ◦C/75% RH, respectively. Each XRD pattern on the first day (0 day) was a diffraction
halo, indicating RBM in granule was an amorphous state in the polymeric matrix by SGR, despite the
various PVP-VA concentrations. The amorphous state was maintained for 6 months at 20 ◦C/30% RH.
Under the high relative humidity conditions (20 ◦C/75% RH), stability was improved depending on
the concentration of PVP-VA. The samples with 0%, 5%, 10%, 20%, and 30% PVP-VA crystallized after
4, 7, 11, and 15 days. Relatively stable ASD granules could be prepared with a high concentration of
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PVP-VA. According to Hancock [36], the glass transition temperature of polymer decreases with the
increase in water content in the polymer matrix. Hence, the glass transition temperature of amorphous
RBM may become lower and the amorphous state is destabilized due to compositing with the polymer.
However, the stability of the amorphous state was improved with increasing the polymer content.
It suggests that the interaction between RBM and PVP-VA restricts crystallization of RBM. Notably,
the diffraction peaks of granules, after crystallization, was different from RBM, as is. There is a
possibility that REB formed co-amorphously with sodium ions in the SGR granule and a sodium salt of
RBM was formed or crystallized by absorption of moisture. The interaction between RBM and sodium
ions is discussed in FT-IR analysis part.
 
Figure 4. XRD patterns of SGR granules after storage at 20 ◦C/30% RH. Percentages indicate the
weight percentage of PVP-VA in the granules.
 
Figure 5. XRD patterns of SGR granules after storage at 20 ◦C/75% RH. Percentages indicate the
weight percentage of PVP-VA in the granules.
Figure 6 shows DSC curves of the SGR granules. Each granule had a baseline shift, according
to the glass transition, at approximately 200.0 ◦C and the crystallization temperatures of 0%, 5%,
10%, 20%, and 30% PVP-VA granules were 263.9 ◦C, 263.5 ◦C, 258.6 ◦C, 255.7 ◦C, and 246.7 ◦C,
respectively. Hence, it was confirmed that the samples were established as ASD granules. To analyze
the glass transition in detail, modulated DSC was employed, and the results are shown in Table 3.
Glass transition temperature is well-known as an important value of ASD. The observed glass transition
of the 0% PVP-VA granule (amorphous RBM) was 215.4 ◦C, while unprocessed pure PVP-VA was
107.8 ◦C, which meant amorphous RBM originally has a high thermodynamic stability. The reason
why the glass transition temperature decreased with increasing concentrations of the polymer was
due to the addition of PVP-VA to the formulation. Furthermore, the value of ΔTg represent a specific
interaction between the API and the polymeric carrier, because the positive deviation reflects an
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increase in interactions. The deviation appeared when the number and strength of interactions
between homo-materials were lower than between hetero-materials [35–37]. The calculated value
showed that SGR granules with PVP-VA have interactions that lead to time scale stabilization, as with
the results of XRD. The strength increased with the PVP-VA concentration. On the other hand, the 0%
PVP-VA granule interaction was low because of the absence of the polymer. These results of XRD and
DSC demonstrated that the thermodynamic stability of the ASD granules by SGR was sufficiently high
because the glass transition was over 178.7 ◦C and also, even pure PVP-VA was high enough (107.8 ◦C),
whereas undesirable crystallization was provoked under the high humidity condition (20 ◦C/75%
RH). The effect of humidity on the crystallization can be prevented by using a high concentration of
polymer or granule coating [38,39].
 
Figure 6. Total heat flow curves of RBM crystals and SGR granules with 0−30% PVP-VA by DSC.









0 215.4 n/a n/a
5 206.9 202.0 4.9
10 203.9 194.3 9.6
20 191.7 175.0 16.7
30 178.7 157.5 21.2
1 Tg experimental, 2 Tg calculated, 3 Tg experimental − Tg calculated.
3.3. Molecular State
SGR granules have intermolecular interactions between the API and PVP-VA in proportion to
the polymer concentration, as described in the preceding section. This section explains in detail
the molecular state change of the granules, according to the interaction. Figure 7A shows the IR
spectra of ASD granules by SGR. Bulk RBM crystals had an absorption peak at 1735 cm−1, due to the
C12=O13 stretching vibration. However, this peak disappeared after the SGR process and different
peaks at 1595 cm−1 and 1394 cm−1, which correspond to COO− asymmetric and symmetric stretching
vibrations, appeared. These indicated that ionization had occurred due to deprotonation at the carboxy
group. Hence, the carboxylate COO− group is suggested to exist without ionic interaction with sodium
ions. The characteristic peak of RBM crystals at 1645 cm−1, which was assigned to the amide I band of
C8=O9 and C18=O19, disappeared in the granules. Bulk PVP-VA peaks of C=O stretching vibration in
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ester and the amide I band were 1724 cm−1 and 1655 cm−1, respectively. The other peaks of the amide
II and III bands were weak, as shown in Figure 7A.
 
Figure 7. (A) Overlays of IR spectra of RBM crystals alone, PVP-VA alone, and SGR granules including
0−30% PVP-VA. (B) Representation of the second derivatives of SGR granules.
To detect some weak peaks, second derivative spectra of the SGR granules were calculated
(Figure 7B). The second derivative preprocessing allows more specific identification of weak peaks in
the original spectra and offers the cancelling of baseline shift [40]. The positive value of the original
data was converted into a strong negative peak using the second derivative. The characteristic peaks
of RBM at 1480 cm−1, 1510 cm−1, and 1540 cm−1 indicated C8-N10 coupled with N10-H and C18-N20
coupled with N20–H vibrations (amide II band). These bands, which were based on amides, appeared
strongly in granules, because the interaction between molecules of RBMs may be weakened by the
amorphization process. These bands were also shifted or disappeared in proportion to the PVP-VA
concentration, the amide of RBM interacts with the matrix though hydrogen bonding. Therefore,
the interaction between RBM and PVP-VA was present in SGR granules. The indication corresponded
to the result of ΔTg analysis, shown in Table 3.
3.4. Dissolution Ability
Figure 8A shows the dissolution profiles of the tablets in water. All tablets, including SGR
granules, showed enhanced solubility of the RBM crystals and the dissolved concentration reached
almost 100% (126.67 μg/mL) at 120 min, whereas RBM crystals dissolved slowly. In Figure 8B,
dissolution testing using an acidic medium was performed with dispersible SGR granules, due to
the low solubility of weakly acidic RBM. The dissolution profiles in the acidic solution were different
compared with in water. All of the SGR granules were more soluble than RBM crystals; however,
the profiles depended on the concentration of PVP-VA in the granules. In low PVP-VA formulations,
such as 0% and 5%, the dissolved concentration reached approximately 2.22 μg/mL. Granules with
10% PVP-VA reached the highest solubility (11.89 μg/mL) among the samples shown in Figure 8B,
which was about 10 times higher than RBM crystals. In granules, including 20% and 30% PVP-VA,
gelation was observed and the dissolved amount of RBM, at 120 min, decreased with increasing
concentration of the polymer. Generally, the recrystallization and crystal growth were prevented by
the interaction with the polymer; thus, the polymer contributes to further improvement of the API
solubility [41,42]. However, the wettability and swellability of granules were in proportion to the
concentration of polymer, while the dispersibility of granules was decreased. Higher the content rate
of the polymer caused aggregation and gelation in the vessel, consequently leading to lower drug
release from granules in this study. It should be noted that the dissolution profile may change if the
amount of contents was revised. Optimized formulation ratios, depending on respective objectives,
are vital for the pharmaceutical industry.
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Figure 8. Integrated dissolution profiles in 900 mL of (A) tablets in water and (B) granules in an acidic
solution of RBM crystal (dark triangles), PVP-VA 0% (blue circles), PVP-VA 5% (light blue crosses),
PVP-VA 10% (green diamonds), PVP-VA 20% (light red rectangles), and PVP-VA 30% (red inversed
triangles). Percentages denote the concentration of PVP-VA in the SGR granules.
The drug release kinetics from ASDs were explained based on mathematical modeling analysis [43–45].
As the result of an R2 analysis of least-squares fitting, the best-fitted was the Korsmeyer−Peppas




where Mt/M∞ is the amount of drug released on time t per unit area, k is the kinetics constant, and n
is the release exponent [43,44]. Each R2 value of the RBM crystal and the granules including 0−30%
PVP-VA in acidic medium was 0.917, 0.989, 0.996, 0.987, 0.930, and 0.997. Additionally, each exponent n
value was 1.16, 0.64, 0.34, 0.31, 0.26, and 0.38, respectively. The exponents indicate the diffusional drug
release mechanism from a matrix, n < 0.43, 0.43 < n < 0.85, and 0.85 < n describes Fickian diffusion,
anomalous (non-Fickian) transport, and super case II transport, respectively [43,44]. These results
suggested the release mechanisms of the enclosed REB, during the dissolution, were changed into
Fickian diffusion due to forming ASD by PVP-VA. The release kinetics from the tablet in water
was also explained by the Korsmeyer−Peppas model. Hence, the drug release mechanism after the
disintegration of the tablet was the same as the granule.
4. Conclusions
One-step granulation methods such as CTS-SGR could be used to prepare ASD granules with
high RBM loading to enhance the solubility of this BCS class IV drug. This method involves no
specific preparation and produces the ASD granules using a continuous spraying and layering system.
According to the concentration of PVP-VA, the obtained granules were found to be heavy and dense,
with a smooth surface. The thermodynamic stability of SGR granules was relatively high and the
humidity stability at 20 ◦C/75% RH depended on the concentration of PVP-VA. Molecular interactions
formed between RBM and PVP-VA, including the carboxy group of RBM becoming ionized in SGR
granules. Dissolution testing demonstrated the improved water solubility of RBM, even in acidic media
due to the formation of an ASD. The SGR method, which directly generates granules from solutions,
has the possibility to reduce manufacturing operations. The SGR methodology can contribute to new
process development in the pharmaceutical industry.
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Abstract: The self-assembly phenomenon of amphiphiles has attracted particular attention in recent
years due to its wide range of applications. The formation of nanoassemblies able to solubilize
sparingly water-soluble drugs was found to be a strategy to solve the problem of poor solubility of
active pharmaceutical ingredients. Binary and ternary solid dispersions containing Biopharmaceutics
Classification System (BCS) class II drug bicalutamide and either Poloxamer®188 or Poloxamer®407
as the surface active agents were obtained by either spray drying or solvent evaporation under
reduced pressure. Both processes led to morphological changes and a reduction of particle size,
as confirmed by scanning electron microscopy and laser diffraction measurements. The increase
in powder wettability was confirmed by means of contact angle measurements. The effect of an
alteration of the crystal structure was followed by powder X-ray diffractometry while thermal
properties were determined using differential scanning calorimetry. Interestingly, bicalutamide
exhibited a polymorph transition after spray drying with the poloxamer and polyvinylpyrrolidone
(PVP), while the poloxamer underwent partial amorphization. Moreover, due to the surface activity
of the carrier, the solid dispersions formed nanoaggregates in water, as confirmed using dynamic
light scattering measurements. The aggregates measuring 200–300 nm in diameter were able to
solubilize bicalutamide inside the hydrophobic inner parts. The self-assembly of binary systems was
found to improve the amount of dissolved bicalutamide by 4- to 8-fold in comparison to untreated
drug. The improvement in drug dissolution was correlated with the solubilization of poorly soluble
molecules by macromolecules, as assessed using emission spectroscopy.
Keywords: bicaludamide; poloxamer; evaporation; spray drying; dissolution enhancement;
nanoaggregates; self-assembly
1. Introduction
The issue of poor solubility of active pharmaceutical ingredients (APIs) is one of the biggest
limitations for drug development. It is a matter of concern, as the bioavailability depends on the
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dissolution of drug in the gastrointestinal fluids. The main determinants of the dissolution kinetics
in vivo are solubility and surface area of the particles. The solubility is a function of the crystal lattice
energy and the affinity of solid phase to the solvent. Thus, three groups of strategies that have
been implemented to improve the rate of dissolution and solubility rely on: (1) the reduction of the
intermolecular forces in solid phase, (2) the enhancement of the solid–solvent interaction, and (3) the
increase of the surface area available for solvation (according to the Noyes–Whitney equation) [1].
Due to the fact that almost 50% of currently marketed drugs and over 70% of new chemical
entities exhibit low solubility in water, numerous techniques have been developed to overcome this
problem [2]. Common strategies include pH adjustment, formation of salts, cosolvency, formation
of cocrystals and inclusion complexes, particle size reduction, supercritical fluid technology (SCF),
and self-emulsification [3,4]. Recently, nanotechnology has emerged as a technique that leads to
the formation of robust delivery systems. Numerous attempts have been applied to obtain several
types of delivery systems, i.e., micelles [5], liposomes [6], capsules [7,8], protein nanocontainers [9],
and silica-based nanoparticles [10,11]. Poorly water-soluble drugs have been frequently processed with
hydrophilic polymers, as the molecular dispersion of drug molecules within the matrix provides better
dissolution of the drug. Moreover, when the systems were further formulated into the nanoparticles,
the results were more pronounced [12–14].
The main factors affecting the choice of a particular method are the physicochemical characteristics
of drugs and carriers. Solid dispersions are commonly formed to enhance the water solubility of APIs;
however, the number of marketed products arising from that strategy is rather low. This is a result of the
thermal instability of drug and carrier during preparation of systems, a poor in vitro–in vivo correlation,
and instability during storage [15]. However, the simplicity of preparation, low cost, and great
improvements in the dissolution of poorly water-soluble drugs have made the solid dispersions
widely investigated. Experimental and theoretical approaches have been involved to determine the
thermodynamic properties of APIs dispersed in polymer matrices as well as the mechanisms and
factors affecting their stability [16–18].
The concept of solid dispersion—one of the earliest methods of solubility enhancement—was
introduced in 1961 by Sekiguchi and Obi, who prepared eutectic mixtures containing microcrystalline
drug and a water-soluble carrier [19–22]. Although crystalline forms provide high stability and
chemical purity, the lattice energy barrier is the major limitation affecting the dissolution rate.
Thus, amorphous carriers such as polyvinylpyrrolidone (PVP) [23,24] and hydroxypropylmethyl
cellulose (HPMC) [25,26] have been introduced to prepare amorphous solid dispersions (ASDs).
The highly water-soluble amorphous carriers provide stabilization of APIs, increasing the wettability
and dispersibility of the drug [27–29]. They limit the precipitation of a drug in water; however,
the supersaturation may lead to precipitation and recrystallization of APIs, which negatively affects
the bioavailability of the drug. To face this problem, surface active agents or self-emulsifiers such as
poloxamers (PLXs) [30,31], Tween 80 [32], or sodium lauryl sulfate (SLS) [33] have been introduced.
They improve the dissolution rate as well as physical and chemical stability of the supersaturated
system. Surfactants or emulsifiers enhance the miscibility and thus limit the recrystallization rate of
the drug. Moreover, they are able to absorb onto the outer layer of drug particles or form micelles
encapsulating drug particles, effectively preventing drug precipitation [34]. On the other hand,
many surfactants can absorb moisture, which may result in phase separation during storage, an increase
in drug mobility, and conversion from the amorphous or metastable form to the more stable crystalline
one. They may change the physical properties of the matrix, increase the water content and cause
adverse side effects in vivo. [35] Thus, their use has to be cautious and their amounts well adjusted.
Among the strategies that allow for obtaining solid dispersions, solvent methods are often used.
In these techniques the drug and the carrier are dissolved in a volatile solvent such as ethanol [36] or
methylene chloride–ethanol mixture [37] that is further evaporated. It requires sufficient solubility
of the drug as well as the carrier in the solvent. Moreover, the type of used solvent, the temperature,
and rate of its evaporation are of key importance due to the fact that the concentration of residual
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solvent needs to be below the detection limit after drying. One of the strategies utilized to fulfill that
requirement is the use of low-toxicity solvent mixtures, e.g., water with ethanol, which decreases
the amount of each solvent in dry formulation. However, this strategy sometimes fails due to
insufficient dissolution of components at a given ratio [35]. Usually, a second drying step is applied
to completely removed the solvent as it may lower the glass transition temperature, enhancing the
recrystallization tendency.
The common feature of evaporation approaches is the removal of small droplets or thin
layers of the solvent from different surfaces. It may lead to the crystal growth of oriented
morphology as described for droplet evaporative crystallization or microwave-accelerated evaporative
crystallization [38–40]. The crystallization of the celocoxib–PVP mixture was found to generate
drug crystals of improved dissolution characteristics [41]. Other approaches such as the evaporative
antisolvent method and supercritical carbon dioxide evaporation were applied to the formation of
nanoparticles, drug-loaded micelles, and liposomes characterized by improved dissolution of the
drug [42,43].
Commonly used solvent methods include vacuum drying using rotary evaporators [44],
spray drying [45], or freeze-drying [46], among others. In rotary evaporators, solvents are removed
under reduced pressure, limiting thermal decomposition of the components of the mixture as
organic solvent evaporation occurs at low temperature. Spray drying combines four processes, i.e.,
(1) atomization of the liquid containing dissolved or suspended drug, which is transported into the
nozzle and then sprayed onto fine droplets, (2) mixing the liquid with the drying gas, (3) evaporation,
and finally (4) separation of obtained particles from the gas using cyclone [47]. Generally, the spray
drying process can be applied for the generation of amorphous materials as well as a technique for
particle engineering, i.e., particle size reduction [48].
In the work reported herein, we study the self-assembly phenomenon of solid dispersions
containing either Poloxamer®188 or Poloxamer®407 and its effect on dissolution enhancement of
the poorly water soluble drug bicalutamide (BCL). Poloxamers are the nonionic surfactants widely
used in pharmaceutical formulations as emulsifiers, wetting agents and solubilizers. They have been
introduced into solid dispersions to enhance solubility and dissolution profiles of poorly water-soluble
APIs from solid dosage forms [49,50]. Bicalutamide was used as a model drug. It is a non-steroidal
antiandrogenic drug assigned to Biopharmaceutics Classification System (BCS) class II because of
poor water solubility (below 3.7 mg/L) and high membrane permeability (logP = 2.92) [51–53]. It is
known to exhibit polymorphism and undergo mechanical activation upon milling [54–58]. Obtained
results indicate that the formation of solid dispersions by means of solvent methods led to the changes
of particles in solid state, i.e., morphological features, increased wettability, phase transition (in case
of ternary solid dispersions containing PVP) and partial disruption of crystal lattice. Moreover,
the formation of nanoaggregates in aqueous media led to the 4- to 8-fold increase in the amount of
dissolved bicalutamide. Emission spectroscopy allowed for a correlation of the effect of dissolution
changes with the solubilization related to the variations of molecular structure of used poloxamers.
2. Materials and Methods
2.1. Materials
Bicalutamide (BCL, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-
hydroxy-2-methylpropanamide, 99.8%, Hangzhou Hyper Chemicals Limited, Zhejiang, China) was
used as a model drug. Poloxamer®188, Poloxamer®407 (BASF, Ludwigshafen am Rhein, Germany),
and polyvinylpyrrolidone K29/32 (PVP, Ashland, Covington, KY, USA) were used as excipients.
Sodium lauryl sulfate (SLS, BASF, Ludwigshafen am Rhein, Germany) was used to prepare dissolution
medium. Ethanol (absolute, 99.8%, pure p.a., Avantor Performance Materials, Gliwice, Poland)
and methanol (p.a., Chempur, Piekary Slaskie, Poland) were used as solvents. Cyclohexane (ACS,
pure p.a., Avantor Performance Materials, Gliwice, Poland) was used as a dispersant in laser
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diffraction measurements. Perylene (Pe, p.a., Koch-Light Laboratories Ltd., Colnbrook, UK) and
pyrene (98%, Sigma-Aldrich, Darmstadt, Germany) were used in fluorescence emission measurements.
All chemicals were used as received. Distilled water was used to prepare all of aqueous solutions.
2.2. Methods of Preparation of Solid Dispersions
2.2.1. Solvent Evaporation (E)
Bicalutamide (2 g) was mixed with either Poloxamer®188 or Poloxamer®407 in a 1:1 and 2:1 wt.
ratio, placed in the round-bottomed flask, and dissolved in 200 mL of absolute ethanol. The solution
was heated up to 40 ◦C in the water bath and after complete dissolution of the mixture the solvent was
evaporated using a Hei-VAP Value rotavapor (Heidolph, Schwabach, Germany). The rotational speed
was equal to 200 rpm and the pressure was reduced stepwise to ca. 40 mbar. The dry solid dispersion
was transferred to a container and dried under vacuum prior to further characterization. The systems
were further labeled as BCL-PLX188 1:1 (E), BCL-PLX188 2:1 (E), BCL-PLX407 1:1 (E) and BCL-PLX407
2:1 (E), respectively.
2.2.2. Spray Drying (SD)
An ethanolic solution containing bicalutamide mixed with the appropriate carrier or carrier
mixture (1:1 and 2:1 wt. ratio, respectively) was spray-dried using a Mini Spray Dryer B-191 (Büchi,
Flawil, Switzerland). The process was conducted using following parameters: Tinlet = 50–53 ◦C,
Toutlet = 39–42 ◦C, aspirator flow 100%, gas flow rate 600 L/min, liquid flow rate 3.4 mL/min, and a
0.7-mm diameter nozzle. The process was carried out under a constant control and the concentration of
ethanol was 10-times lower than the flammability limit. The samples were further dried under vacuum
to remove residual solvent. The systems were labeled as BCL-PLX188 1:1 (SD), BCL-PLX188 2:1 (SD),
BCL-PLX407 1:1 (SD) and BCL-PLX407 2:1 (SD), BCL-PLX188-PVP 2:1:1 (SD), BCL-PLX188-PVP 4:1:1
(SD), BCL-PLX407-PVP 2:1:1 (SD), and BCL-PLX407-PVP 4:1:1 (SD), respectively.
2.2.3. Scanning Electron Microscopy (SEM)
A Phenom Pro desktop electron microscope (PhenomWorld, Thermo Fisher Scientific, Waltham,
MA, USA) equipped with a CeB6 electron source and backscattered electron detector was used to
determine the morphological features of the samples. The acceleration voltage was equal to 10 kV and
the magnification was 750× for evaporated samples, 5000× for spray-dried ternary solid dispersions,
and 10,000× for zoomed sections. The powder was placed on the conductive adhesive tape previously
glued to the specimen mount. The holder for non-conductive samples was used. The excess of sample
(loosely bound to the tape) was removed using a stream of argon. The samples were not sputtered
prior to the measurement.
2.2.4. Differential Scanning Calorimetry (DSC)
A DSC 1 STARe System (Mettler–Toledo, Greifensee, Switzerland) was used in order to examine
the thermal properties of the samples. The measuring device was equipped with a HSS8 ceramic
sensor with 120 thermocouples and a liquid nitrogen cooling station. The apparatus was calibrated for
temperature and enthalpy using zinc and indium standards. Melting points were determined as the
onset of the peak, with the glass transition temperatures as the midpoint of the heat capacity increment.
The samples were measured in an aluminum crucible (40 μL). All measurements were carried out with
a heating rate equal to 10 K/min.
2.2.5. Powder X-ray Diffraction (PXRD)
The diffraction patterns of the samples were registered using an X-ray diffractometer Mini Flex II
(Rigaku, Tokyo, Japan). The angular range 3–70◦ 2θ was scanned with a scan speed of 5◦/min and a
step size equal to 0.02. The measurements were carried out using monochromatic Cu Kα radiation
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(λ = 1.5418 Å) at ambient temperature. The samples in form of powder were placed in a standard glass
sample holder without milling prior the measurement.
2.2.6. Laser Diffraction Measurements
A Mastersizer 3000 equipped with a HydroEV unit (Malvern Instruments, Malvern, UK) was
used to determine the particle size distribution. The samples were analyzed by the wet method using
cyclohexane (reflective index, RI = 1.426) as a dispersant. The cyclohexane was filtered through the G5
sintered disc filter funnel and placed in the beaker. The rotational speed of the mixer was 1500 rpm.
The sample in powder form was added until the obscuration reached the given value (between 5%
and 20%) and then the measurement was carried out. A Fraunhofer diffraction theory was applied
to find the relationship between particle size and light intensity distribution pattern. Reported data
represent the averages from 10 series of measurements for each sample.
2.2.7. Fourier Transform Infrared Spectroscopy (FTIR)
A Nicolet iS10 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped
with a Smart iTR™ ATR (Attenuated Total Reflectance) sampling accessory with diamond as an ATR
crystal was used to collect the vibrational spectra of powders. Spectra were collected within the
range 600–4000 cm−1 with 4 cm−1 resolution. Presented data represent average from 128 scans for
each sample.
2.2.8. Dynamic Light Scattering Measurements (DLS)
The size distribution of aggregates formed by the solid dispersions obtained by either evaporation
or spray drying was determined using a Zetasizer Nano ZS instrument (Malvern Instruments, Malvern,
UK) working at a 173◦ detection angle. The distribution analysis was performed at 25 ◦C using the
general purpose mode. The powder was weighted, dissolved in water (cPLX = 2.5 mg/mL) and shaken
using a KS 130 Basic orbital shaker (IKA, Staufen im Breisgau, Germany) for 24 h. After that the sample
was filtered through the 0.45-μm syringe filter and measured without further dilution. The reported
data represent the averages of three series of measurements (10–100 runs each) of hydrodynamic
diameter and their standard deviations.
2.2.9. Emission Spectroscopy
A SLM 8100 spectrofluorometer of L-geometry (Aminco, Silver Spring, MD, USA) equipped with
a 450W xenon lamp as a light source was used to capture the emission spectra. The microliter quantities
of the molecular probes (c ≈ 10−4 M), i.e., methanolic perylene solution or ethanolic pyrene solution
were slowly injected into a milliliter volume of aqueous PLX188 or PLX407 solutions (cPLX = 5 mg/mL)
as well to the solid dispersions solutions previously filtered through a 0.45-μm syringe membrane
filter and vigorously stirred. The residues of organic solvents were removed by purging the solution
with nitrogen. The samples were equilibrated in the dark for at least 12 h and diluted 10 times before
the measurement.
2.2.10. Contact Angle Determination
The wettability of binary systems was assessed by the contact angle measurements performed
using a DSA255 drop shape analyzer (Krüss, Hamburg, Germany). The sessile drop technique was
used. The droplet of distilled water of volume equal to 2 μL was deposited on the surface of powders
compressed using an AtlasTM manual 15Ton hydraulic press (Specac, Kent, UK) with a load pressure
of 1.5 tons that was applied for each sample for 15 s.
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2.2.11. Dissolution Study
Dissolution of BCL was carried out according to the method recommended by the FDA for
BCL tablets (1000 mL of 1% SLS, 37 ± 0.5 ◦C, 50 rpm) in the pharmacopeial paddle dissolution
apparatus Vision Elite 8 (Hanson Research, Chatsworth, CA, USA) equipped with a VisionG2 AutoPlus
Autosampler. The sink conditions were maintained. Pure drug and binary systems (solid dispersions,
physical mixtures), equivalent of 50 mg of BCL were placed into the beakers. The samples were
analyzed spectrophotometrically at 272 nm using a UV-1800 spectrofotometer (Shimatzu, Kioto, Japan)
equipped with the flow-through cuvettes. The tests were carried out in triplicate and presented results
represents averages with their standard deviations.
3. Results and Discussion
3.1. Solid State Characterization
3.1.1. Size Distribution and Morphology of Particles of Solid Dispersions
The effect of applied processes on the particle size and morphology was studied using both
scanning electron microscopy and laser diffraction measurements. The analysis of size distribution
of BCL-PLX solid dispersions obtained via evaporation in rotavapor confirmed the heterogeneity
of particle size (Figure 1A). Long tails of the distribution curves in the region of small particles
were well pronounced. Moreover, the shape of the distribution suggests that several fractions of
particles of different sizes were present in the sample, as more than one maximum can be noticed.
This is particularly noticeable for the BCL-PLX188 1:1 (E) system, which exhibits a bimodal long-tailed
distribution of particle size. This is reflected by great differences in Dx(90) values between the samples,
i.e., the point in the size distribution, up to which 90% of the total volume of material in the sample is
included. The value was 1190.0 μm for BCL-PLX188 1:1 (E) solid dispersion, while it varied between
630–730 μm for the other evaporated systems. The Dx(10) and Dx(50) values representing the diameter
of particles where 10% and a half of the particle population lie below, respectively, did not vary between
the corresponding samples; however, the values are greater for BCL-PLX188 1:1 (E) and BCL-PLX407
2:1 (E), which also exhibit long tails in the region of particles that exceeded 1000 μm in length.
 
Figure 1. Particle size distribution of solid dispersions obtained by evaporation technique (A)
and spray drying of binary (B) and ternary systems (C). BCL: bicalutamide; PLX: poloxamer;
PVP: polyvinylpyrrolidone.
In spray drying, the liquid is dispersed in a form of droplets and dried with a hot air. This leads
to a formation of particles of consistent size distribution, usually of spherical or ruptured spheres
shape of diameter below 10 micrometers. The data presented in Table 1 indicates that spray-dried
binary systems exhibited particles of greater size that those obtained via evaporation technique.
However, the span values (calculated using Equation (1)) are a bit smaller in case of spray-dried
systems, which indicates that the distributions are narrower. The tails of the distribution suggest that
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the particles aggregated during the process, probably due to the fact of low melting temperature of
poloxamer. This may also result from the fact that some amount of drying samples adhered to the
inner wall of spray dryer, which additionally leads to the decrease in the process yield. The Dx(90)
value of particles of PLX 188-based (SD) solid dispersions are bigger than systems containing PLX407.
Interestingly, BCL-PLX407 2:1 (SD) system exhibited the smallest particles among all investigated
systems, as seen in Figure 2B and the SEM image (Figure 3). The size distributions of PLX407-based
solid dispersions were narrower, with well resolved maxima as compared to those obtained for systems
containing PLX188. Moreover, the maximum of particle size distribution of the system containing
twice as much bicalutamide as PLX407 in binary solid dispersions was shifted towards bigger particles
(Dx(10) = 126.0 μm and Dx(90) = 380.0 μm). All of examined systems exhibited a tailed distribution










Dx(50) ± SD (μm) Span
Evaporation
PLX188
1:1 247.0 ± 55.9 4.698
2:1 227.0 ± 30.7 2.719
PLX407
1:1 203.0 ± 23.1 2.971
2:1 159.0 ± 53.1 4.438
Spray-drying
PLX188
1:1 196.0 ± 27.2 4.405
2:1 355.0 ± 64.7 2.876
PLX407
1:1 445.0 ± 28.7 1.771
2:1 154.0 ± 13.7 2.167
PLX188-PVP
2:1:1 78.0 ± 0.8 3.339
4:1:1 55.6 ± 1.5 3.907
PLX407-PVP
2:1:1 48.6 ± 2.2 5.153
4:1:1 54.2 ± 2.1 4.098
Interestingly, the addition of PVP to BCL-PLX systems led to the formation of fine powders with
the particle size distribution maxima located between 50 and 120 μm. However, the span reaches
greater values than for binary solid dispersions, which may be a consequence of the distributions tailed
towards smaller particles. Obtained ternary systems were also characterized with better flowability
than platelet-like particles of binary solid dispersions. Particle size distributions of all the systems were
more unified; moreover, the formation of a fraction of particles of size below 1 μm was also noticeable
(Figure 1C).
An SEM analysis indicates that the crystals of neat bicalutamide adopt hexagonal shape and
particles of smooth surface exhibiting ca. 160 μm in length [57]. The evaporation process led to the
noticeable changes in the surface and morphology of obtained binary solid dispersions. During the
rotation of the flask, the surface area of solvent increases. This leads to an enhancement of evaporation
rate and fast recrystallization of dissolved bicalutamide. Thus, the formation of sharp-edged aggregates
not exceeding 100 μm in case of BCL-PLX407 1:1 (E) and 200 μm for the other systems was observed
(Figure 2). The systems comprised particles of wide size distribution, as seen in the SEM images as
well as plots obtained using laser diffraction technique (Figure 1A).
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A spray drying process usually leads to the formation of spherical particles with a consistent size
distribution. The SEM micrographs of ternary solid dispersions show that obtained particles formed
spheres of diameter not exceeding several microns, however they tended to agglomerate (Figure 3).
In combination with the recrystallization that also occurred it led to the particle size distribution
determined by means of laser diffraction measurements being much greater as the Dx(90) values
varied between 227 μm and 273 μm.
 
Figure 2. SEM images of binary systems containing bicalutamide and either PLX188 in 1:1 (A) and
2:1 (B) wt. ratio or PLX407 in 1:1 (C) and 2:1 (D) wt. ratio obtained using evaporation method.
 
Figure 3. SEM images of ternary systems containing bicalutamide, PVP and either PLX188 in 4:1:1 (A)
and 2:1:1 (B) wt. ratio or PLX407 in 4:1:1 (C) and 2:1:1 (D) wt. ratio obtained using spray drying.
3.1.2. X-Ray Powder Diffractometry (XRPD)
The XRPD studies were performed to characterize the molecular structure of binary systems.
Obtained results indicate that both of applied processes led to the changes in molecular structure of
the systems (Figure 4). The diffraction pattern of raw bicalutamide indicated by numerous distinctive
Braggs peaks (2θ = 12.18◦, 16.88◦, 18.92◦, 23.82◦, 24.66◦, and 24.94◦) confirms that the drug exhibited
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highly-ordered arrangement on molecular level. The data confirm that bicalutamide existed as a form
I polymorph (according to the 2014 Cambridge Crystallographic Data Centre (CCDC)). The decrease
in crystallinity of the drug after co-processing with poloxamers is manifested by the reduction of
the relative intensities of peaks. This suggests that the crystal lattice was partially destructed during
processing. Moreover, the crystalline diffraction peaks are superimposed on the slightly noticeable
amorphous halos. This indicates that the sample is amorphous to a very small extent. No transition to
metastable polymorph was observed as no shifts in diffraction peaks appeared. This confirms that
used poloxamers did not stabilize the disordered system at low concentration, in agreement with a
previously published paper [59].
Figure 4. X-ray diffraction patterns of binary systems containing bicalutamide and either PLX 188 or
PLX 407 (1:1 and 2:1 wt. ratio) obtained using evaporation technique (E) and spray drying (SD).
Interestingly, the diffraction patterns were more structured in spray-dried systems than
evaporated ones. Moreover, the obtained ternary solid dispersions exhibited one more important
feature, the transition of BCL from form I into form II polymorph [60]. This is clearly marked in
the diffractograms presented in Figure 5 and manifested by the additional intense peak between
25.08◦ and 25.86◦ 2θ, which does not appear in the diffractogram of raw BCL. No such solid–solid
transition of bicalutamide–poloxamer solid dispersions has been described so far. The diffraction
patterns also suggest that ternary systems contain a fraction of amorphous phase as the diffractograms
are superimposed on the amorphous halo further assigned to partial amorphization of poloxamers
(see Section 3.1.4).
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Figure 5. X-ray diffraction patterns of ternary systems containing bicalutamide, PVP, and either PLX
188 or PLX 407 obtained by spray drying.
3.1.3. Vibrational Spectroscopy
FTIR spectroscopy has been applied to determine the molecular structure and possible interactions
between BCL and the carriers in solid dispersions. The intensity, shape and position of peaks (the
presence of shifts) were evaluated with an emphasis placed on the vibrations within the carbonyl and
amine functional groups (Figure 6). Well-resolved bands at 3335 cm−1 correspond to N–H stretching
vibrations, and the broad band with a maximum at 1687 cm−1 originates in C=O stretching vibrations.
The spectra of binary solid dispersions do not differ significantly from those of pure drug, suggesting
that BCL does not interact with any of used poloxamers or that the strength of the interactions is
negligibly small. The new band that appears in the range of 2860–3000 cm−1 corresponds to the
stretching vibrations of aliphatic C–H group in poloxamers.
Figure 6. FTIR spectra of raw bicalutamide and binary and ternary solid dispersions.
Noticeable differences were observed for ternary solid dispersions as the band corresponding to
carbonyl group vibration is broadened and the maximum red-shifted. This indicates the existence of
strong intermolecular interactions between BCL and PVP as we previously showed [57]. Moreover,
the O–H band is fuzzy, which confirms partial amorphization of the system.
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3.1.4. Thermal Properties of Solid Dispersions
The thermal properties of raw systems (i.e., BCL, PLX188, PLX407, and PVP), the binary
formulations containing BCL and either PLX407 or PLX188 polymer (that were obtained by two
different methods—evaporation (E) and spray drying (SD)), and the ternary, spray-dried formulations
of BCL, PLX, and PVP have been examined by means of the differential scanning calorimetry (DSC)
technique. The DSC curves obtained during heating with a rate equal to 10 ◦C/min are presented
in Figure 7.
Figure 7. The DSC thermograms of: binary systems containing bicalutamide and either PLX188 or
PLX407 obtained using the evaporation method (A) and spray drying (B), raw bicalutamide and
polymers (C), and ternary spray-dried systems containing BCL, poloxamer, and PVP (D).
As can be seen in the panel (C) of Figure 7, the DSC trace of raw BCL reveals a single sharp peak
with an onset at 194 ◦C. This endothermal process corresponds to the melting of the investigated
antiandrogen and is in a perfect agreement with the literature data [61]. Both DSC curves of PLX188
as well as PLX 407 exhibit two thermal events. The first (barely visible on the DSC thermograms
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presented in Figure 7C) is step-like transition occurring in the vicinity of −60 ◦C associated with the
glass transition of the amorphous part of PLXs (poly(propylene oxide), PEO blocks). The second,
located at around 50 ◦C, is a sharp endothermal peak originating from the melting of the crystalline
part of the polymers (poly(propylene oxide), PPO block). Two thermal events have been also observed
in the DSC trace of the neat PVP polymer, when measured as received. The first, very broad, thermal
event that is located in the range of 20–100 ◦C is associated with water evaporation (note the absence of
this process, when the sample is re-heated). The second step-like transition (barely visible in Figure 7C)
occurring in the vicinity of 172 ◦C is associated with the polymer glass transition.
In the panels (A) and (B) of Figure 7, the DSC traces of binary drug-polymer compositions prepared
by evaporation (panel A), and spray drying (panel B) are shown. As can be seen all investigated
formulations reveals three thermal events—Tg, Tm1, and Tm2—in the temperature range from −80 ◦C
to 210 ◦C. Because the glass transition event (Tg) is almost invisible in the scale of Figure 7, the data
from the temperature region: −75 ◦C to −40 ◦C are presented in a separate figure (see Figure 8).
In Table 2 the values of all investigated thermal events of all examined systems have been collected..
Figure 8. The zoomed fragment of DSC thermograms presented in the Figure 7 of raw bicalutamide
and poloxamers (A), binary systems containing bicalutamide and either PLX188 or PLX407 obtained
using evaporation method (B) and spray drying (C), and ternary, spray-dried, systems containing BCL,
poloxamer, and PVP (D1,D2).
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Table 2. Comparison of the Tg, Tm1, and Tm2 values of raw BCL, poloxamers, PVP, binary systems
containing bicalutamide and either PLX188 or PLX407 (obtained using evaporation method (E) and


















Raw BCL - - - - 194 110.8
Raw PVP - 172 - - - -
Raw PLX 188 −60 - 53 134.9 - -
Raw PLX 407 −65 - 56 117.3 - -
BCL-PLX 188 1:1 E −60 - 50 65.7 160 39.6
BCL-PLX 188 2:1 E −61 - 49 45.7 176 42.4
BCL-PLX 188 1:1 SD −61 - 49 66.6 160 39.2
BCL-PLX 188 2:1 SD −61 - 48 42.3 176 42.6
BCL-PLX 407 1:1 E −65 - 52 59.6 160 39.5
BCL-PLX 407 2:1 E −65 - 52 39.2 182 52.4
BCL-PLX 407 1:1 SD −66 - 52 58.9 165 39.6
BCL-PLX 407 2:1 SD −66 - 52 38.9 181 49.2
BCL-PLX-PVP 188 2:1:1 SD −61 142 47 188 135 27
BCL-PLX-PVP 188 4:1:1 SD −62 146 45 120 134 50
BCL-PLX-PVP 407 2:1:1 SD −67 141 47 140 135 26
BCL-PLX-PVP 407 4:1:1 SD −67 142 47 95 137 48
Since (1) the glass transitions of BCL-PLX 188 systems are located at the same temperature as
the Tg of raw PLX 188, and (2) the glass transitions of the BCL-PLX 407 systems are located at the
same temperature as the Tg of raw PLX 407, one can conclude that the glass transition event registered
in binary formulations originates from the amorphous fraction of the PLXs (poly(ethylene oxide)
PEO blocks). Comparing the values of the onsets of the thermal events which have been marketed
in Figure 7A,B as Tm1, one can identify them as the melting of the crystalline part of the polymer
which exists in the solid dispersions. The third thermal event that has been registered during the DSC
measurements of the BCL-PLX systems is located in the temperature range from 130 ◦C to 200 ◦C.
This endothermal peak corresponds to the melting of the BCL contained in the solid dispersions.
Therefore, one can observed that its enthalpy (ΔHm2) decreases with decreasing amounts of the BCL
in the system. As can be seen, the onset of Tm2 shifts towards lower temperatures with increasing
amounts of PLX in the formulation. This might be connected with the dissolution of the drug in a
liquid polymer.
In the panel (D) of Figure 7, the DSC traces of ternary drug–polymer–polymer compositions
(prepared by spray drying) are shown. As can be seen, the investigated formulations reveal five thermal
events which are marked in Figure 7D as Tg-PLX, Tg-PVP, Tm1, Tm2, and water evaporation. Since
both Tg-PLX and Tg-PVP are almost invisible in the scale of Figure 7, the data from the temperature
regions −80 ◦C to −40 ◦C and 110◦C to 160◦C are presented in the separate figures (see Figure 7 D1
and D2). From the comparison of the DSC traces of ternary systems to either raw and binary systems
one can conclude that: (1) Tg-PLX originates from the amorphous fraction of the PLXs (PEO blocks);
(2) Tg-PVP is associated with the glass transition temperature of PVP polymer; (3) Tm1 reflects the
melting of the crystalline part of the PLX polymer which exists in the system; and (4) Tm2 corresponds
to the melting of the BCL. Note that with increasing amount of API in the system, ΔHm1 and ΔHm2
are changing.
3.1.5. Wettability of Solid Dispersions
Powder wettability is an important issue in pharmaceutical sciences as the solid–liquid interfacial
interactions can affect drug dissolution, solubilization, and disintegration [62]. Given the heterogeneity
of the surface properties resulting from a specific surface chemistry, variations between polymorphic
and amorphous forms have been reported thus far [63]. They affect the level of supersaturation of
molecularly-disordered systems and physical stability; thus, the assessment of wetting properties
plays a significant role in the systems containing fine particles.
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The wetting behavior of raw compounds as well as binary and ternary solid dispersions were
assessed by contact angle measurements using the sessile drop technique. The difference between
the two used poloxamers is clearly visible (Figure 9). The values of measured contact angle were
equal to 56.8 ± 1.8◦ and 64.7 ± 0.02◦ for PLX188 and PLX407, respectively. The difference may result
from the differences in molecular composition of both polymers, i.e., higher amount of hydrophobic
poly(propylene oxide) units and greater molar mass of PLX407 [49]. Interestingly, no significant effects
of either the type of applied poloxamer or the process on the wettability of binary solid dispersions
were observed. All the systems exhibited improved wettability expressed by the decreased contact
angle in comparison with raw BCL (θ = 74.1 ± 0.3◦) with slightly higher values determined for systems
containing PLX407. Interestingly, the addition of PVP to ternary solid dispersions obtained by spray
drying led to well pronounced increase in wetting behavior of the systems. While the values of contact
angle for binary systems ranged between 60◦–65◦, for the systems comprising polyvinylpirrolidone
they reached ca. 42◦–45◦. Moreover, the effect of molecular structure of poloxamers was less significant
as lower values of the contact angle were obtained for PLX407-based systems. This is of particular
importance as the improved wettability and surface activity of poloxamers can strongly affect the
improvement in bicalutamide dissolution.
Figure 9. The values of contact angles of raw bicalutamide and poloxamers, binary and ternary
systems containing bicalutamide, poloxamers, and PVP obtained using either evaporation method or
spray drying.
3.2. Characterization of Solid Dispersions in Solution
3.2.1. Self-Assembly of Poloxamers in Solid Dispersions
The assembly phenomenon of amphiphilic polymers has been intensively studied in recent
years [64–66]. Their aggregation leads to the formation of hydrophobic domains that are able to
solubilize sparingly water-soluble molecules. This reduces the agglomeration of drug molecules and
increases the dissolution of API.
Poloxamers are low-meltable triblock copolymers consisting of hydrophobic chain of
poly(propylene oxide) bound with two hydrophilic chains of poly(ethylene oxide) able to solubilize
hydrophobic molecules [67]. While PLX188 contains ca. 15% of PPO, PLX407 is composed of ca. 35%
of PPO, which may affect the assembly of copolymer in polar media [68].
The size of molecular assemblies of both used poloxamers did not exceed 6 nm, however the
diameter of PLX407-based particles is ca. 30% greater than those formed by PLX188, which may result
from the higher content of PPO units. Physical mixtures also assembled in particles of diameter below
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6 nm; however, the mixtures containing equal amounts of BCL and PLX formed particles of ca. 10–12%
greater diameter than those containing the excess of the drug (Figure 10).
Figure 10. Hydrodynamic diameters of aggregates formed in aqueous solutions of poloxamers,
physical mixtures, and binary systems obtained using either the evaporation method or spray drying.
Insert: zoomed data corresponding to raw PLXs and physical mixtures.
The mean hydrodynamic diameters of all solid dispersions based on PLX188 are smaller than those
containing PLX407, regardless of the method of preparation and the number of system constituents.
Moreover, solid dispersions containing 50% of the carrier exhibited aggregates of greater diameter
than those with the excess of bicalutamide, similarly to physical mixtures. However, the differences
reached up to 39% for the BCL-PLX407 1:1 (E) system. No significant variations occurred between
the PLX188-based binary systems of corresponding compositions obtained by the two methods.
The systems containing the excess of the drug exhibited particles of ca. 170 nm in diameter, while
the size of aggregates formed by 1:1 systems was equal to 225 nm. The great variation in particle
size was noticed in BCL-PLX407 systems, especially the evaporated one containing an equal amount
of the drug and the carrier. The diameter of these particles reached 350 nm in diameter, while the
aggregates of spray-dried solid dispersion did not exceed 250 nm in diameter (Figure 10). Similar
behavior was observed for BCL-PLX407-PVP 2:1:1 (SD) which exhibited particles much greater that
the other ternary systems. The addition of PVP to solid dispersions did not affect the self-assembly
behavior. The differences in hydrodynamic diameters values follows the same trend as for binary
systems, with slightly greater values for solid dispersions containing equal amount of BCL and the
carriers (PLX and PVP).
The DLS measurements confirmed monomodal and rather narrow distribution of particle size
(Figure 11) with maxima slightly shifted towards greater values for PLX407-based systems, regardless
of the method of solid dispersion preparation. The long tail of distribution of the BCL-PLX407
1:1 (E) binary system assigned to the formation of several aggregated structures that disrupted the
measurement explains the variation in particle size in comparison with the other systems. The size of
the formed aggregates was determined to be almost 40% greater than for BCL-PLX407 2:1 (E) system,
similarly to BCL-PLX407-PVP 2:1:1 (SD) compared with BCL-PLX407-PVP 4:1:1 (SD) solid dispersions.
This confirms that the effect of the applied method of solid dispersion preparation is negligible when
considering that the solution and the composition are the most important factors.
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Figure 11. Number-weighted particle size distribution of aqueous solutions of evaporated (A),
spray-dried binary (B), and ternary (C) solid dispersions.
3.2.2. Solubilization of Molecular Probes
Fluorescence spectroscopy has been applied to the determination of micropolarity, microviscosity
and solubilization ability. Two molecular probes were used due to the act that their fluorescent
properties vary depending on physical parameters of nanoassemblies.
Perylene exhibits unique properties, i.e., low solubility in water (c = 1.6 × 10−9 M) and lack
of fluorescence in polar environment [69]. The presence of characteristic emission bands indicates
that the probe experienced non-polar environment and confirms that the probe is solubilized within
hydrophobic packets formed by self-assembled poloxamer molecules (Figure 12).
Figure 12. Emission spectra of perylene solubilized by either Poloxamer®188 or Poloxamer®407
solution (λex = 405 nm).
The emission spectrum of pyrene yields in the information about the polarity sensed by the
probe in the solubilization site. The intensity of the vibronic fine structure of the monomeric form of
pyrene depends on the polarity of the microenvironment [70]. In polar media there is an increase in the
intensity of the 0-0 band (peak I), whereas band III is affected only slightly [71]. The ratio of the emission
intensities IIII (at 386 nm) and II (at 374 nm) was used to study environmental changes experienced by
the probe. The values presented in Table 3 indicate that the probe experienced less polar environment
while solubilized within any of examined system in comparison to water. However, the increase in the
IIII to II ratio is rather low in solid dispersions (especially the spray-dried ones), which suggests that
the systems formed loosely packed nanoasseblies easily penetrable by water molecules.
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Table 3. The IIII to II ratio calculated based on the fluorescence emission spectra of pyrene solubilized
in aqueous solutions of either pure compounds or solid dispersions (λex = 330 nm).
System IIII/II System IIII/II
Water 0.351 BCL-PLX 188 1:1 (SD) 0.442
Raw PLX188 0.516 BCL-PLX 188 2:1 (SD) 0.430
Raw PLX407 0.503 BCL-PLX 407 1:1 (SD) 0.435
BCL-PLX 407 2:1 (SD) 0.442
BCL-PLX 188 1:1 (E) 0.508 BCL-PLX 188-PVP 2:1:1 (SD) 0.556
BCL-PLX 188 2:1 (E) 0.523 BCL-PLX 188-PVP 4:1:1 (SD) 0.628
BCL-PLX 407 1:1 (E) 0.441 BCL-PLX 407-PVP 2:1:1 (SD) 0.661
BCL-PLX 407 2:1 (E) 0.512 BCL-PLX 407-PVP 4:1:1 (SD) 0.670
3.2.3. Dissolution Study
The methods aimed at the enhancement of the dissolution of bicalutamide have been already
considered in several papers. Solvent evaporation under reduced pressure was applied to obtain
solid dispersions containing bicalutamide and PVP in 1:3, 1:4, and 1:5 drug-to-polymer ratios,
respectively [59,72]. The formation of binary systems led to the amorphization of BCL; however,
a great excess of PVP was required. The authors concluded that such a high proportion of the carrier
may lead to the increase in bulkiness and tablet weight during the development of a formulation.
Solid dispersions with poloxamer were obtained by melting [73] and supercritical carbon dioxide
method [74]. The samples containing 83.8% of the carrier were found to be amorphous, however
gelling properties of PLX retarded the dissolution of the drug from the systems containing high
concentration of the polymer. The increase in the amount of poloxamer in solid dispersions was
concluded not to offer any advantage for the dissolution improvement.
Due to the aforementioned problems caused by the excess of poloxamer, we prepared binary and
ternary systems containing either equal amounts of bicalutamide and polymer or twice as much BCL
as the carriers. The dissolution profiles presented in Figure 13 showed a significant improvement
(from 4- to 8-fold) of the drug dissolution in comparison with raw BCL and BCL-PLX physical
mixtures. Only 8.2% of crystalline bicalutamide dissolved after 1 h of the dissolution test. Moreover,
the formation of the systems in which BCL was physically mixed with the readily soluble carrier
affected the dissolution of the drug only slightly as less than 12.6% of bicalutamide dissolved from
physical mixture containing PLX407 and ca. 8% from PLX188-based systems (Figure 13C).
The dissolution profiles of solid dispersions were found to be independent on the applied
processes. The amount of bicalutamide dissolved from binary systems processed in 2:1 wt. ratio varied
between 36.0% for BCL-PLX407 (SD) and 37.2% for BCL-PLX188 (E) to 44.6% for BCL-PLX188 (SD)
and 46.3% for BCL-PLX188 (E). Solid dispersions containing equal amounts of the drug and the carrier
exhibited better dissolution than those containing the excess of the drug, as 51.3% of bicalutamide
dissolved from BCL-PLX188 (E), 53.3%% from BCL-PLX407 (E), and 54.8% from BCL-PLX407 (SD).
The variation was observed only for BCL-PLX188 1:1 (SD) solid dispersion as 69.6% of the drug
dissolved after 1 h. Interestingly, dissolution curves obtained for spray-dried systems with both
binary and ternary solid dispersions (Figure 13B,D) showed an opposite tendency in comparison
to evaporated systems (Figure 13A), as in evaporated systems more bicalutamide dissolved from
PLX407-based solid dispersions, while after spray drying, systems containing PLX188 exhibited better
dissolution. Importantly, the addition of PVP seems to positively affect BCL dissolution, as 77% of
BCL dissolved from both systems containing PLX188, while 75.6% and 57.3% dissolved from the 2:1:1
and 4:1:1 PLX407-based systems, respectively.
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Figure 13. Dissolution of binary and ternary systems containing bicalutamide, poloxamers and
PVP (in case of ternary systems) obtained using the evaporation technique (A), spray drying (B,D),
and physical mixing (C).
4. Conclusions
The obtained results indicate that co-processing of BCL with PLXs leads to an improvement
of bicalutamide dissolution from 4- to 8-times in comparison with the pure drug. That effect was
assigned to the formation of nanoaggregates. Surface activity of poloxamers leads to the formation
of hydrophobic packets in which bicalutamide was solubilized. Importantly, physical mixtures did
not form aggregates with bicalutamide and thus no significant enhancement in drug dissolution
was observed. While no variations in dissolution between systems obtained by either spray drying
or evaporation processes were noted, some differences in physicochemical characteristics appeared.
The most important observation is that the drug partially lost its highly-ordered molecular structure
after preparation of solid dispersions. The changes in diffractograms were more pronounced in
evaporated systems. The decrease in crystallinity was expressed by the decrease in relative intensity
and lack of several peaks. Moreover, the addition of PVP and formation of ternary solid dispersions
by spray drying led to the transition of polymorph I into polymorphic form II of bicalutamide.
This confirms that the interplay between the process parameters and properties of both drug and
carrier is important to obtain solid dispersion of desired characteristics without a great excess of the
auxiliary compounds.
The type of polymer was found to affect the size of nanoaggregates formed by solid dispersions in
an aqueous medium. The self-assembly of systems containing PLX188 led to the formation of smaller
particles, regardless the applied technique of solid dispersion preparation. This may be a result of
the composition of the macromolecule, as it contains ca. 15% PPO hydrophobic mers, while PLX407
contains ca. 35%.
Thermal analysis confirmed that poloxamers were partially amorphous in solid dispersions,
which indicates that the drug antplasticizes the Tg of the polymer. This would be connected with the
dissolution of the drug in a liquid polymer.
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Abstract: Enrofloxacin (ENRO) is a poorly soluble drug used in veterinary medicine. It differs from
the more widely used fluoroquinolone ciprofloxacin (CIP) by the presence of an ethyl substituent on
its piperazine amino group. While a number of recent studies have examined amorphous composite
formulations of CIP, little research has been conducted with ENRO in this area. Therefore, the main
purpose of this work was to produce amorphous solid dispersions (ASDs) of ENRO. The solid-state
properties of these samples were investigated and compared to those of the equivalent CIP ASDs, and
their water uptake behavior, solubility, dissolution, and antibacterial activity were assessed. Like CIP,
X-ray amorphous solid dispersions were obtained when ENRO was ball milled with acidic polymers,
whereas the use of neutral polymers resulted in semi-crystalline products. Proton transfer from the
carboxylic acids of the polymers to the tertiary amine of ENRO’s piperazine group appears to occur
in the ASDs, resulting in an ionic bond between the two components. Therefore, these ASDs can be
referred to as amorphous polymeric salts (APSs). The glass transition temperatures of the APSs were
significantly higher than that of ENRO, and they were also resistant to crystallization when exposed
to high humidity levels. Greater concentrations were achieved with the APSs than the pure drug
during solubility and dissolution studies, and this enhancement was sustained for the duration of the
experiments. In addition, the antimicrobial activity of ENRO was not affected by APS formation,
while the minimum inhibitory concentrations and minimum bactericidal concentrations obtained
with the APS containing hydroxypropyl methylcellulose acetate succinate grade MG (HPMCAS-MG)
were significantly lower than those of the pure drug. Therefore, APS formation is one method of
improving the pharmaceutical properties of this drug.
Keywords: enrofloxacin; ciprofloxacin; amorphous solid dispersion; amorphous polymeric salt;
polymer; ball milling; solubility; dissolution
1. Introduction
Enrofloxacin (ENRO), or 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid, is a fluoroquinolone antibiotic that is licensed for veterinary use. ENRO differs from
the more widely known fluoroquinolone ciprofloxacin (CIP) by the presence of an ethyl substituent
in the N3 position (Figure 1). Anhydrous CIP generally exists in the zwitterionic state, with a
protonated amino group and negatively charged carboxylate group. These oppositely charged groups
form head-to-tail ionic bonds with neighboring and adjacent molecules, resulting in a tetramer-like
structure [1]. ENRO, on the other hand, is unionized in the solid state and can therefore only form a
number of weak C–H•••O and C–H•••N hydrogen bonds [2].
Pharmaceutics 2019, 11, 268; doi:10.3390/pharmaceutics11060268 www.mdpi.com/journal/pharmaceutics129
Pharmaceutics 2019, 11, 268
  
(a) (b) 
Figure 1. Chemical structure of (a) enrofloxacin and (b) ciprofloxacin.
CIP and ENRO are both poorly water-soluble drugs, with an intrinsic solubility of approximately
0.1 mg/mL and 0.4 mg/mL, respectively [3]. Both drugs are least soluble at pH 7.4 and exist
predominantly in the zwitterionic form in neutral solutions [4]. Despite the theoretically higher
hydrophilicity of CIP due to the absence of an aliphatic group in the N3 position, the strong crystal
lattice of this drug reduces its aqueous solubility below that of ENRO. In addition, the extra ethyl
group of ENRO increases its lipophilicity and permeability, resulting in greater absorption in rat in situ
permeability studies than CIP [3]. However, the permeability of ENRO still falls within the limits of
poorly permeable [5].
One of the most commonly used techniques to improve the solubility of ionizable drugs is salt
formation. A number of crystalline ENRO salts have been produced by Karanam et al. and all were
found to be significantly more water-soluble than the pure drug [2]. The piperazine N3 nitrogen of
ENRO is positively charged in the salts containing acidic counterions, such as succinic acid, fumaric
acid, and maleic acid, and forms an ionic bond with the carboxylate groups of the acids. The carboxylic
acid of the drug, on the other hand, remains unionized. By contrast, ENRO exists in the anionic state
in the ammonium salt, with a negatively charged carboxylate group and neutral piperazine group [2].
The solubility of ENRO was also increased significantly via formulation as the saccharinate salt. Like
the equivalent CIP salt, an ionic interaction between the negatively charged saccharin molecule and
positively charged N3 amino group of ENRO was detected in this compound [6].
The solubility of a drug may also be increased by converting it to the amorphous form. This
involves the disruption of the crystal lattice, producing a disordered, high-energy version of the drug [7].
This approach is usually avoided during commercial drug development due to the intrinsic instability
of amorphous solids. However, suitable excipients can be used to stabilize the amorphous form and
prevent its crystallization. This stabilization is usually brought about via interactions between the
components, such as hydrogen or ionic bonds, and/or through steric hindrance, e.g., by polymers with
long chains [8]. Recently, the formation of various amorphous solid dispersions (ASDs) and amorphous
salts of CIP was investigated by our group. Due to the poor solubility and thermal degradation of the
drug, these were mainly prepared by ball milling [1,9]. Promising results were obtained with a number
of CIP ASDs containing various acidic polymers. They were found to increase the glass transition
temperature (Tg) and solubility of CIP, while the permeability and antibacterial activity of the drug
was either unchanged or moderately improved [9]. As an ionic interaction between the drug and
polymer was identified in each as these ASDs, they may also be referred to as amorphous polymeric
salts (APSs) [9]. The majority of ASDs described in the literature are stabilized by nonionic interactions
between the components, such as hydrogen bonds, and do not involve proton transfer between the
drug and polymer. The apparent solubility of APSs may be even further improved in comparison to
unionized ASDs, due to the amalgamation of both approaches, i.e., drug ionization and amorphization.
Amorphous salts of CIP containing succinic acid or amino acids as counterions have also been
prepared. While these formulations were far more soluble than the CIP ASDs, they were less stable
when exposed to high humidity and in most cases decreased the permeability of the drug [10,11].
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Unlike many other poorly soluble drugs, there is very little in the literature regarding amorphous
solid dispersions of ENRO, and no mention of the pure amorphous form of the drug. However,
one study by Chun and Choi described the preparation of an enrofloxacin–Carbopol “complex” by
mixing a solution of ENRO in 1% acetic acid with that of Carbopol in water, filtering and washing the
precipitate, and then drying and milling the resultant powder [12]. The product was found to be X-ray
amorphous but lacked a clear Tg. The authors hypothesized that the positively charged tertiary amine
of the drug formed an ionic bond with the carboxylate anions of Carbopol. Consequently, when the
dissolution rate of the complex was found to be lower than that of the pure drug, this was attributed to
the strength of the drug–polymer interactions.
Due to the absence of research in this area, the main aim of this project was to prepare ASDs
of ENRO and to examine their solid-state and pharmaceutical properties. As previously mentioned,
the chemical structure of ENRO differs from that of CIP by the presence of an ethyl group on its N3
piperazine amino group. It was of interest to determine whether this has an impact on the interactions
that the drug can form with various polymers and whether the biopharmaceutical properties of
this veterinary drug can be improved. The solid-state characteristics and water uptake behavior
of the successfully prepared dispersions were also examined and compared to those of equivalent
CIP ASDs produced in an earlier study [9]. In addition, the solubility, dissolution, and antibacterial
activity of the ENRO dispersions were investigated in order to determine the effect of physicochemical
transformations on these biopharmaceutical properties of the drug.
2. Materials and Methods
2.1. Materials
Enrofloxacin (ENRO) was obtained from Glentham Life Sciences (Wiltshire, UK) and Ciprofloxacin
(CIP) was purchased from Carbosynth Limited (Berkshire, UK). Polyvinylpyrrolidone K17 (PVP:
Plasdone C-15) was sourced from ISP Technologies (New Jersey, USA), poly(vinyl alcohol) (PVA:
98% hydrolyzed, Mw 13000–23000) was obtained from Sigma-Aldrich (St. Louis, MO, USA), and
Carbopol 981 was purchased from BF Goodrich (OH, USA). Methacrylic acid methyl methacrylate
copolymer (Eudragit L100) and methacrylic acid ethyl acrylate copolymer (Eudragit L100-55) were
kindly donated by Evonik Röhm GmbH (Darmstadt, Germany), while hydroxypropyl methylcellulose
acetate succinate grades LG and MG (HPMCAS-LG and HPMCAS-MG) were provided by Shin-Etsu
Chemical Co., Ltd. (Tokyo, Japan).
Fasted state simulated intestinal fluid (FaSSIF) was produced by adding 2.24 g SIF® Powder
Original (biorelevant.com, Surrey, UK) to one liter of FaSSIF phosphate buffer, consisting of 19.5 mM
NaOH (Riedel-de Haën, Seelze, Germany), 25 mM NaH2PO4·H2O (Merck, Darmstadt, Germany)
and 106 mM NaCl (Sigma-Aldrich Ireland Ltd., Arklow, Ireland), adjusted to pH 6.5 with NaOH.
Triethylamine was obtained from Sigma-Aldrich Ireland Ltd., (Arklow, Ireland). Brain–heart infusion
(BHI) broth was obtained from bioMérieux (Marcy l’Étoile, France), while plates with Columbia agar
supplemented with sheep blood were sourced from Oxoïd (Dardilly, France). All other chemicals and
solvents were of analytical grade.
2.2. Methods
2.2.1. Sample Preparation
Solid dispersions were produced by dry ball milling ENRO and various polymers as described
previously [9]. Briefly, the process was carried out at room temperature (22–25 ◦C) with a Retsch
planetary ball mill PM 100 (Haan, Germany). The polymer concentration used was 40–60% (w/w),
and a total of 2 g of powder was loaded to 50 mL stainless steel grinding jars containing three 20 mm
stainless steel milling balls. Each mixture was milled for 1–6 h in total, in intervals of 15 min with
10 min breaks in between. Crystalline ENRO was quench cooled by heating the drug to the endset
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of melting (~235 ◦C) at 10 ◦C/min in a differential scanning calorimetry (DSC) machine, and then
immediately removing the sample to allow it to cool quickly at room temperature. Physical mixtures
(PMs) were prepared by mixing relevant concentrations of ENRO and the polymers in a pestle and
mortar for a few minutes.
2.2.2. Powder X-ray Diffraction (PXRD)
PXRD was performed at room temperature using a benchtop Rigaku MiniflexII X-ray diffractometer
(Tokyo, Japan) and a Haskris cooler (Illinois, USA) as described previously [1].
2.2.3. Solid-State Fourier Transform Infrared Spectroscopy (FTIR)
A Spectrum One FTIR spectrometer (PerkinElmer, Connecticut, USA) was utilized to obtain FTIR
data [1,9]. The following parameters of the analysis, accumulating 10 scans in total, were employed:
450–4000 cm−1 was spectral range, 4 cm−1 was resolution, while the scan speed was 0.2 cm/s. A sample
concentration of 1% (w/w) was obtained, diluting the powdered sample with KBr and making disks
suitable for FTIR by applying pressure of approximately 10 bar for 1 min.
Deconvolution of the FTIR spectra was conducted to facilitate their comparison. OriginPro 7.5
software was used to subtract the baseline and carry out Gaussian peak fitting on the spectra. In each
case, seven overlapping peaks were detected in the region under examination, whose combined area
and shape were similar to those of the original bands [1].
2.2.4. Differential Scanning Calorimetry (DSC)
DSC analysis on 5–10 mg samples was done using a Mettler Toledo DSC (Schwerzenbach,
Switzerland) under nitrogen purge and employing sealed 40 μL aluminum pans with three pin-holes
in the lid [9]. To expose the glass transition temperature (Tg) of the samples, the powders were first
subjected to a first heating cycle from 25 to 65 ◦C to remove the residual moisture, then the samples
were cooled to 25 ◦C and re-heated to 250 ◦C at a rate of 10 ◦C/min.
2.2.5. Modulated Temperature Differential Scanning Calorimetry (MTDSC)
The Tgs of the ASDs were detected by MTDSC using a Q200 DSC instrument and TA Instruments
DSC Refrigerated Cooling System (TA Instruments, New Castle, Delaware). Samples of 3–4 mg were
heated in aluminum pans with sealed aluminum lids. Nitrogen was used as the purge gas at a flow
rate of 20 mL/min. Samples were heated from 0 ◦C to 110–185 ◦C at 2 ◦C/min, with an amplitude of ±
0.318 ◦C and a modulation period of 60 s. Results were analyzed with the Universal Analysis 2000
software (TA Instruments). The midpoint of the transition was taken as the Tg. Sapphire was used to
calibrate the heat capacity, while indium was used for the calibration of enthalpy and temperature. All
measurements were carried out in triplicate.
2.2.6. Calculation of Theoretical Glass Transition (Tg) Values with Gordon–Taylor Equation









w1 and w2 are the weight fractions of the components, Tg1 and Tg2 are the glass transition temperatures
of ENRO and the polymer, and ρ1 and ρ2 are the true densities of the two constituents. The Tgs of
the polymers were sourced from the literature: HPMCAS-LG, 119 ◦C [15]; HPMCAS-MG, 120 ◦C [15];
Eudragit L100, 130 ◦C [16]; Eudragit L100-55, 96 ◦C [16]; and Carbopol, 105 ◦C [17]. Further, the average
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true density data were obtained from the published resources: ENRO, 1.385 g/cm3 [18]; HPMCAS-LG
and HPMCAS-MG, 1.29 g/cm3 [19]; Eudragit L100, 0.84 g/cm3 [20]; Eudragit L100-55, 0.83 g/cm3 [16];
and Carbopol, 1.4 g/cm3 [21].
2.2.7. High-Speed Differential Scanning Calorimetry (HSDSC)
HSDSC was performed on crystalline ENRO, under helium purge, with a PerkinElmer Diamond
DSC (Waltham, MA, USA) supported by a ULSP B.V. 130 cooling system (Ede, The Netherlands) as
described previously [1]. Around 3–5 mg samples were first encapsulated in aluminum pans (18 μL)
and heated from 25 to 300 ◦C at a rate of 300–500 ◦C/min.
2.2.8. Thermogravimetric Analysis (TGA)
TGA was done using a Mettler TG50 measuring module coupled to a Mettler Toledo MT5 balance
(Schwerzenbach, Switzerland) [1]. The heating rate employed was 10 ◦C/min and samples (8–10 mg)
were loaded into open aluminum pans.
2.2.9. Dynamic Vapor Sorption (DVS) and Mathematical Modeling Using Young–Nelson Equations
DVS studies were performed using an Advantage-1 automated gravimetric vapor sorption
analyzer (Surface Measurement Systems Ltd., London, UK) at 25.0 ± 0.1 ◦C, between 0 and 90% RH,
in steps of 10% RH, as described previously [9]. The complete sorption and desorption profile is
shown as an isotherm. PXRD analysis was performed on all samples following DVS to identify any
solid-state transformations.
In order to determine how water uptake occurs in the ASDs, the experimental sorption and
desorption data were fitted to equations using the Young–Nelson model, as described previously [22,23]:
Ms = A(β + θ) + B(θ)RH, (3)
Md = A(β + θ) + B(θ)RHmax. (4)
Ms and Md are the amount of water sorbed and desorbed, respectively, at each relative humidity
value. This is expressed as a fraction of the dry mass of the sample. A and B are constants which can









ρw is the density of water, Wm is the weight of the dry sample, and VolM and VolA are the volume
of adsorbed and absorbed water, respectively. In Equations (3) and (4), θ represents the fraction of
sample surface that is covered by at least one layer of water molecules, and β is the mass of absorbed
water at 100% RH. B(θ)RH is therefore the mass of absorbed water at a particular fraction of monolayer
coverage, θ, and RH level. A(β + θ) is equal to the total amount of adsorbed water, while Aθ is the
mass of water in an entire adsorbed monolayer, as a fraction of the dry mass of the material. Aβ is the
mass of water adsorbed in a multilayer. θ and β may be further defined as follows [23]:
θ =
RH
RH + E(1−RH) , (7)
β = − ERH
E− (E− 1)RH +
E2
(E− 1) ln a
E− (E− 1)RH
E
a− (E + 1) ln(1−RH). (8)
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E is an equilibrium constant between water in the monolayer and condensed water adsorbed
externally to the monolayer:
E = e
−[ q1−qLkBT ]. (9)
q1 is the heat of adsorption of water on the solid, qL is the heat of condensation of water, both in
Joules/mole, then T is the temperature in Kelvin and kB is Boltzmann’s constant (1.38 × 10−23 J/K).
The experimental data obtained from DVS studies of the ENRO ASDs, as well as equivalent CIP
ASDs that were previously prepared [9], were fitted to Equations (3) and (4) by iterative multiple linear
regression. The sum of the squares of the residuals between the experimental and calculated values
was used as fitting criteria. The multiple correlation coefficient (r) was calculated using Microsoft Excel
2007. Using the calculated values of A, B, θ, and β, the profiles of water adsorbed in monolayer (Aθ)
and multilayer (Aβ), and of absorbed water (Bθ) were determined [23].
2.2.10. Dynamic Solubility Study
A volume of 5 mL of FaSSIF was added to 40 mL glass vials and placed into jacketed beakers
connected to a Lauda M12 waterbath at 37 ◦C (Lauda-Königshofen, Germany). A quantity of pure
drug or ASD, in excess of the expected saturated solubility (25–200 mg, depending on the sample), was
added to the vials containing the aliquot of FaSSIF and stirred at 1000 rpm. At different time points,
over a 2 h period, samples were taken for the stirred suspensions and filtered with 0.45 μm PTFE
membrane filters (VWR, USA). The filtered solutions were then diluted appropriately with a 2.9 g/L
solution of phosphoric acid, previously adjusted to pH 2.3 with trimethylamine [2]. The concentration
of ENRO in each of the diluted samples was determined by UV spectrophotometry as described below.
The solid material left in the vials at the end of the studies was filtered and analyzed by PXRD.
2.2.11. Dissolution Study
Dissolution studies were carried out at 37 ◦C, using a paddle apparatus (Apparatus II) with a
continuous rotation of 100 rpm. A quantity of sample corresponding to approximately 10% of the
final drug concentration obtained in the solubility study was added to 300 mL of FaSSIF (ENRO:
25 mg, ENRO/Eudragit L100: 287.5 mg, ENRO/HPMCAS-LG: 967.5 mg and ENRO/HPMCAS-MG:
517.5 mg). One milliliter aliquots was taken at specific time points over the 2 h period of the study
and replaced with 1 mL of FaSSIF. Each sample was filtered with a 0.45 μm PTFE membrane filter
(VWR, USA) and diluted with a 2.9 g/L solution of phosphoric acid, previously adjusted to pH 2.3 with
triethylamine. The concentration of ENRO in each of the diluted samples was then measured by UV
spectrophotometry. The cumulative quantity of dissolved drug at each time point was calculated by
taking account of the 1 mL aliquots taken for analysis. Each study was carried out in triplicate.
2.2.12. UV Spectrophotometry
UV analysis was performed using a Shimadzu UV-1700 PharmaSpec UV-vis spectrophotometer
(Shimadzu Corp., Kyoto, Japan) using quartz cuvettes with a 1 cm optical path length. The reference
was a 2.9 g/L solution of phosphoric acid, previously adjusted to pH 2.3 with triethylamine. This buffer
was also used to produce a range of concentrations of pure ENRO, in order to construct a calibration
curve. The λmax of these solutions was found to be 277 nm; therefore, UV absorbance was measured at
this wavelength.
2.2.13. Bacterial Studies
For these studies, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas
aeruginosa ATCC 27853, and Klebsiella pneumoniae DSM 16609 were cultured on Columbia agar
supplemented with sheep blood. The inoculum was prepared as previously described [9,24]. The
density of the S. aureus suspension was adjusted so that it equaled that of the 1.1 McFarland standard,
and then further diluted 100-fold with BHI medium. The P. aeruginosa, E. coli, and K. pneumoniae
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suspensions, on the other hand, were adjusted to equal that of the 0.5 McFarland standard, and then
diluted 10-fold.
The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations
(MBCs) of ENRO and the ASDs were determined using a broth microdilution method, as previously
described [9,24].
3. Results and Discussion
3.1. Production of Amorphous Solid Dispersions/Amorphous Polymeric Salts
Ball milling was first carried out on crystalline “as received” ENRO to determine whether it is
possible to amorphize the drug in this manner. However, following four hours of milling at room
temperature, a disordered, semi-crystalline solid was obtained (Figure 2a). This was also the case with
CIP [1]. The most intense peaks in the X-ray diffractogram of the unprocessed ENRO powder are
visible at 7.4, 9.8, 14.9, and 25.8 2θ degrees. These peaks are also present in the diffractogram of ball
milled ENRO; however, their intensity is reduced. Quench cooling ENRO, on the other hand, resulted
in an X-ray amorphous material (Figure 2a).
θ θ  
Figure 2. Powder X-ray diffraction (PXRD) diffractograms of (a) enrofloxacin (ENRO) and
semi-crystalline solid dispersions, and (b) ENRO amorphous solid dispersions (ASDs).
In previous studies with CIP, X-ray amorphous solid dispersions were obtained when the drug
was ball milled with Eudragit L100, Eudragit L100-55, Carbopol, HPMCAS-LG, and HPMCAS-MG. All
of these polymers are acidic, and FTIR analysis confirmed the presence of an ionic bond between the
positively charged piperazine amino group of CIP and the carboxylate groups of the polymers in the
ASDs [9]. These acidic polymers also proved to be suitable co-formers for ENRO, with each resulting
in an X-ray amorphous formulation (Figure 2b). As was the case with CIP, a polymer concentration of
60% (w/w) was required to fully amorphize mixtures of CIP and HPMCAS, whereas 40% (w/w) was
adequate for Eudragit L100, Eudragit L100-55, and Carbopol. Although the product obtained with
40% (w/w) HPMCAS-LG was almost X-ray amorphous following 4 h of milling, very small peaks could
still be detected by PXRD at 9.8 and 25.8 2θ degrees, corresponding to the most prominent peaks of
anhydrous ENRO (Figure S1). A slightly more crystalline product was obtained with HPMCAS-MG
under the same conditions, which decreased in intensity following a further 2 h of milling but did not
disappear entirely. In contrast to CIP, which required a total of 6 h of milling and a reduced temperature
of 2–5 ◦C to form ASDs with 60% (w/w) HPMCAS [9], 4 h of milling at room temperature was adequate
for the corresponding ENRO ASDs (Figure S1). This indicates that the polymers may interact more
readily with ENRO than CIP possibly due to the weaker crystal lattice of ENRO, which would facilitate
its amorphization. These results show that the presence of an extra ethyl group in the structure of
ENRO does not appear to negatively affect its ability to interact with these acidic polymers. To enable
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closer comparison with the equivalent CIP ASDs, the ENRO/HPMCAS ASDs containing 60% (w/w)
polymer that were milled for 6 h were used for further studies.
In contrast to the acidic excipients, when CIP was milled with neutral polymers such as PVP and
PVA at a concentration of 40–60% (w/w), a semi-crystalline product was obtained [9]. This was also
the case with ENRO (Figure 2a). The fact that X-ray amorphous solid dispersions were only formed
when ENRO was milled with acidic polymers containing carboxylic acid groups suggests that the drug
is interacting with these substances via ionic bonds, as was the case with CIP. Likewise, in all of the
ENRO salts produced by Karanam et al. containing an acidic counterion, proton transfer from the acid
to the piperazine tertiary amine (N3) of the drug occurred, resulting in an ionic interaction between the
two moieties [2]. A similar reaction may take place between the N3 of ENRO and the polymers in
these ASDs.
3.2. Solid-State Fourier Transform Infrared Spectroscopy
The results of FTIR analysis of the ASDs, PMs, and starting materials are shown in Figure 3a–d.
A sharp peak is located at 1737 cm−1 in the spectrum of crystalline ENRO due to the carbonyl stretch of
its unionized carboxylic acid group. While the process of ball milling introduced some disorder to the
crystal lattice of ENRO, the FTIR spectrum of the ball milled drug was almost identical to the crystalline
ENRO starting material. The greater molecular disorder of quench cooled ENRO, on the other hand, is
evident in the broader and less intense peaks of its spectrum (Figure 3d). Slight peak shifts were also
seen with this sample, in particular, the carboxylic acid C=O stretch, which shifted to 1728 cm−1. This
can be attributed to changes in the drug’s intermolecular interactions upon amorphization, such as
hydrogen bonding [25]. Interestingly, the COOH carbonyl stretch of the drug also shifted to lower
wavenumbers in the spectrum of the crystalline ENRO saccharinate salt, in which the piperazine N3
amino group of the drug is positively charged [6]. This carbonyl peak underwent a similar shift with all
of the ASDs. Therefore, while the carboxylic acid of ENRO remains unionized in the ASDs, changes in
the hydrogen bonding of this group clearly occur upon amorphization. This shift may also be related
to changes in the ionization state of the drug.
The main differences between the spectra of ENRO and the ASDs may be seen in the 1650–1450 cm−1
region. In the case of crystalline ENRO, the carbonyl stretch of its ketone group appears as a sharp,
strongly absorbing peak at 1628 cm−1. The medium intensity shoulder at 1611 cm−1 may be assigned
to C=C stretching vibrations of the drug’s aromatic ring. While these peaks are not significantly
shifted in the spectra of the ASDs, differences in their relative absorbance were observed. In crystalline
ENRO, the absorbance of the ketone peak is approximately 1.8 times greater than that of the aromatic
peak. This ratio decreases to 1.5–1.7 for each of the ASDs. However, a similar decrease in the relative
absorbance of these peaks was also seen with quench cooled ENRO and is therefore likely due to
changes in the interactions of these groups upon amorphization.
The peaks at 1508 and 1469 cm−1 in the spectrum of ENRO may be attributed to C=C stretching of
the aromatic ring, and C–C stretching of the drug’s piperazine group, respectively [26]. The shape
of these peaks was altered notably in the ASDs, and the presence of multiple overlapping peaks
became evident. In order to separate the individual peaks in this region and to quantify their relative
absorbance, deconvolution of the spectra, with Gaussian peak fitting, was carried out. The resulting
spectra are shown in Figure S2. Deconvolution allowed the detection of a further peak at approximately
1453 cm−1 in the spectrum of ENRO, which may be tentatively assigned to the C–H bending vibrations
of the ethyl group. This peak is also present in the spectra of ball milled and quench cooled ENRO,
and all of the ASDs, along with an additional peak at approximately 1494 cm−1. Although a slight
broadening is visible at this wavenumber in the spectrum of crystalline ENRO, it is not as distinct as
with the other samples. Clear differences in the relative absorbance of these peaks may also be seen
between the pure drug and ASDs. For instance, in crystalline ENRO, the area of the peak at 1508 cm−1
is approximately two times smaller than the combined area of the peaks at 1469–1453 cm−1. While a
similar ratio was obtained with the equivalent peaks in ball milled ENRO, with the quench cooled
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form of the drug, it decreased to 1.9. With the ASDs, on the other hand, this ratio decreased further to
1.3–1.55. Similarly, in the spectra of crystalline and ball milled ENRO, the absorbance of the peak at
1469 cm−1 is clearly greater than that at 1453 cm−1. By contrast, in each of the ASDs, as well as quench
cooled ENRO, the maximum absorbance of these peaks did not differ greatly. Similar changes in this
region were seen in the spectra of the partially crystalline ENRO/PVA solid dispersion, whereas the
less disordered ENRO/PVP more closely resembled the crystalline ENRO starting material (Figure S3).
 
 
Figure 3. FTIR spectra of ASDs and physical mixtures (PM) containing (a) Eudragit L100 and Eudragit
L100-55 40% (w/w) (b) Carbopol 40% (w/w), (c) hydroxypropyl methylcellulose acetate succinate grades
LG and MG (HPMCAS-LG and HPMCAS-MG) 60% (w/w), and (d) ball milled and quench cooled
ENRO. The areas of the spectra that undergo significant changes upon amorphization are highlighted
in violet.
As previously mentioned, the terminal tertiary amine of ENRO (N3) may be protonated in these
ASDs, forming ionic bonds with the carboxylate groups of the polymers. If this is the case, the
main differences in the FTIR spectra of the ASDs compared to the starting materials or PMs can be
attributed to the change in ionization state of the drug, and the presence of an additional +N–H bond.
Unfortunately, the +N–H stretch is difficult to assign with certainty, as it will produce a weak band in
the 3000–2600 cm−1 region that possibly overlaps with others, such as that of the C–H stretch of the
neighbouring aliphatic group [26]. Similarly, the +N–H bend of a tertiary amine salt generally appears
as a very weak band in the 1610–1500 cm−1 region [27] and therefore is likely to be obscured by more
intense peaks in the spectra of the ASDs. However, as described above, a number of differences in the
1450–1550 cm−1 region of the spectra of ENRO and the ASDs were observed. Therefore, it is possible
that the presence of the peak corresponding to the +N–H bend contributed to the variations in this area
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of the spectra. In addition, as the peaks in this region correspond to groups surrounding the terminal
amino group of ENRO, it is likely that they would be altered upon the protonation of N3.
The hypothesis that ENRO is protonated in these ASDs is supported by the FTIR analysis of
ENRO salts conducted by Karanam et al. [2]. In the spectra of each of the salts containing an acidic
counterion, a decrease in the absorbance of the peak around 1469 cm−1 relative to that at 1508 cm−1
can be seen, in common with the ENRO ASDs. Single crystal X-ray diffraction confirmed that the N3
of the drug was protonated in these salts and formed an ionic bond with the carboxylate groups of
the acids. Therefore, it is likely that ENRO is in the same cationic state in these ASDs and interacts
with the acidic groups of the polymers to form amorphous polymeric salts (APSs). The fact that the
spectrum of quench cooled ENRO is similar to that of the ASDs may be due to the partial conversion
of the drug to the zwitterion.
3.3. Thermal Analysis
The conventional DSC thermograms of ENRO and the ASDs are shown in Figure 4. The melting
point onset of crystalline ENRO, as well as the ball milled and quench cooled drug, was approximately
225 ◦C. Its lower melting point in comparison to CIP (approximately 272 ◦C) [1] can be explained by
the less extensive intermolecular bonds in ENRO. In contrast to the pure drug, the thermograms of the
ASDs were missing a clear melting point. Similarly, the ASDs did not show distinct crystallization
exotherms during DSC analysis, although the small, broad peaks visible at approximately 157 ◦C
and 148 ◦C in the thermograms of ENRO/HPMCAS-LG and ENRO/HPMCAS-MG, respectively, may
be due to some crystallization. The indistinct nature of the thermograms can be attributed to the
amorphous nature of these formulations and their stability upon heating [28]. By contrast, ball
milled and quench cooled ENRO had clear crystallization peaks at approximately 73 ◦C and 106 ◦C,
respectively, confirming their lower resistance to crystallization. The particularly low crystallization
temperature of ball milled ENRO is to be expected, as the residual crystallinity present in this sample
would enable crystal growth to occur more quickly upon heating.
 
Figure 4. Differential scanning calorimetry (DSC) thermograms of (a) crystalline ENRO, (b) ball milled
ENRO, (c) quench cooled ENRO, (d) ENRO/HPMCAS-MG, (e) ENRO/HPMCAS-LG, (f) ENRO/Carbopol,
(g) ENRO/Eudragit L100-55, and (h) ENRO/Eudragit L100. The thermograms of the ASDs are those
obtained from the second heating cycle, following initial heating to 65 ◦C to allow for residual
water removal.
The Tg of quench cooled ENRO was detected at 58.9 ◦C, which is significantly lower than that
of CIP (86.7 ◦C). Again, this may be attributed to the weaker intermolecular interactions present in
ENRO. As a distinct Tg could not be found for all of the ENRO ASDs using conventional DSC; they
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were therefore analyzed by MTDSC. The resultant Tgs are listed in Table 1. In each case, a single Tg
was detected. This suggests that the drug is miscible with each of these polymers, and that they form a
single homogeneous phase [29]. Due to its low amorphous content and high crystallization rate, no Tg
could be determined for ball milled ENRO with either DSC technique.
The Gordon–Taylor (G–T) equation was used to calculate the expected Tgs of the ASDs, given
their weight percentage of drug and polymer. From Table 1, it can be seen that the experimental Tgs of
the ASDs containing Carbopol, Eudragit L100, and Eudragit L100-55 were substantially higher than
the theoretically derived values. Such large positive deviations from the predicted Tgs suggest that
strong interactions exist between the components and are particularly indicative of polymeric salt
formation [30]. By contrast, the experimental and G–T Tgs of the HPMCAS-containing ASDs differed
by only a few degrees. This suggests that these polymers are fully miscible with ENRO but do not
form strong interactions with the drug or that the heteromolecular drug–polymer interactions may be
of a similar strength to the homomolecular interactions present in the individual raw materials [31].
Similar results have been obtained with the equivalent CIP ASDs, whereby the experimental
Tgs of those containing Eudragit L100 and L100-55 deviated from the predicted values by a much
greater degree than those containing either grade of HPMCAS. The apparently weaker interactions
present in the latter ASDs were attributed to the lower proportion of carboxylic acid groups present in
HPMCAS compared to the other polymers [9]. This would explain why a polymer concentration of
60% (w/w) was required to produce X-ray amorphous solid dispersions with these polymers, whereas
a concentration of 40% (w/w) was sufficient with the others.
Table 1. Glass transition temperatures (Tg) of ENRO and ENRO ASDs.
Sample Experimental Tg (◦C) G-T Tg (◦C)
ENRO 58.9 N/A
ENRO/Eudragit L100 109.9 ± 1.6 82.5
ENRO/ Eudragit L100-55 103.2 ± 0.2 74.0
ENRO/Carbopol 155.6 ± 0.2 71.4
ENRO/HPMCAS-LG 86.8 ± 0.4 85.6
ENRO/HPMCAS-MG 83.3 ± 0.4 85.9
As previously mentioned, CIP exists as a zwitterion in the solid state, with a positively charged
piperazine amino group and negatively charged carboxylate group. However, it has been shown to
convert to the unionized form upon melting, due to intramolecular proton transfer. This was visualized
as a small endothermic peak in the DSC thermogram of the drug, just prior to the melting endotherm.
However, this low energy event was only visible when CIP was heated at 500 ◦C/min [1]. HSDSC
analysis was therefore carried out on crystalline ENRO in order to determine if it also undergoes
proton transfer at high temperatures, in this case from the unionized form to the zwitterion. However,
even when heated at the maximum heating rate of 500 ◦C/min, the drug did not show any evidence of
solid-state transformation (Figure S4). After heating ENRO to the endset of melting and allowing it to
cool slowly, PXRD and FTIR analysis confirmed that the drug remained in the unionized anhydrous
state; thus, the ethyl moiety attached to N3 prevented the proton transfer.
While crystalline ENRO is pale yellow, quench cooled ENRO is a more vibrant golden color,
and when heated to 250 ◦C, the drug becomes dark orange/rusty. CIP also turns from off-white to a
yellow color prior to melting; however, when heated past its melting point, it becomes brown due
to substantial degradation. From the TGA curves obtained with ENRO and the ASDs (Figure 5),
crystalline and ball milled ENRO do not appear to undergo substantial thermal degradation, decreasing
in mass by only 3.4% over the course of the TGA analysis. CIP, on the other hand, is much more prone
to thermal degradation, with a mass loss of 12.8% and 17.3% being obtained with the crystalline and
ball milled forms of the drug, respectively [1]. An initial mass loss was observed below 70 ◦C with all
of the amorphous formulations due to water evaporation. This is to be expected with ASDs, as the
hygroscopic nature of amorphous drugs and polymers results in the absorption of atmospheric water
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vapor. The amorphous samples also degraded to a greater degree than the pure drug, in particular, the
Carbopol ASD. Amorphous solids are typically more reactive than their crystalline counterparts, as
their higher molecular mobility can enable such degradation reactions to occur [32]. Alternatively, this
mass loss may simply be due to degradation of the polymers.
 
Figure 5. TGA analysis of (a) crystalline ENRO, (b) ball milled (BM) ENRO, (c) ENRO/Eudragit L100,
(d) ENRO/Eudragit L100-55, (e) ENRO/Carbopol, (f) ENRO/HPMCAS-LG, and (g) ENRO/HPMCAS-MG.
3.4. Water Sorption Studies
The stability of the ASDs when exposed to various humidity levels was examined by DVS. At the
end of the sorption cycle, at 90% RH, ENRO absorbed only 0.13% (w/w) water. This increased to 2.9%
for the ball milled drug, due to the increase in disordered material (Figure 6a). CIP also absorbed low
levels of water during DVS analysis, increasing in mass by only 0.6% (w/w) [33]. PXRD analysis of the
drugs at the end of the sorption studies revealed that both ENRO remained in the same solid state, with
PXRD patterns matching those of the starting materials (Figure S5) [33]. In contrast to the crystalline
drug, the ENRO ASDs were far more hygroscopic, absorbing 16–19% of their mass in water. Very
similar levels of water uptake were observed with the CIP ASDs [9]. The higher hygroscopicity of the
amorphous formulations can be explained by the random orientation of their molecules. This leads to
a larger free volume and enables the penetration of water into the samples [34]. In addition, polymers
are often more hygroscopic than the amorphous form of a drug, which increases the tendency of an
ASD to take up moisture [35].
As can be seen in Figure 6b, the isotherms obtained with the ASDs containing Eudragit L100,
Eudragit L100-55 and Carbopol were very similar in shape, with significant hysteresis. Hysteresis is
commonly encountered with amorphous or porous solids, as water can absorb into the interior of the
material [36]. If water diffuses into the sample bulk more quickly than it can return to the surface, then,
at the same RH level, a greater amount of moisture will be present during desorption than sorption,
resulting in the appearance of hysteresis.
Unlike the other ASDs, the isotherms of both ENRO/HPMCAS ASDs were convex in shape with
a small amount of hysteresis, suggesting that water was mainly adsorbed to the outer surfaces of
these samples (Figure 6c). Therefore, the water uptake behavior of the ENRO ASDs differs depending
on the polymer used. This was further examined by fitting the sorption and desorption data to the
Young–Nelson equations. According to the Young–Nelson model, water can be taken up by a sample
in three different ways: adsorbed as a monomolecular layer, adsorbed as a multilayer, or absorbed into
the interior of the solid [22]. The parameters calculated using the Young–Nelson equations are listed in
Table S1, and the isotherms obtained using this approach are shown in Figure 7 and Figure S6. The
corresponding CIP ASDs were also examined for comparison (Figure S7).
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Figure 6. DVS isotherms of (a) crystalline and ball milled ENRO, (b) ENRO ASDs containing 40%
(w/w) Eudragit L100, Eudragit L100-55, and Carbopol, and (c) ENRO ASDs containing 60% (w/w)
HPMCAS-LG and HPMCAS-MG.
As predicted from the DVS isotherms, the major water uptake mechanism of the ENRO ASDs
containing Eudragit L100, Carbopol, and Eudragit L100-55 was water absorption (Figure 7a,b and
Figure S6a). The small degree of absorption that occurred with the ENRO/HPMCAS ASDs confirms
that they are somewhat porous, but less so than the other ASDs, as suggested by the minor hysteresis
in their DVS isotherms. Unlike the other samples, the majority of water taken up by ENRO/HPMCAS
ASDs was bound to their exterior surfaces as a multilayer. Multilayer formation begins at low RH
levels and appears to occur simultaneously with monolayer adsorption (Figure 7c and Figure S6b). By
contrast, the major water uptake mechanism for the CIP ASDs containing HPMCAS was absorption
(Figure S7). This suggests that the CIP/HPMCAS ASDs are more porous than the corresponding ENRO
ASDs, or the polymers may be capable of swelling to a greater degree in the former formulations.
As with the ENRO ASDs, water is primarily absorbed into the interior of the CIP ASDs containing
Eudragit L100, Eudragit L100-55, and Carbopol. However, the water distribution patterns obtained
with the ENRO and CIP ASDs containing Carbopol differed somewhat from the others. The monolayer
adsorption of these samples increased more gradually over the course of the study and was also more
extensive. This may be due to the presence of more hydrophilic groups on the surface of these ASDs,
which can interact with water molecules [23].
With both sets of ASDs, the highest value of E was obtained with those containing HPMCAS-LG,
followed by HPMCAS-MG (Table S1). However, this constant was more than 10 times larger for
the ENRO/HPMCAS samples than those containing CIP. This indicates that water molecules form
much stronger and extensive interactions with the surface of these samples [37] and explains why
water appears to be mainly adsorbed to the surface of these ASDs in a multilayer. The value of the
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regression coefficient, r, was ≥0.98 for all of the ASDs, showing that there was a good fit between the
experimental and estimated values of the different parameters (Table S1). Therefore, application of the
Young–Nelson model is a suitable approach for comparing the water uptake of these samples.
 
 
Figure 7. Water distribution patterns according to the Young–Nelson model in ENRO ASDs containing
(a) Eudragit L100 40% (w/w), (b) Carbopol 40% (w/w), and (c) HPMCAS-LG 60% (w/w).
The permeation of water molecules into the interior of an amorphous solid can increase its free
volume, resulting in a decrease in Tg [38]. Water sorption is also known to increase the molecular
mobility and thus crystallization rate of amorphous substances, and to decrease the crystallization
onset temperature [39]. However, despite the plasticizing effects of sorbed water, all five of the ENRO
ASDs remained X-ray amorphous following DVS analysis (Figure S5). This was also the case for the
corresponding CIP polymeric ASDs [9]. The high stability of these ASDs may be due to stabilizing
drug–polymer interactions, the presence of which was suggested by the results of FTIR and DSC
analysis. Polymers are also known to have anti-plasticizing effects and to reduce the molecular mobility
of amorphous formulations, while steric hindrance from polymer chains can prevent the nucleation
and crystal growth of drug molecules [8,40]. In contrast to the polymeric ASDs, amorphous CIP salts
containing succinic acid or amino acids as counterions were unstable in humid environments and
crystallized during DVS studies [33].
3.5. Solubility and Dissolution Studies
Due to issues with clumping and viscosity, solubility studies could not be carried out accurately on
the ASDs containing Eudragit L100-55 and Carbopol, and these samples were therefore excluded from
further studies. The superior solubility of the remaining ASDs in FaSSIF in comparison to crystalline
ENRO is clear from Figure 8a. With the pure drug, a peak in concentration was seen at 30–60 s, which
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then quickly fell to a constant level of approximately 0.7 mg/mL. A steep initial increase in drug
concentration was also seen with the ASDs containing HPMCAS-LG and HPMCAS-MG, which peaked
after 5 and 2 min, respectively. While this supersaturation then fell after 10–15 min, the concentration
was still significantly higher than that obtained with crystalline ENRO. This solubility enhancement
was sustained for the remainder of the study, with final concentrations of 12.2 mg/mL and 5.6 mg/mL
being obtained with ENRO/HPMCAS-LG and ENRO/HPMCAS-MG, respectively. In contrast to the
other samples, a more gradual increase in drug concentration was seen with ENRO/Eudragit L100,
followed by a plateau after 20 min. This sample was also less soluble than those containing HPMCAS,
reaching a concentration of 4.6 mg/mL after 2 h.
 
Figure 8. (a) Solubility and (b) dissolution studies in FaSSIF at 37 ◦C. The average of three experiments
is plotted, ± the standard deviation.
The dissolution behavior observed with these ASDs is similar to that described by the “spring” and
“parachute” model [41]. In this model, ASDs are described as “springs”, as their high energy and lack
of a crystal lattice results in rapid drug dissolution and supersaturation. However, this supersaturated
state is thermodynamically unstable, and crystallization of a lower energy, less soluble form of the drug
soon follows. Fortunately, excipients such as polymers may be used to inhibit or delay the precipitation
of dissolved drug and thus act as “parachutes” [41]. Polymers can prevent nucleation and crystal
growth via interactions with the drug, steric hindrance, and increased viscosity [42]. Although the
concentration obtained with the ENRO/HPMCAS ASDs did decrease somewhat over the course of
the study, the polymers present in these ASDs most likely prevented extensive crystallization of the
drug in solution, enabling supersaturation to be maintained for at least 2 h. By avoiding the rapid
generation of supersaturation, less nucleation and crystallization would be expected to occur with the
ENRO/Eudragit L100 ASD. This was confirmed by PXRD analysis of the excess solid recovered at the
end of the solubility studies. In each case, enrofloxacin hexahydrate [2] was detected; however, with
ENRO/Eudragit L100, the sample was far less crystalline (Figure S8).
Similarly enhanced concentrations were obtained with the ENRO ASDs in dissolution studies
in comparison to crystalline ENRO. Following 2 h, the highest concentration was achieved
with ENRO/HPMCAS-LG, at 1.45 ± 0.03 mg/mL (44.8 ± 1.2% of ENRO released), followed by
ENRO/HPMCAS-MG (0.70 ± 0.01 mg/mL, 40.5 ± 0.6% of ENRO released) and ENRO/Eudragit
L100 (0.55 ± 0.02 mg/mL, 57.4 ± 1.8% of ENRO released). Crystalline ENRO, on the other hand,
only attained 0.09 ± 0.00 mg/mL (104.7 ± 4.5% of ENRO released) over the course of the study
(Figure 8b). Apart from concentration, the ASDs also differed in the shape of their dissolution profiles.
With ENRO/HPMCAS-LG, the drug concentration increased quite rapidly at the start of the study
and then remained fairly constant for the remainder. While a similar profile was obtained with
ENRO/HPMCAS-MG, the initial drug release was more gradual than with the LG grade of polymer.
As was the case in the solubility study, the final concentration obtained with ENRO/HPMCAS-MG
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was approximately half that of ENRO/HPMCAS-LG. However, ASDs containing different grades of
HPMCAS are known to demonstrate different rates and extents of drug release, due to differences in
their succinoyl and acetyl content [43]. This may affect the pH of the diffusion layer surrounding the
ASD particles, or the strength of drug–polymer interactions.
A steady, linear increase in drug concentration was observed with ENRO/Eudragit L100. As no
leveling off occurred during the study, it is possible that the drug concentration would continue to
rise during longer-term studies, similar to an extended release formulation. The gradual dissolution
of ENRO from this ASD may be due to strong drug–polymer interactions, which could delay the
dissociation and dissolution of the drug [44]. Such interactions would also explain the higher than
predicted Tg of this formulation and the absence of crystallization during DSC analysis, unlike the
ASDs containing HPMCAS. Alternatively, this polymer may be less soluble than HPMCAS, which
would reduce the diffusion of water into the ASD and, thus, its dissolution rate.
Visible differences in the behavior of the ENRO ASD powders were also evident during dissolution
studies. Both ENRO/Eudragit L100 and ENRO/HPMCAS-MG formed clumps when added to the
dissolution vessels. While these eventually dissolved in the case of ENRO/HPMCAS-MG, with
ENRO/Eudragit L100, they remained largely intact for the duration of the study. This would have
hindered the release of the drug and reduced the surface area exposed to the dissolution medium.
By contrast, no clumping was observed with ENRO/HPMCAS-LG, which enabled faster dissolution
and higher concentrations of ENRO to be achieved.
From the results of this study and that of a previous investigation involving CIP, it can be
concluded that ENRO is the more soluble of the two fluoroquinolones in FaSSIF. CIP was found to
have a solubility of only 0.14 mg/mL in this medium [9], which is five times lower than that of ENRO.
Higher drug concentrations were also obtained with the ENRO ASDs than the equivalent CIP ASDs.
Similarly, ENRO has been reported to be more soluble than CIP in pH 7.4 phosphate buffer [5]. As
previously mentioned, the greater solubility of ENRO may be explained by its weaker crystal lattice,
which would facilitate the release of drug molecules into solution.
3.6. Bacterial Studies
The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)
of ENRO and the ASDs are listed in Table 2. Values that differ significantly from those of ENRO are
shown in bold. In each case, the MBC should be greater than the MIC, as a larger quantity of drug is
required to bring about bacterial death rather than growth inhibition. If the ratio of MBC to MIC is ≤4,
this indicates that a drug is bactericidal [45], which was the case for ENRO and the ASDs in all species
of bacteria in this study. A MIC of ≤0.5 μg/mL may be considered as susceptible to ENRO, while
≥2 μg/mL indicates bacterial resistance, and 1 μg/mL is intermediate [46]. Therefore, from the results
of this study, it can be concluded that E. coli, S. aureus, and K. pneumoniae are susceptible to ENRO,
while P. aeruginosa is not. As was the case with CIP, E. coli was found to be the most susceptible of
these bacteria to ENRO, having a MIC of 0.004–0.0016 μg/mL. Quite low MIC levels were also obtained
in K. pneumoniae (0.032–0.125 μg/mL), followed by S. aureus (MIC 0.125–0.25 μg/mL). By contrast, much
higher MIC and MBC values of 4–8 μg/mL were obtained with P. aeruginosa. However, the outer
membrane of this bacteria is known to be far less permeable than that of E. coli, while fluoroquinolones
are also believed to be substrates for an active efflux system within P. aeruginosa [47]. In each case, the
MIC values obtained for ENRO in these four species agree well with those reported previously [46].
As can be seen from Table 2, the formulation of ENRO as an ASD did not significantly
affect its antibacterial activity in any species of bacteria, while the MIC and MBC obtained with
ENRO/HPMCAS-MG was significantly lower in E. coli and K. pneumoniae than in the pure drug. Similar
results were previously obtained with CIP ASDs, whereby the MIC and MBC of CIP/HPMCAS-MG was
significantly lower than crystalline CIP in all four of these species, while the MIC of CIP/HPMCAS-LG
was also significantly reduced in E. coli, and its MBC was lower in both E. coli and S. aureus. These
ASDs were also found to increase the passive transmembrane permeability of CIP [9]. Therefore, it is
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possible that the formulation of ENRO as an ASD with HPMCAS-MG also improved its permeability,
enabling more of the drug to be transported through the bacterial cell membranes via passive diffusion.
Table 2. Minimum inhibitory concentration and minimum bactericidal concentration of enrofloxacin
and ASDs in various bacteria a.
Sample S. aureus P. aeruginosa E. coli K. pneumoniae
Minimum Inhibitory Concentration (μg/mL)
ENRO 0.25 4 0.016 0.125
ENRO/Eudragit L100 0.125–0.25 4 0.008–0.016 0.063–0.125
ENRO/HPMCAS-LG 0.125–0.25 4–8 0.008–0.016 0.063–0.125
ENRO/HPMCAS-MG 0.125 4 0.004–0.008 0.032–0.063
Minimum Bactericidal Concentration (μg/mL)
ENRO 0.25 4 0.032 0.25
ENRO/Eudragit L100 0.25 8 0.016 0.125
ENRO/HPMCAS-LG 0.125 8 0.016 0.125
ENRO/HPMCAS-MG 0.125 4 0.008 0.063
a The values shown in bold differ significantly from those of pure crystalline ENRO.
4. Conclusions
In this study, ball milling was successfully used to produce several ASDs of ENRO. Despite its
extra ethyl group, ENRO behaved similarly to CIP in terms of polymer compatibility, with each drug
only forming X-ray amorphous ASDs with acidic polymers. The results of FTIR analysis indicate that
the terminal tertiary amine of ENRO is protonated in these ASDs and forms an ionic bond with the
carboxylate groups of the polymers. The high Tgs of the ASDs and their resistance to crystallization
during DSC analysis reinforces the suggestion that strong interactions exist between the components
and formation of amorphous polymeric salts. Although the ASDs were hygroscopic, they remained
X-ray amorphous during water sorption studies due to the stabilizing effects of the polymers. The ASDs
also generated significantly higher drug concentrations than crystalline ENRO during solubility and
dissolution testing, and these levels were sustained for the duration of the studies. As the prolongation
of supersaturation is believed to increase drug absorption, the in vivo absorption of these formulations
is likely to be superior to that of the pure drug. In addition, the antimicrobial activity of ENRO was not
decreased by ASD formation, while it was improved by ENRO/HPMCAS-MG in E. coli and S. aureus.
This study has therefore demonstrated that the formulation of ENRO as a polymeric ASD, or more
accurately, an APS, can improve a number of the drug’s biopharmaceutical properties, making this an
attractive formulation option.
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Abstract: Among the many methods available for solubility enhancement, mesoporous carriers
are generating significant industrial interest. Owing to the spatial confinement of drug molecules
within the mesopore network, low solubility crystalline drugs can be converted into their amorphous
counterparts, which exhibit higher solubility. This work aims to understand the impact of drug
overloading, i.e., above theoretical monolayer surface coverage, within mesoporous silica on the
release behaviour and the thermal properties of loaded drugs. The study also looks at the inclusion of
hypromellose acetate succinate (HPMCAS) to improve amorphisation. Various techniques including
DSC, TGA, SEM, assay and dissolution were employed to investigate critical formulation factors of
drug-loaded mesoporous silica prepared at drug loads of 100–300% of monolayer surface coverage,
i.e., monolayer, double layer and triple layer coverage. A significant improvement in the dissolution of
both Felodipine and Furosemide was obtained (96.4% and 96.2%, respectively). However, incomplete
drug release was also observed at low drug load in both drugs, possibly due to a reversible adsorption
to mesoporous silica. The addition of a polymeric precipitation inhibitor HPMCAS to mesoporous
silica did not promote amorphisation. In fact, a partial coating of HPMCAS was observed on the
exterior surface of mesoporous silica particles, which resulted in slower release for both drugs.
Keywords: mesoporous; poorly soluble drugs; solubility enhancement; solid dispersion;
amorphisation; spray drying
1. Introduction
The most important properties of promising drug candidates for oral dosage form are aqueous
solubility and intestinal permeability. Over 40% of drugs on the market are BCS class II and IV,
which have low solubility. Furthermore, new chemical entities are even less soluble compared to
marketed products with a projection of up to 70–90% of drug candidates in the pipeline suffer from low
solubility [1]. Following oral administration, drugs must dissolve in gastrointestinal fluids in order to
be absorbed into the systemic circulation and exert a therapeutic action. The formulation development
of low solubility drugs (BCS class II and IV) faces a great challenge as these drugs are poorly absorbed
and usually exhibit subsequent low or variable oral bioavailability [2].
The problem of low solubility can be addressed by using solubilisation techniques, namely solid
dispersion systems, size reduction, salt formation, prodrug, liposomes, etc. Among those techniques,
solid dispersions are preferred by the industry due to their practicality and low cost. This technique
is mainly based on a so-called “amorphisation”, whereby the crystalline drugs are converted into
their high energy amorphous form, which exhibits a superior solubility in comparison with that of the
original ones [3]. Mesoporous materials, e.g., mesoporous silica, a subclass of solid dispersion systems,
are considered highly effective for drug amorphisation due to their ability to achieve the spatial
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confinement of drug molecules within their nanometre-scale pore structure [4]. Shen et al. [5] suggested
that drugs would exist in an amorphous state within the mesoporous silica if the pore size were smaller
than 12 times the drug’s molecular size. Mesoporous carriers also offer formulation flexibility due to
tunable pore size and surface area [6]. Furthermore, this approach has shown applicability for both
existing poorly soluble drugs and drug candidates in the pipeline with various chemical structures.
Utilising mesoporous silica to enhance the bioavailability of poorly soluble drugs has been successfully
demonstrated in various clinical studies conducted on rabbits, dogs, and mice [7].
For loading a drug into mesoporous silica, there are several techniques, which can be categorised
into two main approaches: solvent-free methods and solvent-based methods. Solvent-free methods are
comprised of physical mixing followed by heating to melt the drug, co-milling between the drug and
mesoporous materials, and using supercritical carbon dioxide. Although solvent-free loading methods
offer apparent advantages, e.g., no requirement for checking the residual solvent in drug products and
low environmental impact, these methods are still under investigation to exhibit better performance in
terms of the loading efficiency and stability of thermolabile drugs. On the other hand, solvent-based
approaches offer a practical and straightforward solution for drug amorphisation within mesoporous
silica. Simply put, a drug is dissolved in a suitable solvent, e.g., ethanol, then mixed/impregnated
with mesoporous silica. The solvent can be removed by appropriate drying techniques at the end
of the process. There are various factors that influence drug loading into mesoporous silica, such
as the type of solvent, drug load, accessible surface area, and the pore volume of the mesoporous
silica. In general, solvent-based loading techniques, especially spray drying, produce drug-loaded
mesoporous silica with a high loading efficiency compared to solvent-free techniques [6]. However,
higher drug loadings above 30% (w/w) could lead to incomplete amorphisation, i.e., a small amount of
crystalline drug will remain on the exterior surface of the generated particles [5]. Drug molecules can
theoretically adsorb onto the silica surface of mesopores as a monolayer or multilayers, depending on
the drug’s molecular dimension, accessible surface area, and pore size [8]. Dening and Taylor [9] studied
ritonavir–loaded–mesoporous silica at various drug loads of a 25–150% monolayer surface coverage
and found that drug release decreased significantly as the drug load increased. Therefore, it would be
prudent to systematically investigate the impact of drug loading beyond monolayer surface coverage
(overloading) on the thermal behaviour of drug within mesoporous silica. Furthermore, the addition
of a precipitation inhibitor to the mesoporous silica has been previously investigated to overcome this
recrystallisation challenge. Lainé et al. [10] found that hypromellose acetate succinate (HPMCAS),
when combined with mesoporous silica, promoted a complete amorphisation of Celecoxib. However,
the advantage of such ternary system combining mesoporous silica with drug and precipitation
inhibitors still requires further study, to confirm whether poorly soluble drugs with different chemical
natures and crystallisation tendencies can benefit from it.
Felodipine and Furosemide are BCS class II and class IV drugs, respectively. Felodipine is mainly
absorbed in the small intestine [11], i.e., and alkaline pH environment, while the stomach is the favoured
absorption site for Furosemide [12], i.e., acidic pH environment. Hence, Felodipine and Furosemide
were selected as model drugs in this study to represent two scenarios after oral administration in drug
release from mesoporous silica. The aim of this study was to investigate the impact of drug overloading
within mesoporous silica at 100–300% of the theoretical monolayer’s surface coverage on the release
behaviour and thermal properties of loaded drugs. This included investigating the release profiles
of the model drugs after loading within mesoporous silica alone and in combination with HPMCAS.
Thermal profiles and particle morphology were also studied to confirm the amorphous/crystalline
nature of the drug within the carrier system and the presence or lack of surface crystals. These studies
will help elucidate the link between theoretical drug load and important formulation properties, such as
loading efficiency, release behaviour, and the nature of the drug within mesoporous carriers.
150
Pharmaceutics 2019, 11, 269
2. Materials and Methods
2.1. Materials
Felodipine (FELO) and Furosemide (FURO) were obtained from Discovery Fine Chemicals
(Dorset, UK) and Chemical Point (Surrey, UK), respectively. Mesoporous silica Syloid® XDP 3050
(specific surface area of 310 m2/g, average pore size of 22.4 nm, pore volume of 1.74 cm3/g) was kindly
provided by W.R. Grace and Co. (Worms, Germany). Aqoat® (HPMCAS) was a generous gift from
Harke Pharma (Muelheim an der Ruhr, Germany). Sodium phosphate monobasic, sodium phosphate
dibasic, sodium chloride, and sodium lauryl sulfate (SLS) were purchased from Sigma-Aldrich
(Dorset, UK). Hydrochloric acid 37%, acetone and ethanol were purchased from Fisher Scientific
(Loughborough, UK). Deionised water was produced by Milli-Q Integral system (Hertfordshire, UK).
2.2. Methods
2.2.1. Preparation of Drug-Loaded Mesoporous Silica Particles
Theoretical drug load was calculated based on an assumption that drug molecules would adsorb
to the surface area of mesoporous silica particles in a packing geometry that increases the bonding
between drug molecules and silica surface, i.e., to maximise the contact surface [9]. The following
equation described by Dening and Taylor [9] was used to calculate the drug load (%, wdrug/wSyloid) to
theoretically obtain monolayer adsorption (equivalent to 100% surface coverage) in mesoporous silica:








SAM ×NA . (1)
SSA: Specific surface area of mesoporous silica (m2/g), e.g., 310 m2/g for Syloid XDP 3050 (in-house
data measured by gas adsorption porosimetry).
Mw: Molecular weight of model drug (g/mol).
SAM: Maximum projected contact surface area of single molecule (Å2): calculated using the two
largest molecular dimensions of drug molecule (Figure 1).
 
Figure 1. Molecular structures [13,14] and estimated molecular dimensions of Felodipine and
Furosemide generated from the Cambridge Crystallographic Data Centre.
NA: Avogadro’s number (6.022 × 1023).
Syloid was added to either FELO or FURO in ethanol (10 mg/mL) to form suspensions at
various theoretical drug loads (%, w/w): 10.8, 21.6, and 32.4% for FURO; 12.6, 25.2, and 37.8%
for FELO to represent monolayer adsorption (100% surface coverage), double layer adsorption
(200% surface coverage), and triple layer adsorption (300% surface coverage), respectively. The
ternary Drug–Syloid–HPMCAS formulations were prepared in a similar fashion with the ratio of
drug to HPMCAS at 10:1. Syloid was added to solutions of HPMCAS and either FELO or FURO in
ethanol-acetone 50:50 (10 mg/mL). All of the suspensions were gently stirred for 12 h, then spray-dried
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at inlet temperature of 100 ◦C using a mini spray dryer Buchi B-290 and inert loop Buchi B-295
(Flawil, Switzerland) in closed mode with a nitrogen flow rate of 600 L/min, with a feed rate of
5 mL/min and a drying gas flow rate of 30 m3/h. Spray-dried FELO or FURO (prepared in the same
procedure without the incorporation of either Syloid or HPMCAS), physical mixtures between Syloid
and either FELO, or FURO with a ratio of 1:1 were used as control samples.
2.2.2. Drug Loading Quantification
Drug loading within mesoporous silica samples was determined according to a TGA-based
method described elsewhere [15–17]. Approximately 10 mg of drug–loaded mesoporous silica
samples were placed into a platinum pan, then transferred to TGA instrument Perkin-Elmer Pyris
1 (Buckinghamshire, UK). The sample was treated with following temperature programme under a
nitrogen flow of 20 mL/min: (1) heated from 50 to 120 ◦C and held for 5 min at 120 ◦C; (2) heated
from 120 to 800 ◦C at a heating rate of 20 ◦C/min; and (3) held for 30 min at 800 ◦C. The drug load of
FURO or FELO inside mesoporous silica was determined by the difference in weight loss between
samples and blanks at a temperature range of 200–800 ◦C, whereby FELO or FURO were incinerated.
The drug load was normalised to the surface area of the mesoporous silica to facilitate the comparison
between studies using various types of mesoporous silica. Normalised surface area-based drug load
and loading efficiency was calculated based on the two following equations.






Specific surface area of mesoporou silica
(2)




2.2.3. In Vitro Drug Release Studies
Dissolution testing was performed by using a USP I apparatus (rotating basket, 50 rpm) in
an Erweka DT 126 dissolution tester (Heusenstamm, Germany). Each sample containing 20 mg
of FELO was filled into a HPMC hard-shell capsule and tested in 500 mL of pH 6.5 medium with
0.25% SLS at 37 ◦C (adapted from USP 36 monograph with a reduction of SLS concentration from
1.0 to 0.25%). Samples were withdrawn during a 120 min period at the following timepoints: 15,
30, 60, 90, and 120 min. The concentrations of dissolved FELO were determined according to a
HPLC method described in United States Pharmacopoeia [18] with mobile phase of pH 3 phosphate
buffer:acetonitrile:methanol (30:45:25), column C18 (15 cm × 4.6 mm, 5 μm), flow rate of 1 mL/min,
injection volume of 40 μL, and UV detector at 362 nm in an Agilent 1200 HPLC system (Santa Clara,
CA, USA).
For FURO, samples containing 40 mg was filled into a HPMC hard-shell capsule and tested in
900 mL of a pH 3.0 medium with 0.25% SLS at 37 ◦C. The medium was prepared by dissolving 2 g of
sodium chloride and 2.5 g of SLS in 400 mL of deionised water, then adding 0.1 mL of hydrochloric
acid 37% and diluting with deionised water to 1000.0 mL [17]. The concentrations of dissolved FURO
were determined using a HPLC method described elsewhere [19] with mobile phase of a phosphate
buffer of pH 3: acetonitrile 60:40, C18 column, column temperature: 35 ◦C, flow rate of 1 mL/min,
injection volume of 10 μL, and UV detection at 234 nm.
2.2.4. Differential Scanning Calorimetry (DSC)
The thermal properties of samples were characterised by DSC instrument TA Q200 (New Castle,
DE, USA). Each sample was accurately weighed (equivalently to 1 mg of FELO or FURO) into Tzero
low-mass aluminium pan (sensitivity for a minimum sample size of 0.5 mg), and heated in the range of
50–250 ◦C (for FELO) or 100–300 ◦C (for FURO) at a scanning rate of 10 ◦C/min under nitrogen airflow
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of 50 mL/min. TA universal analysis 2000 software (version 4.5) was employed to analyse the resulting
DSC thermograms.
2.2.5. Scanning Electron Microscopy (SEM)
The surface of the drug-loaded mesoporous silica particles was examined by a Philips XL30 ESEM
FEG (Hillsboro, OR, USA) operating at 10 kV under a high vacuum. Prior to SEM imaging, samples
were coated with gold by a sputter coater. Approximately 1 mg of each sample was placed onto a
double-sided adhesive strip on a sample holder. SEM images were taken at 2000×magnification.
2.2.6. Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 7.03 software. Statistically significant
difference was considered at a p value < 0.05. All results are presented as mean ± standard deviation
where applicable.
3. Results and Discussion
3.1. Thermal Profiles and Morphology of Drug-Loaded Mesoporous Silica
DSC analysis of Felodipine and Furosemide samples were presented in Figures 2 and 3. Results
revealed that Felodipine was completely converted to amorphous form inside mesoporous silica at all
drug loads. This can be confirmed through the lack of melting peak of crystalline Felodipine (146.0 ◦C)
in DSC thermograms of any Felodipine-Syloid formulations. In contrast, raw material and spray
dried Felodipine (without mesoporous silica), exhibited sharp endothermic peaks at 146.0 ± 0.6 ◦C,
144.3 ± 1.8 ◦C, respectively, confirming their crystalline state [20], as can be seen in Figure 4b. The DSC
data also indicated there was no interaction between Felodipine and Syloid in their physical mixture
as there was no change in temperature (146.0 ± 0.5 ◦C) and the shape of the Felodipine melting peak.
 
Figure 2. Differential Scanning Calorimetry (DSC) thermograms of Felodipine raw and spray-dried
materials, Felodipine (FELO)-Syloid formulations at various drug loads, FELO-Syloid physical mixture.
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Figure 3. DSC thermograms of Furosemide raw and spray-dried materials, Furosemide (FURO)-Syloid
formulations at various drug loads, FURO-Syloid physical mixture.
Sharp endothermic peaks at 222.8 ± 0.8 ◦C and 223.9 ± 0.3 ◦C were observed in DSC curves
of Furosemide raw material and FURO-Syloid physical mixture respectively (Figure 3), which is in
agreement with the crystalline Furosemide in previous study [21,22]. This was further verified by SEM
image (Figure 4e). The DSC data of physical mixtures between Syloid and Furosemide or Felodipine
suggested that the drug still remains crystalline if deposited externally onto mesoporous silica particles,
i.e., the physical mixture had no effect on amorphisation. Spray-dried Furosemide exists in crystalline
form after the spray drying process, as confirmed through endothermic peak at 218.9 ± 0.7 ◦C. DSC
analysis also revealed that Furosemide loaded within Syloid was completely amorphised at drug
loads of 100% and 200% surface coverage as no endothermic peak was detected. However, at 300%
coverage a broad endothermic peak was detected at a temperature of 198.7 ± 4.3 ◦C, indicating a small
amount of crystalline Furosemide. In addition, this endothermic peak is shifted slightly to a lower
temperature (198.7 ◦C) compared to that of raw material (222.8 ◦C), possibly due to the presence of
nanocrystals. This result is consistent with a previous observation of Ibuprofen-loaded mesoporous
silica [15], whereby researchers suggested that a nanocrystal form would cause a melting point shift.
The formation of Furosemide nanocrystals at the highest drug load of 300% surface coverage can be
observed in SEM image (Figure 4f). After drug loading, the surface of silica becomes rough as can
be seen in FELO-Syloid (Figure 4c), particularly in FURO-Syloid with many surface crystallites in
comparison with original surface of mesoporous silica, which is relatively smoother (Figure 4a).
TGA results (Figure 5) were used to determine the drug load and loading efficiency and complement
the thermal events observed in the DSC data. TGA curves of the original Syloid as well as the
drug-loaded Syloid revealed a small weight loss at 130.9 ± 0.6 ◦C, which can be attributed to
bound water loss. There was no further significant weight loss in the original Syloid from 200 to
800 ◦C. TGA weight% versus temperature and 1st derivative curves of Felodipine-Syloid showed a
substantial weight loss caused by the drug decomposition in the range 200–800 ◦C. Felodipine has
one-step decomposition starting from 277.7 ± 0.8 ◦C and reach the maximum decomposition rate at
338.3 ± 5.7 ◦C, while Furosemide has a multi-step decomposition, which takes place between 200 and
800 ◦C with an onset temperature of 227.5 ± 3.4 ◦C. Thermal decomposition of both Felodipine and
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Furosemide are similar to the reported studies [22,23]. There was no notable difference in the shape of
the TGA curves, as well as 1st derivative of the weight between the drug-loaded Syloid and ternary
systems. This may have been caused by an overlap between the decomposition of drugs and that of
the HPMCAS which happens in the range of 270 to 300 ◦C.
  
         
         








Figure 4. Particle surfaces of (a) mesoporous silica Syloid, (b) Felodipine raw material,
(c) FELO-Syloid, (d) FELO-Syloid-hypromellose acetate succinate (HPMCAS), (e) Furosemide raw
material, (f) FURO-Syloid, and (g) FURO-Syloid-HPMCAS. SEM images were taken for samples at a
drug load of 300% surface coverage.
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Figure 5. TGA weight% versus temperature and derivative weight% curves of Syloid, Felodipine-Syloid,
Furosemide-Syloid, Felodipine-Syloid-HPMCAS, and Furosemide-Syloid-HPMCAS at a drug load
of 300% surface coverage. Temperature programme under a nitrogen flow of 20 mL/min: (1) heat
from 50 ◦C to 120 ◦C and held for 5 min at 120 ◦C; (2) heat from 120 ◦C to 800 ◦C at a heating rate of
20 ◦C/min; (3) held for 30 min at 800 ◦C.
Actual drug loads and loading efficiencies of Felodipine and Furosemide in mesoporous silica are
presented in Table 1. As expected, the actual drug load increased as the theoretical surface coverage
increased. Loading into mesoporous silica could be explained by physical adsorption, which depends
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on the extent of the available surface area of adsorbent and the amount of adsorbate. The loading
process carried out at a low drug load, i.e., a 100% surface coverage, resulted in maximum loading
efficiency (99.2% for Furosemide and 101.9% for Felodipine) and complete amorphisation. However,
at higher drug load at 300% surface coverage, the free surface area of the adsorbent (mesoporous silica)
became lower as more drug was added, leading to a lower loading efficiency of 57.4% and 73.8% for
Furosemide and Felodipine, respectively.
Table 1. Drug loads and loading efficiency of Felodipine and Furosemide in mesoporous silica Syloid






























100% 12.6 12.5 ± 0.3 0.403 ± 0.010 99.2 ± 2.4 10.8 11.0 ± 0.9 0.355 ± 0.029 101.9 ± 8.3
200% 25.2 15.6 ± 0.2 0.503 ± 0.006 61.9 ± 0.8 21.6 16.6 ± 0.3 0.535 ± 0.010 * 76.9 ± 1.4
300% 37.8 21.6 ± 0.3 0.697 ± 0.010 * 57.4 ± 0.8 32.4 23.9 ± 0.5 0.771 ± 0.016 73.8 ± 1.5
(*): Drug load at which a complete amorphisation was successfully obtained.
Previously, Ambrogi et al. [17] studied Furosemide-loaded mesoporous silica prepared by rotary
evaporation and were able to attain an amorphous state Furosemide with SBA-15 silica at a drug content
of up to 30.0% ± 0.2% (0.3 g of Furosemide per 0.7 g of SBA-15 mesoporous silica). Furosemide-Syloid
in our study exhibited complete amorphisation with a drug load of up to 16.6 ± 0.3%, i.e., 0.166 g
of Furosemide per 1 g of Syloid. However, it should be noted that the SBA-15 silica used by
Ambrogi et al. [17] had a surface area which was 2.5 times larger than that of Syloid (791 m2/g vs.
310 m2/g, respectively). Hence, despite the apparent difference in weight-per-weight drug load,
after normalisation based on surface area, there is no difference in weight-per-surface area drug load
between the two studies (0.542 ± 0.004 × 10−3 g/m2 in comparison with 0.535 ± 0.010 × 10−3 g/m2).
For Felodipine-loaded mesoporous silica, there were two previous studies using solvent
impregnation methods, in which silica had a specific surface area of 584 m2/g and 1051 m2/g with a drug
load of 25% [24] and 18.3% [25], respectively. The amorphous Felodipine inside Syloid was obtained at a
drug load of 21.7%. Similar to Furosemide, the weight-per-weight drug load of Felodipine-mesoporous
silica was converted to weight-per-surface area to enable a like-for-like comparison between different
studies. The Felodipine-Syloid in our study produced a higher weight-per-surface area drug load
in comparison with those of the other two studies (0.697 × 10−3 compared to 0.428 × 10−3 g/m2 and
0.174 × 10−3/m2).
In general, the drug loading process for mesoporous particles is usually established on a
case-by-case basis due to the differences in loading solvent, solubility, targeted drug load, surface area,
pore size, and pore volume of the mesoporous materials being used. The use of co-spray drying in the
current study as a solvent-based technique produced comparable or slightly higher drug loads to those
reported in the literature using traditional solvent-evaporation. However, the real added advantage of
using co-spray drying lies in the better drug loading efficiency and shorter processing time. During
spray drying, there is a possibility that solute/drug diffusion towards the particle centre might facilitate
drug entrapment inside the pores. The findings of higher drug loading efficiency via spray drying are
also in agreement with previous studies [26,27].
3.2. In Vitro Drug Release from Mesoporous Silica
Results showed that after 30 min the dissolution of all Felodipine-Syloid or Furosemide-Syloid
samples were much higher than that of the physical mixtures, both raw and spray-dried materials
(p < 0.05). Felodipine exhibited a low dissolution within 60 min with only 9.8%, 11.4%, and 15.5%
dissolution for the physical mixture, raw materials, and spray-dried materials, respectively, compared
to over 70% dissolution in any Felodipine-Syloid samples (Figure 6). Similarly, within the first 60 min,
the percentage of Furosemide released from mesoporous silica at 100%, 200%, and 300% of theoretical
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surface coverage reached 69.7%, 83.4%, and 86.5%, respectively while the physical mixture, the raw
























Figure 6. Release profiles of Felodipine raw and spray-dried materials, Felodipine-Syloid formulations
at various drug loads, Felodipine-Syloid physical mixture. Testing conditions: phosphate buffer
pH 6.5 + 0.25% SLS, 500 mL, USP apparatus 1, 50 rpm. The medium was adapted from a USP 36























Figure 7. Release profiles of Furosemide raw and spray-dried materials, Furosemide-Syloid
formulations at various drug loads, Furosemide-Syloid physical mixture. Testing conditions: HCL-NaCl
medium pH 3 + 0.25% sodium lauryl sulfate (SLS), 900 mL, USP apparatus 1, 100 rpm. Medium
was adapted from a study carried out by Ambrogi et al. [17] with the addition of SLS to maintain
sink condition.
Although mesoporous silica is capable of enhancing the dissolution of Felodipine and Furosemide,
a reversible adsorption between drug molecules and silica surface might happen. This result is in
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agreement with a previous study by Dening and Taylor [9], which investigated the release of ritonavir
from mesoporous silica. The authors also found that drug release of ritonavir-loaded-mesoporous silica
was incomplete. They suggested that there is a dynamic adsorption equilibrium between the drug
adsorbed to mesoporous silica and the free drug dissolved in a dissolution medium. This dynamic
equilibrium caused an incomplete drug release in dissolution testing, especially at a low drug load
of 100% surface coverage (72.0% and 73.5% dissolution after 2 h for Felodipine and Furosemide,
respectively). At this point, drug release from the drug-mesoporous silica samples reached a plateau,
indicating that an adsorption equilibrium had been formed. However, as can be seen in our study,
this dynamic equilibrium can be shifted in favour of more drug release via increasing the degree of
drug load, i.e., silica surface coverage, possibly because the amount of drug adsorbed to the silica
particles is negligible to that of the dissolved drug. Generally, the dissolution increased for both drugs,
as the percentage of silica surface coverage increased. This is expected, as the higher amount of drug
loaded inside the mesoporous silica released more drugs to the dissolution medium before reaching an
adsorption equilibrium.
3.3. Influence of the Addition of HPMCAS to Mesoporous Silica on Drug Loading and Dissolution
In an attempt to increase loading efficiency and overcome the incomplete amorphisation at the
highest drug load of 300% (in Section 3.1), HPMCAS was added to the drug-mesoporous silica to
create a ternary system. The addition of HPMCAS to the Syloid resulted in increasing the Felodipine
loading efficiency compared to that of the Syloid alone (p < 0.05). A weak basic drug Felodipine in a
loading solution can partially dissociate to form a negatively charged anion, which might be converted
into a conjugation with an acidic polymer HPMCAS. Such a conjugation between Felodipine and
HPCMAS could enhance the loading efficiency as there could be an extra amount of Felodipine staying
within the polymer matrix. However, there were no significant improvements in loading efficiency
for Furosemide with the presence of HPMCAS (p > 0.05). This result could be explained because
Furosemide is an acidic drug, and, therefore, no conjugation was formed between Furosemide and
HPMCAS in comparison to the synergistic effect in drug loading between Felodipine and HPMCAS
(Table 2).
Table 2. Drug load and loading efficiency of Felodipine and Furosimide in mesoporous silica Syloid
























100% 12.6 13.1 ± 0.2 104.0 ± 1.6 10.8 10.7 ± 0.6 99.1 ± 5.5
200% 25.2 20.3 ± 0.5 80.6 ± 1.9 21.6 14.7 ± 1.3 68.1 ± 6.0
300% 37.8 30.3 ± 0.2 80.2 ± 0.5 32.4 23.8 ± 0.6 73.5 ± 1.9
DSC results suggested that the addition of HPMCAS to the mesoporous silica did not result in the
promotion of drug amorphisation. A small endothermic peak at 139.9 ± 0.2 ◦C was detected in the
DSC thermogram of ternary Felodipine-Syloid-HPMCAS, at a drug load of 300% surface coverage
(Figure 8). This indicated a small amount of crystalline Felodipine in the ternary system, although
Felodipine-Syloid stayed amorphous in the absence of HPMCAS. The negative impact on amorphisation
was clearly evidenced by the DSC data of the ternary Furosemide-Syloid-HPMCAS. Furosemide-Syloid
at drug load of 100% or 200% surface coverage existed in an amorphous state (Section 3.1). Contrastingly,
ternary Furosemide-Syloid-HPMCAS exhibited an incomplete amorphisation at all drug loads which
was confirmed by broad endothermic peaks (Figure 9).
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Figure 8. DSC thermograms of raw Felodipine material and FELO-Syloid-HPMCAS at various drug
loads. Scanning rate: 10 ◦C/min. Scanning range: 50–250 ◦C.
 
Figure 9. DSC thermograms of the raw Furosemide material and FURO-Syloid-HPMCAS at various
drug loads. Scanning rate: 10 ◦C/min. Scanning range: 100–300 ◦C.
SEM images showed, to a certain extent, that HPMCAS might work as a coating polymer outside
silica particles. In fact, a partial coating effect of HPMCAS as new surface ruggedness or layers could
be seen in both Felodipine-Syloid-HPMCAS (Figure 4d) or Furosemide-Syloid-HPMCAS (Figure 4g),
compared to the original surface of Syloid, which was relatively smoother (Figure 4a). The partial
coating effect of HPMCAS was more apparent on the Furosemide-Syloid samples. There was a
great number of Furosemide crystals on the external surface of the Furosemide-Syloid particles
(Figure 4c), which was verified with the DSC result. Ternary Furosemide-Syloid-HPMCAS also
contained crystalline Furosemide, as confirmed by DSC (Figure 9). However, there was no notable
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difference in the particle surface between Furosemide-Syloid and ternary Furosemide-Syloid-HPMCAS.
Owing to the addition of HPMCAS, no surface crystals could be observed on the exterior of silica
particles, possibly due to the layers of HPMCAS covering them (Figure 4g). SEM images, together with
DSC data, suggested that HPMCAS might hinder the migration of drug molecules into the internal
mesopores due to their coating effect, leading to more drug staying externally in silica particles.
The inclusion of HPMCAS with Syloid did not help in enhancing the release rate or overall
dissolution of Felodipine (Figure 10). In fact, the dissolution of Felodipine-Syloid-HPMCAS was
significantly lower than that of Felodipine-Syloid within the first 90 min (p < 0.05). This polymer is
only soluble at pH 5.5 or above, hence the partial coating of HPMCAS on the mesoporous silica was
not dissolved at pH 3 acidic environment (optimal pH for Furosemide absorption) and resulted in an




















Figure 10. Release profiles of the raw Felodipine material, Felodipine-Syloid, and Felodipine-
Syloid-HPMCAS at drug load of 300% monolayer coverage. Testing conditions: phosphate buffer




















Figure 11. Release profiles of Furosemide raw material, Furosemide-Syloid, Furosemide-
Syloid-HPMCAS at drug load of 300% surface coverage. Testing conditions: medium pH 3 + 0.25% SLS,
900 mL, USP apparatus 1, 100 rpm.
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Furosemide-Syloid-HPMCAS still obtained 29% dissolution after 120 min as the drug was possibly
released from silica particles through incomplete coating layers. A previous study [10] showed a
more significant effect of HPMCAS on the dissolution of the poorly soluble drug celecoxib when
loaded into the mesoporous silica Parteck (approximately a 5-fold solubility increase). The difference
in the observation could be due to the different conditions, e.g., the dissolution medium of Tris
buffered water pH 7.4 and a fasted state simulated intestinal fluid with pH 7.0 and the model drug
Celecoxib used in their study. It is noticeable that the ratio of HPMCAS to Parteck silica was calculated
as 14.7%, which was much higher than the 6.1% ratio of HPMCAS to Syloid silica in our study
(calculated for Felodipine-Syloid-HPMCAS at a drug load of 300% surface coverage). Generally,
a higher HPMCAS-to-silica particle ratio led to a thicker coating layer, if formed, and produced a more
pronounced gastro-resistant effect, which could result in a delayed release effect in oral administration.
4. Conclusions
Syloid enhanced the dissolution of both model poorly soluble drugs, Felodipine and Furosemide,
due to amorphisation within its mesoporous network. Increasing the drug load or percentage of
theoretical surface coverage increased the maximum attained dissolution. However, overloading could
lead to the formation of surface nanocrystals, as observed in the thermal and morphological studies.
Incomplete drug release happened at all drug loads, which could be due to the reversible adsorption
phenomenon mentioned in previous reports. This was predominant at the lower drug loads as less
drug is available to dissolve before reaching an adsorption equilibrium. In addition, overloading
resulted in a decrease of loading efficiency for both tested model drugs. A new drug load based on
the drug amount to specific surface area of materials could be used in order to enable the comparison
between various types of mesoporous materials. The addition of HPMCAS at a low concentration
prevented the complete amorphisation of the drugs. Furthermore, it also slowed down the drug release
due to partial coating, which formed on the exterior surface of mesoporous silica particles. In the
future, this concept of combining mesoporous silica and polymers in hybrid structures will be further
investigated for potential application in sustained release drug delivery systems.
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Abstract: The aims of this study were to investigate how the release of tadalafil is influenced by two
grades of polyvinylpyrrolidone (Kollidon® 12 PF and Kollidon® VA 64) and various methods of
preparing solid dispersions (solvent evaporation, spray drying and hot-melt extrusion). Tadalafil
is poorly water-soluble and its high melting point makes it very sensitive to the solid dispersion
preparation method. Therefore, the objectives were to make a comparative evaluation among different
solid dispersions and to assess the effect of the physicochemical nature of solid dispersions on the
drug release profile with respect to the erosion-diffusion mechanism. The solid dispersions were
evaluated for dissolution profiles, XRD, SEM, FT-IR, DSC, and solubility or stability studies. It was
found that tadalafil release was influenced by polymer molecular weight. Therefore, solid dispersions
containing Kollidon® 12 PF showed a faster dissolution rate compared to Kollidon® VA 64. Tadalafil
was released from solid dispersions containing Kollidon® 12 PF because of the combination of erosion
and diffusion mechanisms. The diffusion mechanisms were predominant in the initial phase of the
experiment and the slow erosion was dissolution-controlling at the second stage of the dissolution.
On the contrary, the tadalafil release rate from solid dispersions containing Kollidon® VA 64 was
controlled solely by the erosion mechanism.
Keywords: solid dispersion; tadalafil; Wood’s apparatus; intrinsic dissolution rate; Weibull dissolution
model; dissolution rate
1. Introduction
Poorly water-soluble drugs showing pharmacological activity are a common and ongoing issue
for the pharmaceutical industry and associated with the complexity of the drug development [1–3].
It has been reported that approximately 40% of marketed drugs and 75% of active pharmaceutical
ingredients under development are classified as practically insoluble in water [3].
Solid dispersions of such drugs in hydrophilic carriers have provided a promising possibility
of improving their dissolution rate, and thereby absorption [4]. Basically, the solid dispersions are
two-component systems which can improve drug wettability and bioavailability significantly by
reducing the effective drug particle size to the absolute minimum, increasing the drug surface area,
reducing its crystallinity, and increasing wettability by surrounding hydrophilic carriers due to their
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unique morphology [5–8]. They are very attractive for formulators due to well-known preparation
processes and devices, high effectiveness, flexibility in designing the composition, or low batch-to-batch
variability [6,9]. However, the ideal state of molecular dispersion may not be always achieved, and
the solid dispersions may only approach the molecular level of an ideal solid solution. That is the
case especially in formulations where the melting point of the drug exceeds the maximum processing
temperature of the polymer, so that the dispersion is formed effectively by dissolving the drug in
molten polymer or by introducing additional solvent, rather than by co-melting of the drug-polymer
mixture. In such systems, the preparation method is likely to have strong impact on the apparent
solubility and drug release. While different preparation techniques were reported in the literature for
many systems, the link between the preparation method and the dissolution properties has not been
clearly established, and therefore it requires further study [5].
The objective of this study was to investigate and to provide insights into how the drug release is
influenced by various polymer carriers and methods of preparation. Tadalafil (TAD) solid dispersions
formulated with two grades of polyvinylpyrrolidone (Kollidon® 12 PF and Kollidon® VA 64) were
used as model system for this study. TAD was selected as a poorly soluble, hydrophobic drug, with a
melting point around 300 ◦C, which is well above the processing temperature of common polymers
used for the solid dispersion formulations. Therefore, it provides a very sensitive system for studying
the effects of preparation methods on the dispersion properties and the subsequent dissolution behavior.
At the same time, it represents a compound which was the subject of many formulation studies recently
(see next section for the details) and thus this choice is relevant from the application point of view.
The polymers were selected due to their widespread use in solid dispersion formulations. They are
hydrophilic in nature, which have potential to change the crystalline drug to amorphous by solid
dispersion technique, enhancing TAD wettability.
The specific goals to disclose within this paper include the comprehensive analysis of TAD solid
dispersions, analysis of the dissolution profiles of different TAD formulations with respect to the
erosion-diffusion mechanism, and a comparison of the dissolution behavior of TAD from physical
mixtures and corresponding solid dispersions, as studied by different dissolution techniques like
apparent intrinsic dissolution and flow-through cell apparatus. Those results are then linked to the
preparation methods of solvent evaporation, spray drying, and hot-melt extrusion.
1.1. Theoretical Background
This section provides detailed background information summarizing the reported techniques
used for improving the dissolution properties of TAD and dissolution phenomena in polymer matrix
systems, which were separated from the general introduction for the sake of clarity, but which can help
in understanding the methods and the discussed results, and provide necessary reference for state of
the art.
1.1.1. Techniques for Improving Dissolution Rate of TAD
Based upon aqueous solubility and dissolution parameters, the efficacy TAD used for the treatment
of erectile dysfunction, pulmonary arterial hypertension, and now also for therapy in pyelonephritis
can be limited by its highly hydrophobic particles [10,11]. The dissolution is considered as the
first step in the absorption process and therefore, a critical disadvantage of TAD is its poor water
solubility [12,13]. Since the pKa value of TAD is 16.68, it is a non-ionizable drug via the range of
physiological pH. Therefore, neither ionization nor salt formation can be applied for the enhancement
of its aqueous solubility and dissolution rate and thus, it was undertaken to develop effective methods
for improvement of these properties [5,14]. The transformation of pure crystalline TAD into the
amorphous form is considered to be troublesome [15]. Wlodarski et al. obtained the amorphous
forms of TAD by amorphization methods and without excipients, i.e., by cryogenic grinding, ball
milling, spray drying, freeze-drying and antisolvent precipitation. On the other hand, they also reveal
that vitrification was an inappropriate method to convert to amorphous counterpart of crystalline
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TAD because of its decomposition at the melting point temperature. Their study also revealed that
the techniques influence the apparent water TAD solubility insubstantially; however, disk intrinsic
dissolution rate tests of amorphous TAD obtained by ball milling and spray drying did not improve
in the rate of its dissolution [16]. Therefore, several technologies have been used to enhance the
dissolution rate and solubility of TAD, including solid dispersion systems, e.g., in [3,6,17–20], the
formulation of self-microemulsifying composition (SMEC) [11], self-nanoemulsifying drug delivery
system (SNEDDS) [21], nanostructured lipid carriers (NLCs) [22], nanoparticles [13,23], cyclodextrin
complexation [24], incorporation in microporous silica [25] or microemulsion system [17]. Of these
formulations, however, solid dispersion is currently favored in the pharmaceutical industry [19].
Solid dispersion of TAD has been prepared using different methods, these include solvent
evaporation method [8,10,12,18,19], spray drying [6,16,26], melting method [5,17], hot-melt
extrusion [15], supercritical anti-solvent process [14,27], ball milling [26–28] or freeze-drying [3].
1.1.2. Dissolution Phenomena in Polymer Matrix Systems
The polymeric matrix systems, such as hydrogel-based dosage forms, are commonly used for
manufacturing sustained release drug delivery systems [29,30]. Solid dispersions can also be used for
controlling drug release [31]. However, the drug release from such systems involves many phenomena
which can contribute to the final progress of dissolution and therefore, the complete description is very
complex and not completely understood [32–34]. The critical factors in the release of drugs from matrix
system are clearly summarized and reported in [35]. Briefly, when the solid dosage forms, based on
a hydrophilic polymer matrix, are immersed in a dissolution medium, the surface of the matrix is
wetted, the water penetrates into the systems and polymer surface swells to form a gel leading to the
polymer chain relaxation, drug dissolution, drug diffusion through the hydrated polymeric network,
chain disentanglement of polymer, matrix erosion and moving boundaries [36,37]. Since the polymer
undergoes a relaxation leading to its erosion, the diffusion is generally not the main mechanisms that
control the drug release [38]. Moreover, three fronts, and of course corresponding boundaries, can
be identified in the polymer-based drug delivery, i.e., polymer glassy-rubbery transition boundary
(swelling front), solid drug-drug solution boundary (diffusion front) and swollen matrix-solvent
boundary (erosion front) [39,40]. Therefore, the dissolution rate of drug is affected by the movement of
these fronts and the mechanisms of release can operate simultaneously [38,39]. In other words, the rate
of water uptake is widely associated with the position of the swelling front [41]. However, it can be
expected that erosion front movement determines the kinetics whilst the diffusion front movement
determines the rate of drug release [39]. Of course, some of the phenomena occurring during water
uptake can also be observed in the matrix size (its size enlargement or reduction), e.g., the swelling
causes its increase and the erosion, which can only take place after complete hydration of outer layer,
causes its decrease [29,42]. However, there is no universal drug release mechanism that can be valid
for all systems containing polymer [43].
The mobility of the polymer chains is affected by the dissolution medium composition which
should be thermodynamically compatible with the matrix [44,45]. The polymer can then undergo
the relaxation process due to the decrease in the glass transition temperature, its chains become
more flexible giving volume expansion which is followed by swelling of the system [44–46]. It can
be expected that hydrophilic polymer may lead to improving of wetting properties leading to the
enhancing the diffusion of dissolution medium to the solid powder. However, this assumption can
be also greatly influenced by the intermolecular interactions and therefore, also by the arrangement
of drug-polymeric carrier structures in the solid dispersions resulting in the changes of functional
groups orientation. For this reason, some polar functional groups can be then available or vice versa
unavailable for the interaction with dissolution medium during absorption [47].
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2. Materials and Methods
2.1. Materials
Tadalafil (TAD) was obtained from Zentiva Group, a.s. (Prague, Czech Republic). Kollidon® 12
PF (K12) and Kollidon® VA 64 (K64) were purchased from BASF Pharma (Ludwigshafen, Germany).
Methanol and acetonitrile were of LC/MS grades and were obtained from Fisher Scientific Ltd.
(Pardubice, Czech Republic). Methanol for solvent evaporation method, hydrochloric acid, potassium
dihydrogenphosphate (KDP) and sodium hydroxide were purchased from Penta s.r.o. (Prague,
Czech Republic). Sodium dodecyl sulfate (SDS) was obtained from Fluka (Buchs, Germany).
2.2. Preparation of Physical Mixtures
Physical mixtures (PMs) were prepared by mixing TAD and K12 or K64 (5% of TAD in PM) with a
conventional tumbling Turbula mixer (T2F model, W.A. Bachofen, Basel, Switzerland) for 1 h at 50 rpm.
2.3. Preparation of Solid Dispersions
Solid dispersions (SDs) were prepared by various methods. The methods are described in more
detail below.
2.3.1. Solvent Evaporation Method (SE)
To prepare for amorphous SDs of TAD in one of the polymeric carriers at 5% drug loading, 2 g
of PM was dissolved in 50 or 100 mL of methanol. The drug/polymer solution was then evaporated
at 35–40 ◦C and at 150 rpm under vacuum (150 mbar) with rotary vacuum evaporator LABOROTA
4000 Heidolph (Maneko, Prague, Czech Republic). The thin cast film was collected in a flask and
subsequently dried at 40 ◦C in an oven at least 24 h. The resulting SD was ground using mortar
and pestle.
2.3.2. Spray Drying Technique (SPD)
PM (2 g) containing TAD and K12 or K64 was dissolved in methanol (50 mL) to form the solution
which was mixed using sonification. After complete dissolution in methanol, the solution was spray
dried using the Mini Spray Dryer B-290 (Büchi, Flawil, Switzerland) with an inert nitrogen loop. The
aspirator flow was set at 90%, the inlet temperature was kept at 90 ◦C and the outlet temperature was
set at 50 ◦C. The atomization gas flow was 35% and the pump speed was 3 mL/min.
2.3.3. Hot-Melt Extrusion (HME)
Hot-melt extrusion was performed using universal single screw (L/D ratio 19/25D)
PLASTI-CORDER Lab-Station extruder (Brabender Technologie GmbH & Co. KG, Duisburg, Germany)
equipped with the heating barrel which is divided into three temperatures zones and a homogenization
zone at the end of the screw. The following extrusion temperatures were used for TAD-K12 PM: 140,
150, and 155 ◦C, and for TAD-K64 PM: 160, 165, and 160 ◦C. The extruder was manually fed with the
50 g of each PMs. The screw speed was set to 15 rpm for both PMs. The extrudates were then cooled to
laboratory temperature on a conveyor belt and milled to fine powder using hammer mill PolymixTM
PX-MFC 90 D (KinematicaTM, Loughborough, UK) equipped with sieve (mesh size 0.2 mm). The
rotational speed was 5000 rpm. The obtained powder was subsequently sieved using a vibratory sieve
(AS 200 basic, Retsch, Haan, Germany) for 10 min (amplitude of vibration was 50 mm). The particle
size fractions of 125–250 μm (HME125) and 250–425 μm (HME250) were used for further analysis.
2.4. X-Ray Powder Diffraction (XRD)
X-ray powder diffraction patterns were determined with D2 PHASER diffractometer (Bruker,
Billerica, MA, USA) configured with 1D SSD detector in Bragg-Brentano parafocussing geometry. A
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Cu Kα radiation was used (wavelength = 1.5416 Å, voltage = 30 kV, current = 10 mA). The samples
were analyzed at room temperature over the range of 5◦–80◦ (2θ). The time per step was 0.3 s and the
increment was 0.020◦ (2θ). The obtained data were evaluated using X´Pert High Score Plus program
with the PDF2 database (Malvern Panalytical Ltd., Royston, UK).
2.5. Scanning Electron Microscopy (SEM)
To observe the surface morphology of all components, their PMs and SDs, scanning electron
microscopy studies were performed using TESCAN VEGA 3 LMU (Tescan, Brno, Czech Republic).
A graphite double-sided adhesive tape was covered by samples and then the samples were made
conductive by sputter-coating with 5 nm of gold using rotary-pumped sputter coater (Quorum Q150R
ES, Quorum Technologies Ltd., Laughton, UK). The images were captured at magnifications factors
of 500.
2.6. Fourier Transform-Infrared (FT-IR) Spectroscopy
FT-IR spectra were recorded with the NICOLET iS FT-IR spectrometer (Thermo Fisher Scientific
Waltham, MA, USA). ATR module was used to measure FT-IR spectra. Each spectrum was measured
using spectral resolution of 2 cm−1 in 4000–400 cm−1 range.
2.7. Stability Studies
SDs were exposed to the temperature of 40 ◦C and to the relative humidity (RH) of 75% in the
humidity chamber, model HCP 108 (Verkon s.r.o., Prague, Czech Republic) for twelve months. The
samples were stored in powder form and in the case of SDs prepared by hot-melt extrusion also in
extrudate form.
2.8. Tadalafil Solubility Test
The solubility test was performed in a paddle dissolution apparatus Sotax AT7 Smart (USP 2; Sotax,
Basel, Switzerland). Solubility testing was measured for powder TAD (2.5 mg) in various dissolution
media (1000 mL), i.e., phosphate buffer (pH 7.2 and containing 6.8 g KDP and 0.9 g NaOH), phosphate
buffer + SDS (pH 7.2 and containing 6.8 g KDP, 0.9 g NaOH and 5 g SDS), 0.1 M hydrochloric acid, and
0.1 M hydrochloric acid + SDS (containing 5 g SDS), which were heated to 37 ◦C. The rotational speed
was set to 150 rpm. The samples of 5 mL were taken in following times: 2, 5, 10, 20, 30, and 45 min,
and the concentration of TAD was measured using HPLC. Each experiment was performed twice and
the mean values of TAD concentration with their standard deviations were calculated.
2.9. Dissolution Studies
The release of TAD from PMs and corresponding SDs was studied by different dissolution
techniques which are described in more detail below. Each dissolution experiment was performed
twice and the mean values of TAD release amount with their standard deviations were calculated.
2.9.1. Flow-Through Cell Method
The dissolution studies for SDs and PMs were carried out in the USP 4 compliant flow-through
cell apparatus Sotax CE1 (Sotax, Basel, Switzerland) with piston pump Sotax CY1 (Sotax, Basel,
Switzerland). The dissolution flow-through cell for powders and granules having the diameter of
12 mm and a height of 32 mm was employed to study the different samples in all experiments. Each
experiment was conducted using the cell in an open-loop system with fresh dissolution medium from
the reservoir continuously passing through the cell. The open-loop system was selected for samples
due to the low solubility of TAD and requirement of high volume of solvent. The dissolution medium
was pumped through the cell with a piston pump. One glass bead of 5 mm diameter was placed in the
apex of the cone to protect the inlet tube according to the manufacturer´s instruction. The conical part
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of the cell was filled with glass beads of 1 mm diameter to ensure laminar flow profile. Two sieves
and the amount of powder (approximately 0.02 g) to be studied were placed on the top of the layer of
small beads. One sieve was also placed above the powder. The cell was closed with the filter assembly
(containing glass microfiber filter GF/D, Whatman®, Fisher Scientific Ltd., Pardubice, Czech Republic)
to prevent undissolved material from escaping.
The dissolution medium and the apparatus were placed into the water bath and heated to 37 ◦C.
0.1M hydrochloric acid with 0.5% SDS (w/v) was used as dissolution medium. The dissolution medium
was then degassed. The flow rate of dissolution medium through the cell was set to 23 mL/min.
The samples were collected into the beakers for the following times: 10, 20, 30, 40, 50, 60, 70, 80, 90,
100, 110, 120, 150, 180, 240, 360, 480, 600, and 900 s. Aliquots of 1 mL were then withdrawn for the
HPLC analysis.
The TAD concentration in the dissolution medium was calculated using a calibration curve which
was obtained from the samples of known concentration and the dissolution profiles were normalized
to 100% TAD released at the end of the experiment.






where Q is the flow rate of dissolution medium (mL/min) and VC is cell volume (dm3).






2.9.2. Apparent Intrinsic Dissolution Rate (Wood´s Apparatus)
The apparent intrinsic dissolution rate (AIDR) technique was introduced in our previous study [48]
as an extension to intrinsic dissolution rate (IDR) to measure matrix related dissolution effects of
drug formulation rather than pure drug substance. Dissolution testing of compressed formulations
was performed in dissolution apparatus Sotax AT7 Smart (Sotax, Basel, Switzerland) equipped by a
rotating disc device. For rotating disk dissolution rate, 200 mg of the PMs or SDs were compressed
by the compaction force of about 2.5 tons and using standard die of 10 mm diameter for 1 min using
laboratory manual hydraulic press (Specac, Orpington, UK). The die was then attached to the rotor
shaft and was immersed into 1000 mL of the dissolution medium. The rotational speed was 150 rpm.
The tablets were dissolved in 0.1M hydrochloric acid with 0.5% SDS (w/v) which was maintained at
37 ◦C. The samples of 1 mL were taken in following times: 2, 4, 5, 6, 8, 10, 15, 20, 25, and 30 min. The
concentration of TAD was measured by HPLC. The apparent intrinsic dissolution rate can be then







where V is volume of dissolution medium (L) and A is area of exposed tablet surface (cm2), c is
concentration of dissolved TAD (mg/L) and t is time (s). Unlike IDR measurement, the dissolution
profile can be non-linear and thus AIDR is time-sensitive. For example, IDR at t = 0 can be used as a
measure of drug dissolution unhindered by formed polymer layer.
2.10. HPLC
The concentration of TAD in the samples was determined by LC Prominence system (Shimadzu,
Kyoto, Japan) equipped with a PDA detector without further dilution and a Kinetex®, 5 μm, C18, 100 Å
column (Phenomenex®, Prague, Czech Republic). Separation was performed with 20 μL injection
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volume. The flow rate of mobile phase was 1 mL/min and oven temperature was 30 ◦C. Tadalafil was
monitored at 284 nm.
A solution of methanol, acetonitrile and distilled water in ratio 45:40:15 (v/v/v) was used as the
mobile phase. The mobile phase was then degassed prior to analysis.
2.11. Differential Scanning Calorimetry (DSC)
DSC was performed on the pure TAD, polymers, PMs and SDs. DSC analyses were examined using
a differential scanning calorimeter DSC 131 (Setaram, Caluire, France) under nitrogen atmosphere in the
temperature range of 25–350 ◦C. The temperature program was set to a linear increase of temperature
at a heating rate of 10 ◦C/min.
3. Results and Discussion
3.1. Characterization of Solid Dispersions
It has been documented that the physicochemical properties of amorphous forms can be largely
dependent on methods for their production, as well [16].
3.1.1. SEM
For morphological characterization, SEM analysis was performed on the pure drug and both
polymer, their PMs and SDs. The SEM images for pure drug, polymers, PMs and SDs of both polymers
are shown in Figures 1 and 2. Pure drug images (Figure 1a or Figure 2a) showed fine crystalline powder
of irregular shapes and uniform sizes, whereas the images of polymers (Figure 1b for K12 and Figure 2b
for K64) showed a spherical particle shape with holes. From the SEM of both pure polymers, it is clear
that the K64 contained larger particles in comparison to K12. In the PMs (Figures 1c and 2c), the small
particle size TAD was adsorbed on the surface of polymers. The images of SDs of TAD with K12 or
K64 did not show any crystalline materials (Figures 1d–g and 2d–g) and the SDs appeared as particles
of irregular shape. As can be seen, the type of carrier and different methods strongly affected the
morphology of the SDs. Further, only spray drying led to the formation of round and small particles.
 
Figure 1. Morphology images of TAD, K12, their PM and SDs: (a) pure TAD, (b) pure K12, (c) TAD-K12
PM, (d) TAD-K12 SD (SE), (e) TAD-K12 SD (SPD), (f) TAD-K12 SD (HME125) and (g) TAD-K12 SD
(HME250).
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Figure 2. Morphology images of TAD, K64, their PM and SDs: (a) pure TAD, (b) pure K64, (c) TAD-K64
PM, (d) TAD-K64 SD (SE), (e) TAD-K64 SD (SPD), (f) TAD-K64 SD (HME125) and (g) TAD-K64 SD
(HME250).
3.1.2. FT-IR
FT-IR spectra were measured to study TAD-polymer matrix interactions. In the Figures 3a and 4a,
the FT-IR spectra of pure TAD, K12 and K64, their PMs and SDs at 500–4000 cm−1 are shown. The
Figures 3b and 4b also show the detail spectra at 1600–1750 cm−1 or 1600–1800 cm−1, respectively.
Figure 3. FT-IR spectra of pure TAD, K12, their PM and SDs: (a) 1—TAD-K12 SD (HME250), 2—TAD-K12
SD (HME125), 3—TAD-K12 SD (SPD), 4—TAD-K12 SD (SE), 5—TAD-K12 PM, 6—pure K12, 7—pure
TAD and (b) their detail spectra at 1600–1750 cm−1.
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Figure 4. FT-IR spectra of pure TAD, K64, their PM and SDs: (a) 1—TAD-K64 SD (HME250), 2—TAD-K64
SD (HME125), 3—TAD-K64 SD (SPD), 4—TAD-K64 SD (SE), 5—TAD-K64 PM, 6—pure K64, 7—pure
TAD and (b) their detail spectra at 1600–1800 cm−1.
TAD showed the signal of the stretching vibration of secondary amine group (3321 cm−1), the
signal of aliphatic methyl group (2904 cm−1), the dual signal of carbonyl groups (1673 cm−1), the signal
of aromatic C=C bending (1649 cm−1) and the signal of tertiary amine group (1270–1285 cm−1). K12
had the carbonyl stretching band that is at 1661 cm−1. The FT-IR spectra of pure K64 had aliphatic
alkyl C–H stretch that is in mutual association at 2937 cm−1, the signal of vinyl acetate (1730 cm−1)
and the signal of carbonyl group (1669 cm−1). The spectra of all physical mixtures displayed tadalafil
and polymer peaks with decreased peak intensity but with no shifting of the peaks. FT-IR spectra
of all SDs showed the presence of some TAD peaks with decreased intensity as was described e.g.,
in [8]. Shifts of characteristic bands are not visible in the spectra, but only changes in their intensity or
changes in the sub-band intensity of multi-component bands, as confirmed by a detailed analysis of
the second spectra derivatives. All other tadalafil peaks were smoothened, indicating a strong physical
intermolecular interaction of TAD with polymers. The decreasing intensity of the carbonyl group was
observed for TAD-K12 PM and its SDs suggesting the presence of hydrogen bonds between the TAD
secondary amine group and K12 carbonyl groups. Molecular interaction with polymer, predominantly
through hydrogen bonding which was also described in [19], leads to better miscibility of TAD in the
polymer matrix and the formation of amorphous SDs, as confirmed by XRD results. The interactions
were stronger in the TAD-K12 SDs in comparison to TAD-K12 PM. Stronger drug-polymer interactions
could be generated for example due to the melt extrusion [2].
The changes in the intensity of the carbonyl group were also observed in the TAD-K64 PM and
its SDs. Even the pure polymer has other sub peaks visible on the deconvolution by curve fitting of
its characteristic absorbing bands for carbonyl (1662 cm−1) and for vinyl acetate (1730 cm−1). These
are vibrations of different types of groups, in which the carbonyl may be influenced by either two
other carbonyls, optionally one or two vinyl acetate group in the neighboring position, or it may be a
terminal group where the bond energy and its vibration depends on the neighboring monomer unit.
After deconvolution of main bands, changes in the intensity of some peaks can be observed. In the case
of a TAD-K64 PM, the vinylacetate group is also weakened. As a result of the different preparation
of SDs, different relaxation of the polymer and its recombination occurs and leads to the change in
the structural arrangement exhibiting different carbonyl group orientations. This is reflected in the
change in the intensity ratio between the deconvoluted peaks, which is most noticeable between the
TAD-K64 SD (SE) and TAD-K64 SD (HME125) spectra. Each of these mixtures was prepared at a
completely different temperature and manifested in, for example, different dissolution behavior (see
below). However, the interaction between the polymer and TAD can be observed with other vibrations
than with the NH-vibration. Several different types of structures can be observed relative to each other
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for the vibrations of –CH– in the region 3000–2800 cm−1 range, or 2925 cm−1 corresponding to –CH2
groups. CH deformation oscillations in the area of 1460 cm−1 again show the differences between the
SDs and the PM when the PM exhibits more pronounced peaks, whereas, for example, in the TAD-K64
SD (SE), the absorption bands are more diffuse and overlap each other. However, no additional peak
was observed in any binary system indicating absence of any another chemical interaction between
TAD and polymer [5,49].
3.1.3. XRD
The powder X-ray diffraction patterns of pure TAD, K12 and K64, their PMs and SDs prepared
by various method are shown in Figures 5 and 6, respectively. The diffraction pattern of the TAD
had sharp intensive peaks throughout its pattern suggesting that it is crystalline in nature [15]. On
the contrary, the polymeric carriers showed broad amorphous bands and no sharp diffraction peaks
suggesting that the Kollidons were in amorphous state. The diffraction patterns of PMs showed sharp
peaks corresponding to crystalline TAD and therefore, we can assume that crystalline TAD can be
detected in its low concentration in all binary mixtures. The TAD peaks then disappeared in all SDs
loaded with 5% TAD and therefore, their amorphous forms were confirmed. All extrudates were
transparent, that means the dissolution of TAD in amorphous polymers.
Figure 5. X-ray diffraction patterns of TAD, K12, their PM and SDs.
Figure 6. X-ray diffraction patterns of TAD, K64, their PM and SDs.
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3.1.4. DSC Analysis
Figures A1 and A2 (see Appendix A) present DSC thermograms for crystalline TAD, amorphous
K12 or K64, their PMs and SDs prepared by HME as an example. DSC thermograms of both SDs reveal
the absence of any melting peak which means that these results suggest amorphous characteristics
of SDs. In other words, it indicates the absence of crystalline trace of TAD in SDs. Besides, a broad
endotherm ranging from 25 to 100 ◦C was observed in thermograms of pure K12, K64, both PMs and
SDs which can be attributed to the water loss from the hygroscopic polymer upon heating. Figure A1 or
Figure A2 also show a sharp melting endotherm at 302 ◦C corresponding to crystalline TAD. Moreover,
no significant glass transition temperature was seen in thermograms. In order to detect the Tg, it is
necessary to decrease heating rate. However, both Kollidons tend to degrade at lower heating rates.
Figure A2 also show broad endotherms ranging from 300 to 350 ◦C. The degradation temperature of
K64 is 230 ◦C. Based on this, broad endotherms can be attributed to some thermal event corresponding
to the decomposed polymer.
3.2. Physical Stability of Solid Dispersions
The samples were stored in powder form and in the case of SDs prepared by HME also in
extruded form. Stability testing at 40 ◦C and 75% RH for 12 months revealed that extrudates of both
Kollidons to be amorphous for nine months and their powder forms to be amorphous for 6 months
which was confirmed using XRD analysis as shown Figure A3a,b in Appendix A. Figure A3 shows
results from XRD only for extrudates because X-ray diffraction patterns were identical also for powder
forms prepared by various methods. Therefore, no crystalline form of the TAD was noticed after
this period. The presence of hydrogen bonds between the drug and the polymer can lead to their
better miscibility and effectively improves the physical stability of the SDs and therefore, they are
essential [2,50]. Hydrogen bonds stiffen the structure and thus, hinder the diffusion of molecules [3].
In our case, the hydrogen bonds between the components were observed. SDs of both polymers in
powder form changed their character after 6 months and for this reason, the sticky viscous solution
was formed. Since the glass transition temperature is dependent on relative humidity [51], its decline
can be expected leading to the glass solutions. In the case of SDs in extruded form, this phenomenon
was observed after 9 months. However, all these viscous solutions were still transparent which could
mean that TAD maintain its amorphous form.
3.3. Dissolution Tests of TAD Solid Dispersions
It has been reported that amorphous solid dispersion formulations require the use of many
excipients for the optimal design, especially to maintain supersaturation and improve physical stability
or to ensure shelf-life stability and better absorption during intestinal transit [52]. Choi et al. prepared
tadalafil solid dispersion coupled with the incorporation of an acidifier and solubilizer. They found
that both tartaric acid increasing wettability and Soluplus® improving solubility contribute to the
dissolution rate. Their optimal formulation also contained Aerosil 200 to ensure better flow properties
and drug stability [12]. In another study, Choi et al. used malic acid and meglumine at lower contents
in the preparation of tadalafil solid dispersion to improve drug solubility and dissolution rate, and
Aerosil 200 to improve drug dispersibility [19]. Choi et al. also investigated the effect of various weak
acids and bases on tadalafil solid dispersion formulation. Their results indicate that only meglumine
significantly improve the apparent drug solubility and dissolution [20]. Obeidat et al. evaluated a
mixture of surfactants (Tween 80 and Span) as stabilizers [13]. However, we focused primarily on the
effect of different structural polymers and methods of solid dispersion preparation on the dissolution
mechanism and release kinetics of tadalafil from amorphous solid dispersions. These properties
strongly depend upon the nature of all components, but the dissolution rate of the drug is mainly
affected by the aforementioned factors (see Introduction) which are associated with the polymer carrier.
Therefore, the drug to polymer carrier ratio was fixed at 5% drug loading in order to maximize the
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effect of polymer solubilisation and probability complete amorphous form. The pure TAD drug and
PMs thereof with the carrier materials were used as references.
3.3.1. Solubility Testing
Prior to the dissolution tests with the polymer, the solubility studies of pure TAD (as was received)
were compared in various dissolution media, as shown in Figure 7.
Figure 7. Solubility testing of TAD in various dissolution media.
TAD is classified as class IV in the Biopharmaceutical Classification System and is practically
insoluble in water (2 μg/mL) [53]. It was found that the solubility of TAD was maximum in 0.1 M
hydrochloric acid + SDS. On the other hand, the solubility of TAD was minimum in 0.1 M hydrochloric
acid. Moreover, the results of TAD solubility in phosphate buffer (pH 7.2) + SDS were affected by the
ion exchange between phosphate buffer and SDS. For this reason, these data were not included in the
evaluation. Dissolution tests were then performed in 0.1M hydrochloric acid + SDS. The addition of
SDS to the dissolution medium can have an impact on the magnitude of drug concentrations, but the
relative order of the release profiles should not be changed, particularly at low drug concentration [16].
3.3.2. Assessment of the Erosion-Diffusion Mechanism of TAD Release Using Wood´s Apparatus
(AIDR Measurements)
A general mathematical model describing the dissolution behavior was proposed e.g., in [48,54,55].
Moreover, AIDR was described in [48]. However, there is still no model currently available to describe
the solubility and dissolution behavior of amorphous SDs formulated with hydrophilic polymers [56].
Drug release from hydrophilic matrices is generally considered to be governed by the complex
interactions between dissolution, diffusion and erosion mechanisms [57]. Pharmacopoeia defines the
intrinsic dissolution rate for pure API (active pharmaceutical ingredient). Therefore, if some excipient
is added to this drug, we can then observe whether the release rate is accelerated or retarded (see
Figure 8).
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Figure 8. Scheme of front position during dissolution.
Such dissolution tests can be performed using Wood´s apparatus [1]. The transport phenomena
can then only be allowed in axial direction. It gives the advantages of exposing a constant surface area
of the formulation to the dissolution medium, and therefore it eliminates the influence of different
surface area of powders by their compaction [26].
Prior to dissolution tests with the polymer, the release rates of pure TAD were performed as
reference. The release profiles of TAD from PMs and SDs with various polymers prepared by different
methods are shown in Figure 9.
 
Figure 9. Release profiles of TAD from PMs and SDs prepared by different methods measured as
apparent IDR using Wood´s apparatus: (a) K12 groups and (b) K64 groups.
Tables 1 and 2 summarize the values of AIDR for all tested samples. The slope of the initial linear
part of a release profile was used as AIDR for samples which exhibited curved profiles (namely up to
the 10th minute for PM and SDs containing K12).
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TAD-K12 SD (SE) 0.662
TAD-K12 SD (SPD) 0.433
TAD-K12 SD (HME125) 0.245
TAD-K12 SD (HME250) 0.279




TAD-K64 SD (SE) 0.247
TAD-K64 SD (SPD) 0.156
TAD-K64 SD (HME125) 0.245
TAD-K64 SD (HME250) 0.194
The release profile from SDs obviously varied depending on the methods of preparation but
there is notable improvement in release rate and the quantity of released TAD for all SDs over pure
TAD. The release rates of TAD were found to be significantly different from each specific method and
polymer. Figure 9 reveals that there was noticeable influence of polymers and preparation methods
on TAD dissolution rate. It is also clear that the pure TAD had the lowest dissolution rate. As can be
seen in Figure 9a, the presence of hydrophilic soluble K12 caused faster medium penetration, faster
release and faster polymer erosion in comparison to pure TAD. The initial TAD release rate is faster
from PM and SDs than pure TAD release rate in the first 15 min followed by a second stage with a
slower almost constant drug release rate. A subsequent slowdown in the dissolution was not caused by
saturation of the solution with TAD but might have been the effect of progressive swelling of polymers
and hindered diffusion of TAD molecules from polymer, as was described e.g., in [3]. During this
diffusion period, the thickness of the viscous gel layer on the tablet surface increased over time, leading
to longer diffusion path for TAD into the bulk dissolution medium. Consequently, the release of TAD
was then limited by water penetration to the tablets as well as drug diffusion through the gel layer.
That suggests this type of release is only due to the combination of erosion and diffusion mechanisms.
In general, up to three phases can be observed in the AIDR profiles in Figure 9. The initial AIDR
increase for SDs over that of the pure TAD is caused by improving TAD wettability by surrounding
hydrophilic carrier, reducing TAD particle size effectively to single molecules and reducing its
crystallinity. This is also facilitated by enhanced water penetration into the matrix and the polymer
swelling. As the swelling and the diffusion fronts travel deeper into the matrix, the distance between
the matrix surface (erosion front) and the diffusion front increase, thus increasing the diffusion path
length, leading to reduced AIDR over time, which is represented by the second (transient) phase of
gradually decreasing slope of the release profile for some formulations, especially those using the K12
polymer. This AIDR reduction means also slower progress of the diffusion front. Once the diffusion
front progress become equal to that of the erosion front, the thickness of the diffusion layer and length
of the diffusion path of TAD approaches its steady state, which results in the third phase of steady
release at slower rate than in the initial phase. This phase is displayed for the PM and SD (prepared
by SE or SPD) formulations using the K12 polymer at dissolution times over approximately 20 min.
Some formulations may never reach the third phase (e.g., HME formulations using K12), which means
the progress of the erosion front is negligible. Yet other formulations may maintain their initial AIDR
(e.g., K64 formulations) without entering the transient second phase, which means the erosion front
progress at the same rate as the diffusion front from the very start of the experiment and no significant
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diffusion barrier is developed. The fastest TAD release, as well as its largest amount released, was
observed in SD prepared by SE. The different morphology of particles (obtained SEM) resulted in
differences in disk intrinsic dissolution rate or also in medium apparent solubility (see below). This
is probably because SD particles contain irregular fracture edges (Figure 1d) leading to increase in
surface area and therefore, to faster TAD release. Furthermore, it is shown that TAD release rate of SD
prepared by SPD is almost comparable to the corresponding PM. The incorporation or encapsulation of
drug into the matrices during spray drying can affect the drug release rate [2,58]. The swellability has
a significant effect on the release kinetics of an incorporated drug [43]. Therefore, TAD was probably
encapsulated by K12 during spray drying and TAD release was then slower. In the case of SD prepared
by HME, TAD release is the slowest in comparison to other SDs or PM containing K12. TAD dissolution
rates from these extrudates were considerably greater in comparison with the pure TAD and PM at
the initial phase, even though they were observed to decrease over the duration of the study. Their
dissolution profiles overtake that of the PM at the beginning of the experiment (approximately during
10 min). This is probably because TAD is better wetted in the both sieve fractions of extrudates. Since
their dissolution profiles overlap, they were no noteworthy differences in the porosity between both
extrudates as was described e.g., in [15]. Subsequently, its release is probably retarded by the gel layer
and therefore, diffusion mechanism predominated.
It is clear from Figure 9b that polymer dissolution influences the TAD release profile significantly.
Drug release decreased if polymer molecular weight increased [59] and for this reason, polymer erosion
rate increased with the decrease of polymer molecular weight. K12 has a lower molecular weight
(2500 g/mol) in comparison to K64 (45,000 g/mol), wherein greater the molecular weight, higher the
viscosity and slower the release can be observed. During SDs preparation, solid dispersions containing
K64 was of high viscosity, especially in HME. Consequently, the pathways to be overcome by the
TAD to be released were very much shortened in the case of the systems containing K12. For this
reason, the TAD releases were influenced by the polymer molecular weight because at high molecular
weights, the polymer was also more entangled. The initial polymer dissolution rate is usually zero
until the entanglement strength is reduced by the increased penetrant concentration and the polymer
dissolves because of chain disentanglement [60,61]. Therefore, the polymeric segments of K12 were not
so entangled and for this reason, the thickness of the viscous layer on the tablet surface was weaker in
comparison to tablets containing K64. The gel strength corresponds actually to resistance to dissolution
media penetration [62]. The tablets containing K64 displayed a totally linear release profile, whereas
the tablets containing K12 showed a non-linear release (Figure 9). Therefore, the tablets containing
K12 seems to reach the plateau where no more TAD is dissolved after 15 min, whereas the TAD
still continues to be released from the tablets containing K64 even after 30 min of the experiment as
explained by the different erosion rate above. The linear release providing that the releasing area is kept
constant was also observed in [39] when the polymer was sufficiently soluble and therefore, the gel
layer thickness remained constant because the fronts in the matrix moved in a synchronized way. It can
be caused by the chemical structure of the Kollidons. Figure 9b shows the swelling of the tablets (upon
complete hydration approximately during 5 min) and gradual erosion of K64. It can be attributed
to the fact that K64 contains lipophilic vinyl acetate which is insoluble in the aqueous medium and
hydrophilic vinylpyrrolidone which can form the channels in the tablets. This phenomenon was
described in [29] for Kollidon® SR. Therefore, this monomer allows better capture and penetration of
water by the tablets and hence a greater viscosity of the gel. Medium then penetrates into the free
spaces on the surface between the polymer chains. TAD can diffuse slowly through these channels
which is reflected in its slower release rates in comparison to the tablets containing K12. However,
the release rate would be controlled solely by mechanisms of erosion due to higher AIDR values in
comparison to pure TAD.
Dissolution from both PMs showed also improvement in the release rate of TAD. However, the
fastest TAD release, as well as its largest amount released, was also observed in SD prepared by SE as
compared with that of solid dispersions and pure form of TAD. This is probably because SD particles
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also contain irregular fracture edges (Figure 2d) leading to increase in surface area and therefore, to
faster TAD release. Furthermore, it is also shown that the TAD release rate of SD prepared by SPD
was retarded in comparison to other SDs. TAD was probably also encapsulated by K64 during SPD.
TAD release is then slower, although, the very small SD particles were obtained by this method of
preparation (Figure 2e). There was not significant difference between the release rates of SDs sieve
fractions prepared by HME and their profiles were practically superimposed. Therefore, the utilization
of the same compression conditions for different SDs can paradoxically lead to varying degree of
compaction and is crucial in dissolution, as was described in [16]. However, best solid dispersion form
of TAD was prepared by solvent evaporation using both polymers. Slower and lower TAD release from
all extrudates might also be due to the property of the polymer to undergo thermoreversible gelling at
high concentration after the melting process and subsequent cooling during the formulation of SDs [5].
3.3.3. Effect of the Preparation Method on the Dissolution Behavior of TAD from Solid Dispersions
Flow-through cell apparatus for powders was used to describe the dissolution behavior of SDs.
The dissolution profiles from the SDs containing K12 or K64 obviously varied depending on the
methods of preparation and polymer type. Figure 10 represents normalized data. The normalization
was used to more easily compare data from different SDs because possibly non-homogeneity of some
samples (especially in the case of TAD-K12 SD HME125 or HME250) were observed. The original data
are then shown below (namely in Figure 13). Figure 10a,b shows that the powders containing K12
allow a faster gradual release of TAD from K12 in comparison to powders containing K64.
 
Figure 10. Release profiles of TAD from PMs and SDs prepared by different methods: (a) K12 groups
and (b) K64 groups.
SDs containing K12 also show similar dissolution profiles that reach the identical asymptotic amounts
of TAD in the medium. After the initial dissolution times, most of the TAD released at comparable release
rates except for PM which showed the lowest release rates among all SDs. As shown in Figure 10, the
TAD amounts, therefore, are very high in the first 3 min, and then the amounts become slower and are
almost constant. The same trend can be observed for SDs containing K64, but the dissolution is slower
compared to K12. It can be attributed to enhancement of powders wettability. Molecular dispersion
of poorly water-soluble drug is the most desirable type in the theory and practice of amorphous solid
dispersions because it is related to the enhancement of the solubility by the weakening of solute-solute
interactions. TAD has a very high binding energy between its molecules due to its high melting point
(302 ◦C). For this reason, the reduction in the binding energy allows for the easier passage of molecules
from the amorphous solid state to the medium. It is additionally facilitated by detachment of polymer
chains and subsequent increase in the contact surface with medium leading to the considerable solubility
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improvement [3]. Therefore, in the case of SDs containing K64, this could be attributed to the lowered
mobility of TAD particles or molecules embedded within the K64 matrix system particularly in the initial
phase. From the above AIDR measurements, it appears that although the SDs enhance the TAD release
rate, in these dissolution experiments, there was not a significant difference between the dissolution
behaviors of the SDs. It may be therefore concluded that flow-through cell data measured on powders
emphasize the effects related to the prepared particles of SDs and therefore are relevant to situations
corresponding to the first phase of the AIDR experiments. Since the particles are relatively small and no
tablet was compressed the swelling and erosion effects are suppressed, while the particle surface effects
are more pronounced. It is also obvious that the largest amount of TAD was dissolved in the case of SDs
containing K12 or K64 prepared by SE. As mentioned above, their SDs contained irregular fracture edges
leading to the increase in surface area (Figures 1d and 2d). On the other hand, the TAD slowest release
was observed in the SDs containing K12 or K64 prepared by SPD. This was also commented above. The
incorporation of TAD into the K12 or K64 matrix also affects the dissolution behavior. Therefore, SDs
prepared by SE showed the highest dissolution rate among them, and both extrudates having particles of
125–250 μm showed the second highest dissolution rate among them.
The results of dissolution studies and the initial dissolution rates during the first 1.5 min (for the
systems containing K12) and 4 min (for the systems containing K64) for all SDs and corresponding
PMs are depicted in the Figure 11a,b and Figure 12a,b.
 
Figure 11. Dissolution rates of TAD from PM and SDs containing K12: (a) during 15 min and (b) during
1.5 min.
 
Figure 12. Dissolution rates of TAD from PM and SDs containing K64: (a) during 15 min and (b) during
4 min.
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The most significant differences between the prepared samples were observed within 1.5 min. For
this reason, the Figures 11b and 12b show more detail of the dissolution experiments. The results are
represented as data points. From these values, dissolution rates of TAD were always higher from the
SDs compared with pure TAD or the PMs. It was also found that the presence of hydrophilic K12 or
K64 in the SDs caused faster dissolution rate that was in compliance with the results mentioned above.
It was also observed that the SDs containing K12 showed faster dissolution rate compared to K64.
The fastest TAD dissolution rate was also measured in the SDs containing K12 or K64 prepared by SE
due to the presence of irregular fracture edges. The fast initial rate can be attributed to the hydrogen
bonding between TAD and both polymers, which breaks relatively easily during dissolution compared
with pure drug [17].
3.3.4. Weibull Dissolution Model
In order to describe the TAD release, the obtained dissolution profiles were fitted to the Weibull
model which is adapted to the release process. This kinetic model can be expressed by the Equation (4):




−k · (t− t0)b
)]
, (4)
where At is the amount of drug released in time t, A∞ is the maximum releasable amount of API, k
corresponds to the reciprocal value of time scale of the release process, t0 is the location parameter
and represents the lag time before the onset of the dissolution (in most case is equal to zero) and b
describes the shape of the dissolution curve [63]. When the shape parameter b is equal to one, the
Weibull model corresponds to the first order kinetic model and therefore, the parameter k corresponds
to the first order release rate constant. ERA software [64] was used for the fitting the Weibull equation
to the experimental data. Figure 13 shows TAD release profiles fitted by the Weibull model. As can
be seen in Figure 13, the model was in agreement with the dissolution profile and therefore, it was
appropriately used. Therefore, the kinetic parameters of the model and their standard deviations
(STDs) are summarized in Tables 3 and 4.
 
Figure 13. Dissolution profiles of TAD formulations (points) fitted by Weibull model (lines): (a) K12
groups and (b) K64 groups.
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Table 3. Kinetic parameters of TAD release (K12 polymer matrix).
Sample k (s−b) ± STD b (-) ± STD t0 (s) ± STD
pure TAD 0.21 ± 0.04 0.99 ± 0.10 0.00 ± 0.19
TAD-K12 PM 0.29 ± 0.04 1.13 ± 0.08 0.26 ± 0.10
TAD-K12 SD (SE) 1.92 ± 0.06 0.33 ± 0.04 0.17 ± 0.00
TAD-K12 SD (SPD) 1.27 ± 0.87 1.02 ± 1.15 0.13 ± 0.46
TAD-K12 SD (HME125) 2.30 ± 0.36 0.66 ± 0.21 0.15 ± 0.03
TAD-K12 SD (HME250) 1.76 ± 1.15 0.86 ± 1.16 0.14 ± 0.31
Table 4. Kinetic parameters of TAD release (K64 polymer matrix).
Sample k (s−b) ± STD b (-) ± STD t0 (s) ± STD
pure TAD 0.21 ± 0.04 0.99 ± 0.10 0.00 ± 0.19
TAD-K64 PM 0.23 ± 0.03 0.96 ± 0.07 0.11 ± 0.12
TAD-K64 SD (SE) 0.93 ± 0.23 1.71 ± 0.29 0.00 ± 0.13
TAD-K64 SD (SPD) 0.38 ± 0.05 1.20 ± 0.10 0.21 ± 0.09
TAD-K64 SD (HME125) 0.77 ± 0.09 1.06 ± 0.14 0.13 ± 0.08
TAD-K64 SD (HME250) 0.61 ± 0.06 0.85 ± 0.10 0.41 ± 0.09
Since the parameter k corresponds primarily to the initially release rate, the Figure 14a,b represents
TAD release profile with respect to this fact only up to the second minute.
 
Figure 14. TAD release profile during 2 min: (a) K12 groups and (b) K64 groups.
The values of b about 1 were found for pure TAD, SD containing K12 prepared by SPD, PM
containing K64 and SD containing K64 prepared by HME (specially for the sieve fraction 125–250 μm)
(Tables 3 and 4). In other case, the release rate is retarded in comparison to the first order kinetic
(b < 1), i.e., for SDs containing K12 prepared by SE and HME (both sieve fractions) and SD containing
K64 prepared by HME (sieve fraction 250–425 μm). On the other hand, the release rate is accelerated
in comparison to the first order kinetics (b > 1), i.e., for PM containing K12 and SDs containing K64
prepared by SE and SPD. These results confirm the fact that the parameter k correlate with the amount
of drug released at the beginning of the dissolution experiment.
4. Conclusions
In this study, TAD amorphous solid dispersions were successfully obtained using the solvent
evaporation method, spray drying technique, as well as hot-melt extrusion. Two grades of
polyvinylpyrrolidone (K12 and K64) were used as a polymeric carrier. Therefore, the use of different
preparation methods for SDs and polymers having different physicochemical properties can provide
greater insights into the importance of various mechanisms of the dissolution process.
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SEM revealed significant differences in morphology of all samples which were reflected in the
dissolution tests. FT-IR spectra confirmed the interactions between the drug and both Kollidons as
well as the presence of hydrogen bonds between the components. These interactions were weaker in
the binary mixtures containing K64 compared to K12. The presence of hydrogen bonds between the
drug and the polymers improved the physical stability of the SDs in their extruded forms. Therefore,
stability studies for nine months confirmed the extrudates to be amorphous. On the contrary, the SDs
of both polymers in powder form changed their character due to high relative humidity.
The Wood’s apparatus was found to be suitable for determining the apparent intrinsic dissolution
rate and for identification of critical factors affecting the erosion-diffusion mechanism of TAD release. TAD
release from compressed SDs containing K12 was controlled by combination of erosion and diffusion
mechanisms. The diffusion mechanisms were predominant in the initial phase of experiment and the
slow erosion was dissolution-controlling at the second stage. TAD release rate from SDs containing K64
was controlled solely by mechanisms of erosion. The dissolution profiles obtained by Wood´s apparatus
were in agreement with dissolution profiles obtained using flow-through cell apparatus. The fastest TAD
release, as well as its largest amount released, was observed in SD containing K12 or K64 prepared by
solvent evaporation method. This is probably because SD particles contain irregular fracture edges, which
was revealed by SEM, leading to increase in surface area and to faster TAD release. In the case of SDs
containing K12 or K64 prepared by spray drying, TAD was probably encapsulated by K12 or K64 during
spray drying. TAD release was then slower, although, the very small SD particles were obtained by this
method of preparation. The effect of polymer molecular weight on the release rate was also observed.
K12 has a lower molecular weight in comparison to K64. The TAD releases were then influenced by the
polymer molecular weight because at high molecular weights, the polymer was more entangled. For this
reason, the SDs containing K12 showed faster dissolution rate compared to K64. Weibull dissolution model
was suitably used to describe the TAD release at the beginning of the dissolution experiment as well as
to assess whether the release corresponds to the first order kinetics. There was noticeable influence of
polymers on TAD solubility. All solid dispersions improved the TAD intrinsic dissolution rate, however,
the greatest increase in the TAD dissolution rate was obtained from SD containing K12 prepared solvent
evaporation. It can also be concluded that all SDs of TAD showed considerable enhancement in dissolution
rate compared to both PMs and the dissolution rate of both PMs was higher compared to the pure TAD.
The rapid dissolution of TAD from SDs, especially in the initial phase, may be attributed to its molecular
dispersion in polymer carriers.
In order to summarize, the dissolution experiments revealed that the TAD release from the solid
dispersion is controlled by different processes in combined mechanism of surface hydrophilization,
dissolution, diffusion in swollen matrix, and the matrix erosion, depending not only on the polymer used,
but also on the method of preparing the solid dispersion and further processing thereof. All SDs with
hydrophilic polymers enhanced the initial dissolution rate of TAD in both the AIDR arrangement and the
USP 4 for solid dispersion over the dissolution rate of pure TAD or TAD PMs. While the enhancement
occurred for all SDs systematically, it was of different strength for both the different polymers and the
different preparation methods. In general, the dissolution was more enhanced by K12 than K64 polymers
and the SDs prepared by the solvent evaporation released the TAD faster than SDs prepared by other
methods. Those results should be interpreted as the contribution of hydrophilization and TAD dispersion
to dissolution. The AIDR experiments also showed the differences in compressed forms prepared from
SD particles. Most notably, the two polymers tested exhibited entirely different behavior. While K64 SDs
dissolution was not hindered by the diffusion because the polymer matrix erosion controlled the process
and the AIDR proceeded at a steady rate for all samples, K12 dispersions exhibited different erosion
rates for different preparation methods resulting in very different AIDR profiles and diffusion hindrance,
corresponding to different diffusion layers formed by the diffusion-erosion rate equilibrium.
Apparent intrinsic dissolution rate studies and apparent solubility revealed the greatest increase in
TAD solubility and significant dissolution rate enhancement for all SDs in comparison with crystalline
TAD and its PMs. The proposed SDs based on K12 or K64 showed an interesting potential for improving
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the oral bioavailability of the poorly water-soluble tadalafil. This information can be also used either
to optimize formulation to obtain the desired release profile or provide a better understanding into the
mechanism of TAD release from solid dispersions.
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Appendix A
 
Figure A1. DSC thermograms of (from bottom to top) crystalline TAD, amorphous K12, TAD-K12 PM,
and TAD-K12 SD (HME).
 
Figure A2. DSC thermograms of (from bottom to top) crystalline TAD, amorphous K64, TAD-K64 PM,
and TAD-K164 SD (HME).
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Figure A3. X-ray diffraction patterns of extruded SDs after 9 months: (a) TAD-K12 and (b) TAD-K64.
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